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INTRODUCTION, AIMS AND OUTLINES OF THE THESIS 
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Ileal brake history  
Digestion and absorption of nutrients are complex processes that involve 
various functions of the gastrointestinal (GI) tract. This includes the interplay 
between nutrients, digestive enzymes and gut surface area. Motility, transport 
of intraluminal content, secretion of enzymes and fluids are regulated by 
hormonal, neural (enteric and central nervous system) and local regulatory 
mechanisms. Intraluminal nutrients by themselves have a major role in 
controlling gastrointestinal transport, digestion and absorption.  The presence 
of nutrients  in the small intestine stimulates pancreatic enzyme secretion, 
gallbladder contraction and converts intestinal motility from the fasted into a 
fed motility pattern (1). On the other hand, intestinal nutrients also trigger 
feedback inhibitory mechanisms that will modify gastrointestinal transport, 
digestion and absorption. For instance, duodenal nutrients inhibit gastric acid 
secretion and delay gastric emptying. This phenomenon is called the duodenal 
brake, a negative feedback loop from the proximal gut on gastric functions (1-
3).
A nutrient-triggered inhibitory feedback loop from the more distal to the 
proximal gut was first described by Spiller et al and Read et al (4,5). These 
two groups of researchers showed that transit of a meal through the small 
intestine was significantly delayed when a lipid emulsion was administered 
into the ileum. This  phenomenon is called the ileal brake. Since then, 
evidence has increased showing in both humans and animals that intraileal 
nutrients alter intestinal motility, reduce transit time, delay gastric emptying 
and inhibit gastric acid and exocrine pancreatic secretion (6-8,15-20,25-28). 
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One may conclude that non-absorbed nutrients reaching the distal small 
bowel bring the process of transport, secretion, digestion and absorption to an 
end.
1. Ileal brake and gastric emptying 
Earlier studies in both humans and dogs have demonstrated that infusion of 
nutrients into the ileum delays gastric emptying of  both solid and liquid 
meals (6,7). These findings have been further extended by Fone et al,  who 
showed that ileal fat inhibits antral and duodenal motility while stimulating 
pyloric contractions. Especially the latter may be responsible for the delayed 
gastric emptying (8). However, this is the only study  demonstrating an 
association between antropyloroduodenal motility changes and delayed 
gastric emptying induced by ileal nutrients in humans. Not only the distal 
stomach,  but also the proximal stomach contributes to gastric emptying. The 
motor function of the proximal stomach is characterised by receptive and 
adaptive relaxation (9,10). Receptive relaxation is induced by pharyngeal 
stimulation (swallowing) and distention of the eosophagus by the bolus of 
food. Adaptive relaxation or accommodation is the ability of the proximal 
stomach to distend in response to an intragastric load with only minimal 
changes in intragastric pressure (gastric tone) (11). A relationship between 
proximal gastric tone and gastric emptying has been described previously (12-
14).  Up till now it is not known whether nutrients in  the distal gut affect 
proximal gastric motor functions.  
2. Ileal brake and intestinal motility and transit  
The inhibitory effect of ileal nutrients on small intestinal transit has been 
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confirmed by several studies since the original publications of Spiller et al and 
Read et al (4,5,15,16). On the other hand, data on  the effect of ileal nutrients on 
digestive intestinal motility patterns are scarce and the various studies differ in 
methodology. Welch et al demonstrated the early occurrence of phase III after 
meal ingestion in 3 of 14 healthy subjects by infusion of lipid into the ileum 
(17). A study by Layer et al, using duodenal perfusion of a mixture of essential 
amino acids instead of a meal to induce a fed-like motor pattern, showed that 
ileal infusion of fat or carbohydrate induces premature phase III-like activity in 
12 of 14 healthy subjects (18). With respect to the effects of ileal nutrients on 
fasting motor patterns, results are contrasting. Ileal fatty acids in dogs prolong 
interdigestive cycles and inhibit jejunal motility (19) whereas in humans, ileal 
perfusion of carbohydrates or fat during interdigestive phase I markedly 
decreases the duration of phase II motor activity, induces premature phase III 
motility and shortens the length of the interdigestive cycle (20). Although 
contradictory, these results nonetheless suggest that fasting motor activities may 
be modulated by the presence of nutrients in the distal small intestine. However, 
further research is needed to exactly define the effect of ileal nutrients on 
intestinal motility patterns in humans.
3. Ileal brake and gastric acid and exocrine pancreatic secretion 
It is known that nutrients in the proximal small intestine, especially fat,  potently 
inhibit gastric acid secretion (21,22). However, there is also evidence suggesting 
that gastric acid secretory function is regulated by the distal intestine. For 
instance, colonic perfusion of lipids or protein decreases exogenously stimulated 
gastric acid secretion in humans and dogs (23, 24). In addition, ileal perfusion of 
lipids or carbohydrates inhibits both unstimulated and endogenously stimulated 
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gastric acid secretion in humans (25). The effects of ileal nutrients on the 
secretory function have been more extensively studied in humans and animals 
with respect to exocrine pancreatic secretion (26-28, 18, 20). However, the 
obtained results are contradictory. While in rats and cats, ileal fat decreases 
pancreatic enzyme secretion this is not the case in dogs (26-28). Layer et al 
showed in humans that ileal perfusion with either carbohydrates or triglycerides 
inhibits the secretion of all exocrine pancreatic enzymes to an equal extent (18). 
On the other hand, results presented by Jain et al indicate that ileal 
carbohydrates do not inhibit but increase the release of the pancreatic enzyme 
amylase when compared to trypsin (29). Thus, the question whether ileal 
nutrients inhibit exocrine pancreatic secretion still remains to be answered. 
4. Ileal brake and satiety 
Although the role of the stomach and intraduodenal nutrients in the regulation of 
food intake and satiety is well established (30-33), effects from the distal gut are 
poorly defined because of the limited number of studies on this subject up till 
now. There are two human studies, both by Welch et al, who have demonstrated 
that ileal nutrients significantly reduce the total amount of food intake (34, 35).  
In addition, one study in rats showed that while ileal infusion of glucose reduces 
both meal frequency and size, ileal free fatty acids reduce only the latter (36). 
Although scarce, these consistent data imply that activation of the ileal brake 
decreases food intake and may induce early satiety. However, further studies are 
necessary to prove this theory. 
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Triggers of the ileal brake 
The ileal brake is an intraluminal nutrient-triggered feedback control from the 
distal to the proximal gut. The inhibitory response of upper gastrointestinal 
motility differs with respect to the type of the nutrients administered into the 
ileum. In both humans and dogs, infusion of fat into the ileum delays gastric 
emptying and increases intestinal transit time (4-8; 37, 38). Within the range 
of different lipid emulsions, free fatty acids and digested triglycerides have 
been shown to be more potent than neutral triglycerides in eliciting the ileal 
brake effect (15). Intraileal carbohydrates, on the other hand, delay gastric 
emptying only at high concentrations (15). Data concerning intraileal proteins 
and the activation of the ileal brake are contradictory. Read at al found that 
ileal proteins delay small intestinal transit (5) whereas other investigators 
were not able to demonstrate any inhibitory effects of ileal proteins on 
gastrointestinal motility in humans (6, 15). These contrasting data may result 
from methodological differences. Nevertheless, it is generally accepted, based 
on consistent results from numerous studies, that fat is the most potent trigger 
of the ileal brake (39).  However, it is important to bear in mind that species 
differences exist concerning triggers for the ileal brake. For instance, free 
fatty acid, a potent trigger of the ileal brake in humans and dogs, has no effect 
on the pig (40).
Mediators of the ileal brake 
The mechanisms involved in the control of the ileal brake remain to be 
explored. The ileal brake may be mediated by hormonal and/or neural factors.  
Hormonal factors: A number of gut peptides, including glucagon-like 
peptide 1 (GLP-1), neurotensin and peptide YY (PYY) have been 
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hypothesized as possible humoral mediators of the ileal brake. Attention has 
been focused mainly on these peptides because of the localisation of their 
secretory cells, mainly in the distal gut. 
GLP-1 is synthesized within the endocrine L cells in the intestine, primarily 
in the ileum and colon (41, 42). The release of GLP-1 is stimulated by the 
direct contact of the L cells to luminal nutrients (25, 43). However, given the 
rapid release of GLP-1 after meal intake, there is also evidence suggesting 
that GLP-1 release results from an indirect neural or humoral signals arising 
from the proximal gut (44, 45). GLP-1 plasma levels have been shown to 
increase in parallel with the inhibitory effects of the ileal brake on antral 
motility, gastric acid and exocrine pancreatic secretion (18, 25). However, up 
to now, there are no studies using a specific GLP-1 antagonist to clearly 
define the role of endogenous GLP-1 as a hormonal mediator of the ileal 
brake.
Neurotensin is produced by the mucosal endocrine N cells which are 
distributed throughout the small intestine, with the highest concentration 
found in the ileum (46-48). There is only scarce, indirect evidence available 
suggesting the role of neurotensin as a hormonal mediator of the ileal brake. 
Spiller et al have shown that ileal fat perfusion inhibits jejunal motility and 
significantly increases plasma neurotensin concentrations (5, 15).
PYY is, like GLP-1, also synthesized and secreted by L cells in the distal 
ileum and colon (49). The presence of nutrients, especially fats, in the ileum 
stimulates PYY release (4-8, 15). In contrast to the poorly established role of 
GLP-1 and neurotensin as hormonal mediators of the ileal brake, associations 
between plasma PYY concentrations and delayed small intestinal transit and 
gastric emptying have been shown by numerous investigators (5, 15, 37, 38). 
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In addition, the role of endogenous PYY as a mediator of the ileal brake has 
been elucidated using a PYY antagonist. In dogs, administration of PYY 
antibodies abolishes the prolonged small intestinal transit induced by 
intraileal fat (38). Although similar studies in humans are lacking, this direct 
evidence nonetheless suggests that PYY is very likely the humoral mediator 
of the ileal brake.  
Neural factors: Several neural pathways have been suggested to contribute to 
the regulation of the ileal brake. The role of the extrinsic nervous system, in 
particular the vagus nerve, has been suggested but evidence is mostly indirect. 
It has been shown that intraileal fats increase vagal afferent activity in rats 
(50). In animals, the inhibitory effect of PYY and GLP-1 on meal stimulated 
gastric acid secretion and gastric motility was significantly reduced or even 
abolished after vagotomy (51, 52). These results suggest that both the 
candidate ileal brake hormones PYY and GLP-1 act through vagal 
innervation but a direct relationship between vagal cholinergic control and the 
fat induced ileal brake has not yet been proven. On the other hand, direct 
evidence exists demonstrating the involvement of the sympatho-adrenergic 
pathway in the inhibitory effect of the ileal brake. In dogs, administration of a 
combined �- and �-adrenergic blockade totally abolishes the inhibitory action 
of exogenous PYY en endogenous PYY release by ileal fat on exocrine 
pancreatic secretion (53). In addition, an adrenoceptor antagonist reverses the 
delayed intestinal transit induced by intraileal fat (54). Furthermore, evidence 
exists showing that the intrinsic nervous system (myenteric en submucosal 
plexus) also plays an important role the regulation of the ileal brake. The fat-
induced ileal brake in dogs is abolished when ondansetron, a 5-HT3-receptor 
antagonist was administered into the proximal but not the distal small bowel 
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(55). Similarly, the prolonged intestinal transit induced by fat in the ileum 
was blocked when naloxon, an opioid receptor antagonist was infused into the 
proximal small intestine (56). These findings suggest that both peripheral 
serotonergic and also opioid pathways are involved in the regulation of the 
ileal brake. However, it is plausible to assume that all the abovementioned 
different neural pathways interact and regulate the ileal brake.
Clinical implications of altered ileal brake function 
Theoretically, the feedback function of the ileal brake could be impaired due 
to mucosal defects as in Crohn’s ileitis and celiac disease or could be absent 
following resection of the distal small intestine. It is plausible to hypothesize 
that when the inhibitory feedback mechanism of the ileal brake is impaired or 
absent, gastric emptying and small intestinal transit are accelerated, resulting 
in increased concentrations of undigested and unabsorbed nutrients in the 
distal gut.  This in turn could contribute to the development of symptoms such 
as diarrhea and malabsorption seen in inflammatory bowel diseases and after 
small intestine resection.  
On the other hand, malabsorption and/or accelerated intestinal transit, 
irrespective of its cause, may also alter the ileal brake function. Given that 
PYY is a candidate hormonal mediator of the ileal brake, plasma PYY release 
could be considered as a marker for the activation of this feedback 
mechanism. Plasma PYY levels have been found to be increased in chronic 
pancreatitis and in patients with dumping syndrome after (partial) gastric 
resection (57-59). These findings suggest that the activation of the ileal brake 
is enhanced in these disease states due to the increased amount of unabsorbed 
nutrients reaching the distal small intestine. Based on the above made 
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assumptions, altered ileal brake function could be a primary defect, thereby 
giving rise to disease manifestations or secondary, in response to changes 
caused by the disease. 
AIMS AND OUTLINES OF THE THESIS 
Given its important role as a nutrient-triggered feedback control mechanism, 
increasing knowledge and understanding of the ileal brake is relevant for 
physiology and pathophysiology and may help to develop novel strategies in 
treating patients with malabsorption and maldigestion. The studies presented 
in this thesis have been designed to gain further insight into the physiology 
and pathophysiology of the ileal brake. The following issues were addressed:
Physiology of the ileal brake 
� It has been shown in dogs that the ileal brake is a more potent feedback 
mechanism compared to the more proximal, so called jejunal brake. 
However, a comparative study between jejunal and ileal brake has not been 
performed in humans. Chapter II was therefore designed to compare the 
effect of intraileal versus intrajejunal fat on digestive and interdigestive 
gastrointestinal motor patterns and postprandial gallbladder motility. The 
latter plays a role in delivering bile acids into the duodenum for the 
digestion of dietery fats. Furthermore, impaired gallbladder motility 
contributes to the pathogenesis of sludge and stone formation. Up til now 
little is known about the effect of the ileal brake on gallbladder motility. 
Gallbladder volumes were measured by real time ultrasonography and 
gastrointestinal motility was measured by means of the stationary water 
perfusion manometry system. 
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� The study in Chapter III was designed to investigate whether pancreatic 
and biliary secretion will be affected when nutrients are administered more 
distally into the small intestine than usual during enteral feeding. Duodenal 
outputs of pancreatic enzymes and bilirubin were measured by aspiration 
using a recovery marker in healthy volunteers.  
� It has been shown in recent years that the distal gut hormone PYY has an 
important role in satiety and eating behaviour. However, little is known 
about the effect of the ileal brake on satiety and proximal gastric motor 
function. Chapter IV was undertaken to compare the effects of ileal brake 
activation with ileal fat (endogenous PYY release) versus exogenous PYY3-
36 infusion on satiety and on proximal gastric motor function. Two 
experimental protocols were used. In the first protocol, the effect of ileal fat 
and subsequent endogenous PYY release was studied and in the second 
protocol, the dose-response relationship of exogenous PYY was 
investigated. In both protocols satiety and motor function of the proximal 
stomach were monitored using Visual Analog Scale (VAS) and an 
electronic barostat, respectively. Plasma PYY levels were measured by 
radioimmunoassay.  
� Medium chain triglycerides (MCT) are thought to be hydrolysed and 
absorbed more rapidly and completely compared to long chain triglycerides 
(LCT). However, patients receiving MCT frequently complain of nausea, 
cramps, abdominal pain and diarrhoea. We hypothesized that MCT are less 
rapidly absorbed and cause these gastrointestinal side effects. The release of 
the distal gut hormone PYY induced by intraduodenal MCT was used as 
evidence for the hypothesized malabsorption of MCT. Results are described 
in Chapter V. 
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� Chapter VI investigates whether artificially induced malabsorption in 
healthy volunteers affects gastrointestinal and gallbladder motility through 
activation of the ileal brake. The osmotic laxative magnesium sulphate was 
used to induce malabsorption after ingestion of a fatty meal. 
Pathophysiology of the ileal brake 
� Altered gastrointestinal motility has been observed in patients with chronic 
pancreatitis with impaired exocrine function. However, the reported results 
are conflicting. In Chapter VII we therefore investigated digestive and 
interdigestive antroduodenal motility and secretion of several relevant gut 
hormones in a large group of patients with chronic pancreatitis. Differences 
in gut motility and hormone secretion were compared between patients with 
and without exocrine pancreatic insufficiency. Gastrointestinal motility and 
hormone secretion were also studied after pancreatic enzyme 
supplementation in order to further elucidate the role of exocrine pancreatic 
insufficiency and subsequent maldigestion in patient with chronic 
pancreatitis
� Chapter VIII deals with patients with systemic sclerosis. This systemic 
disorder may give rise to various complications within the gastrointestinal 
tract. In this chapter we focused on antroduodenojejunal motility and 
proximal and distal gut hormone release in patients with diffuse and limited 
type of systemic sclerosis. The obtained data were related to esophageal 
manometry findings and gastrointestinal symptoms. 
� It is known that patients with Crohn’s disease have an increased risk of 
developing gallstones. When considering the possible mechanisms that 
contribute to gallstone formation in these patients the questions are: 1) 
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whether gallbladder motility plays a role in the pathogenesis of gallstone 
formation in Crohn's disease and 2) whether changes in gallbladder motility 
are explained by altered ileal brake function due to disease localization and 
bowel resection. These items have been investigated and results are 
described in chapter IX.
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formation in Crohn's disease and 2) whether changes in gallbladder motility 
are explained by altered ileal brake function due to disease localization and 
bowel resection. These items have been investigated and results are 
described in chapter IX.
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Chapter 2 
DOES THE INTESTINAL SITE OF FAT DELIVERY INFLUENCE 
FEEDBACK CONTROL ON GASTROINTESTINAL MOTILITY IN 
HUMANS ?
M.K. Vu, A. Dijkstra, I.C. Schut, I. Biemond, A.A.M. Masclee 





This study was performed to compare in healthy volunteers the effect of 
intrajejunal versus intraileal fat administration on gastrointestinal and 
gallbladder motility. Eight healthy volunteers (age 22±5 yr) participated in 
three experiments, performed in random order with: 1) intrajejunal fat 2) 
intraileal fat and 3) placebo after oral ingestion of a mixed liquid meal. 
Antroduodenojejunal motility, gallbladder volumes, and plasma 
cholecystokinin (CCK) and peptide YY (PYY) were measured. Results: 1) 
both intrajejunal and intraileal fat significantly (p<0.01) prolonged the 
duration of the fed motor pattern. The duration of the fed pattern correlated 
significantly with PYY but not with CCK secretion; 2) intrajejunal fat 
significantly (p<0.05) prolonged MMC cycle length while intraileal fat 
shortened MMC cycle length; 3) postprandial gallbladder emptying was 
significantly (p<0.01) reduced with intraileal fat and increased with 
intrajejunal fat. Conclusion: Feedback control mechanisms on gastrointestinal 
motility and hormone release, evoked by intestinal fat, are qualitatively and 
quantitatively dependent on the site of fat delivery (jejunum versus ileum). 
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INTRODUCTION
Feedback control mechanisms triggered by intraluminal nutrients have an 
important role in the proces of digestion and absorption. The responses evoked 
by intraluminal nutrients differ with respect to the intestinal site. For instance, fat 
administration in the duodenum stimulates exocrine pancreatic secretion, 
gallbladder contraction and intestinal transit (1-3) while administration of fat into 
the ileum inhibits exocrine pancreatic secretion and intestinal transit (4-6). The 
latter is called the “ileal brake”, a negative feedback loop from the distal to the 
proximal gut.  
In addition to the ileal brake, the existance of an inhibitory feedback control 
located in the proximal half of the small intestine, the so called “jejunal brake” 
has also been proposed (7-9). Intrajejunal nutrients inhibit exocrine pancreatic 
secretion and prolong intestinal transit in both humans and dogs (7-9). It has 
been shown in a study in dogs that intestinal transit is more potently inhibited by 
fat delivered in the distal than in the proximal small intestine, suggesting a more 
potent inhibitory feedback mechanism of the ileal brake compared to the jejunal 
brake (10). Although in humans both jejunal and ileal brake are operative, they 
have not been compared quantitatively.  
The present study was undertaken to compare in healthy volunteers the effects of 
intrajejunal versus intraileal fat administration on gastrointestinal and gallbladder 
motility. The latter plays a role in delivering bile acids into the duodenum for the 
digestion of dietery fats. It is generally accepted that the proximal gut peptide 
cholecystokinin (CCK) is the most potent hormonal stimulator of gallbladder 
contraction (11,12). In addition, there is also evidence for the involvement of the 
distal gut peptide PYY in the regulation of gallbladder emptying (13,14). 
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However, little is known about the effect of the ileal brake on gallbladder 
motility. In the present study, plasma levels of CCK and PYY were measured 
and related to gastrointestinal and gallbladder motility data.  
SUBJECTS
Eight healthy volunteers (2 male, 6 female; mean (±SEM) age 22±5 year; mean 
(±SEM) BMI 22±2) participated in this study. None of the subjects had gastro-
intestinal complaints or history of abdominal surgery. Informed consent was 
obtained from each person and the study protocol had been approved by the 
ethical committee of the Leiden University Medical Center. 
METHODS
Antroduodenojejunal manometry 
Antroduodenojejunal motility was recorded by stationary perfusion manometry 
using an ileal catheter (outer diameter 4 mm; length 350 cm) consisting of a 
central perfusion port, 12 side holes, a stainless steel tip weight and a distal 
inflatable balloon. The 12 side holes are divided in three clusters each consisting 
of four side hole openings spaced 2,5 cm apart (antrum) and 5 cm apart 
(duodenum/jejunum). The manometry catheter was connected to a low-
compliance pneumohydraulic perfusion system (Arndorfer Medical Systems) 
and perfused with distilled water at a rate of 0.3 ml/min. Resistance to infusion 
within the system was detected with pressure transducers (Medex, Hilliard, 
Ohio, USA). The output of the pressure transducers was translated in a 
polygraph (PC Polygraph, Metronics, Denmark) and displayed continuously on 
a monitor. Data were stored on a personal computer for analysis.  
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Gallbladder measurements
Gallbladder volumes were measured by real time ultrasonography (Toshiba, 
3.75 MHz transducer) and calculated by the sum of cylinders method using 
computerized system (15,16). In this method the longitudinal image of the 
gallbladder is divided into series of equal height, with diameter perpendicular 
to the longitudinal axis of the gallbladder image. The uncorrected volume is 
the sum of volumes of these separate cylinders. To correct for the 
displacement of the longitudinal image of the gallbladder from the central 
axis, a correction factor is calculated from the longitudinal and transversal 
scans of the gallbladder. Gallbladder volume is calculated by multiplication 
of the uncorrected volume with the square of the correction factor. The mean 
of two measurements was used for analysis. The assumptions and the 
mathematical formula used to calculate gallbladder volume have been 
described and validated previously 15,16). 
Study design 
Each subject participated in three experiments, performed in random order on 
three consecutive days in a single blind manner. The experiments started at 
7:45 AM.
Day 0: Catheter intubation
Subjects were intubated transnasally with the ileal catheter after an overnight 
fast. Once the tip of the catheter passed the ligament of Treitz, the distal 
balloon was inflated with 10 ml air to facilitate further progression of the tube 
through the small intestine. The progression of the tube was monitored by 
fluoroscopy. The tip of the catheter was located so that the most distal cluster 
of four side hole openings was in the jejunum, the second one was in the 
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duodenum and the most proximal cluster was situated in the antrum. The time 
required for the tube to reach the distal ileum varied between 10-24 hours. 
Correct position was verified by fluoroscopy on day 0 and at the start of day 
1, 2 and 3. Additionally, the correct position of the tube was fluoroscopically 
checked at the end of each experiment.
Day 1, day 2, day 3 and day 4: manometry measurements
Measurements were performed in random order with intrajejunal saline, 
intraileal saline, intrajejunal fat, or intraileal fat.  
After the correct position of the catheter was verified, an intravenous cannula 
was inserted into the antecubital vein of one arm for blood sampling. The 
spontanous occurrence of a phase III was defined as the start point for all the 
experiments. During measurements subjects were lying comfortably in a bed. 
At time 0 min (15 min after the occurrence of the spontanous phase III) the study 
was started with oral ingestion of 400 ml of a commercially available polymeric 
liquid meal (Nutrison; Nutricia Zoetermeer, The Netherlands) containing 16 g 
protein, 48 g carbohydrates and 12 g of saturated and unsaturated triglycerides 
(400 ml = 400 kcal; osmolality 260 mOsm). At the same time intrajejunal or 
intraileal infusion with fat emulsion (Intralipid 20%) or saline was started and 
continued for three hours at a rate of 1 ml/min (2 kcal/min). Intralipd 20% 
(Pharmacia & Upjohn BV, Woerden) consists of 20 g soybean-oil, 12 g 
partitionated egg-phospholipids and 22 g glycerol anhydrates per 100 ml.  
Gallbladder volume was measured and blood was sampled at regular intervals at 
: t=-15, 0, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, 300, 330, and 360 
min. Antroduodenojejunal motility was recorded for at least 6 hr after ingestion 
of the liquid meal. 
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duodenum and the most proximal cluster was situated in the antrum. The time 
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partitionated egg-phospholipids and 22 g glycerol anhydrates per 100 ml.  
Gallbladder volume was measured and blood was sampled at regular intervals at 
: t=-15, 0, 15, 30, 45, 60, 75, 90, 120, 150, 180, 210, 240, 270, 300, 330, and 360 
min. Antroduodenojejunal motility was recorded for at least 6 hr after ingestion 
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Hormone assays 
Plasma CCK was measured by a sensitive and specific radioimmunoassay. This 
antibody binds to all CCK peptides including sulfated CCK octapeptide, but not 
with gastrin. The detection limit of the assay is 0.1 pmol/l plasma. The intra-
assay variation ranges from 4.6 to 11.5% and the inter-assay variation from 11.3 
to 26.1% (17). Plasma PYY was measured by radioimmunoassay. PYY 
antiserum was generated in rabbits by intracutaneous injections of synthetic 
human PYY (BACHEM Biochemica GmbH, Switzerland). PYY was labelled 
with 125Iodine with chloramine T. The assay is highly specific. There is no cross-
reactivity with PP or VIP. The detection limit is 10 pmol/l. Both PYY (1-36) and 
PYY (3-36) bind to the antibody in dilutions up to 250000. 
Analysis of manometric data 
Motility patterns from antroduodenojejunal manometry were analyzed both 
visually and by computer. Pressure waves with an amplitude � 10 mmHg and 
duration � 1.5 sec were considered as true contractions. Artifacts due to 
increments in intra-abdominal pressure or any other reason were excluded from 
analysis.
The postprandial period was defined as the time interval between the end of the 
meal and the occurrence of the first small intestinal phase III propagated over at 
least two channels, independent of the intestinal site of onset. The motility 
indices (MI) of the postprandial period were calculated semi-automatically for 
antrum, duodenum and jejunum using the formula MI= Ln(�(mmHgxsec)/min).  
Phases of the MMC were defined as follows: phase I, no more than 1 
contractions per 5 min for at least 5 min and preceded by phase III; phase II: 
irregular contractile activity at a frequency of more than 2 per 10 min and 
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amplitude above 10 mmHg; phase III: regular contractile activity at a frequency 
of 10-12 contractions per min for at least 2 min. Phase III activity had to be 
propagated over at least 2 recording sites. Antral phase III activity was defined 
as rhythmic contractile activity at maximum frequency (3 contractions/min) for 
at least 1 min in temporal relationship with duodenal phase III activity (18). The 
duration of the MMC cycle was calculated as the interval between the beginning 
of phase III in the duodenum or jejunum until the beginning of the next phase III 
cycle.
Data and statistical analysis 
Results are expressed as mean ± SEM. Postprandial gallbladder contraction was 
calculated as percentage decrement over basal gallbladder volume. Integrated 
incremental values for plasma hormone secretion and postprandial gallbladder 
contraction were calculated as the area under the plasma concentration and 
percentage gallbladder contraction curve respectively after subtraction of the 
basal value. For all parameters, multiple analysis of variance (MANOVA) was 
used to test for statistical significance. When this indicated a probability of less 
than 0.05 for the null hypothesis, Student-Newman-Keuls analyses were 
performed to determine which values between or within subjects differ 
significantly. Coefficient of linear correlation (Spearman) was used to calculate 
correlations between motility parameters and integrated plasma hormone 
secretions. The significance level was set at p<0.05.
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After meal ingestion, fed motor patterns were observed in all experiments. 
However, the duration of the fed motility pattern was significantly (p<0.01) 
prolonged after intrajejunal fat (377±39 min) and intraileal fat administration 
(326±44 min) compared to control (238±17 min). No significant difference was 
found in the duration of the fed pattern between the intrajejunal and intraileal fat 
experiment.  
The postprandial duodenal and jejunal MI were significantly (p<0.05) decreased 
in both the intrajejunal and intraileal fat experiment compared to the control 
(Table 1). The reduction in MI was more pronounced during intraileal fat 
infusion. The difference in postprandial MI between intraileal and intrajejunal fat 
was significant (p<0.05) from 120-180 min in the duodenum and during the first 
two postprandial hours in the jejunum (Table 1). In contrast to intestinal MI, 
postprandial antral MI during intrajejunal and intraileal fat infusion did not differ 
between the two experiments and controls (Table 1).  
Interdigestive pattern 
After transition from a digestive into an interdigestive motility pattern 17 complete 
MMC cycles were observed in the control, six complete MMC cycles in the 
intrajejunal fat and seven complete MMC cycles in the intraileal fat experiment. 
Complete MMC cycles were found in all eight subjects in the control experiment 
but only in two subjects in the intrajejunal fat  and three subjects in the intraileal fat 
experiment. The duration of the MMC cycles was significantly (p<0.05) prolonged
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Table 1. Postprandial antral, duodenal and jejunal motility index (MI= 
Ln(�(mmHgxsec)/min) in 60 min periods and for the total fed period, after ingestion of a 
liquid meal in the intrajejunal fat, intraileal fat and control experiment. * p<0.05 
compared to controls; # p<0.05 compared to intrajejunal fat 
MI Control Intrajejunal fat Intraileal fat 
antrum 0-60 min 5.4±0.5 5.0±0.5 5.3±0.2 
antrum 60-120 min 5.3±0.4 5.1±0.4 5.4±0.2 
antrum 120-180 min 5.0±0.5 5.0±0.3 5.2±0.1 
total fed period 5.1±0.6 5.1±0.3 5.3±0.3 
    
duodenum 0-60 min 5.7±0.3 5.1±0.1 4.4±0.2 
duodenum 60-120 min 5.2±0.2 4.2±0.1* 4.0±0.3* 
duodenum 120-180 min 5.4±0.3 4.3±0.3* 3.9±0.2*# 
total fed period 5.5±0.3 4.8±0.3* 4.3±0.2* 
    
jejunum 0-60 min 5.4±0.2 5.1±0.3 3.8±0.1*# 
jejunum 60-120 min 5.2±0.3 4.3±0.4* 3.8±0.2*# 
jejunum 120-180 min 5.5±0.2 4.1±0.3* 3.9±0.2* 
total fed period 5.5±0.3 4.2±0.4* 3.9±0.2* 
in the intrajejunal fat compared to the control experiment. In contrast, the 
duration of the MMC cycle in the intraileal fat experiment was significantly 
(p<0.05) shorter compared to the control experiment (Table 2). The differences 
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in the intrajejunal fat compared to the control experiment. In contrast, the 
duration of the MMC cycle in the intraileal fat experiment was significantly 
(p<0.05) shorter compared to the control experiment (Table 2). The differences 
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in MMC cycle length between the experiments result from significant (p<0.05) 
differences in the duration of phase II (Table 2). 
Table 2. Characteristics of MMC cycles (mean�SEM; min) during the intrajejunal 
fat, intraileal fat and the control experiment. * p<0.05 compared to the control 







Cycle length 86�9 129±26* 58±4*# 
Phase I 16�2 18±3 16±5 
Phase II 65�10 107±25* 38±4*# 
Phase III 5�0.5 4±1 4±0.2 
Gallbladder volumes 
Basal gallbladder volumes were not significantly different between the saline 
(18.7±2.4 ml), the intrajeunal fat (18.2±2.4 ml) and the intrailela fat experiments 
(18.0�3.0 ml). After meal ingestion, gallbladder volumes significantly (p<0.01) 
decreased compared to basal volumes in the control and the fat experiments 
(Figure 1). Postprandial gallbladder volumes in the intrajejunal fat experiment 
were significantly (p<0.01) smaller compared to those in the intraileal fat 
experiment from 30 to 240 min and to those in the control experiment from 90 to 
240 min. Postprandial gallbladder volumes in the intraileal fat experiment were 
significantly (p<0.05) larger compared to control during the period from 30 to 60 
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min (Figure 1). Integrated gallbladder contraction during the 6 hour postprandial 
period was significantly (p<0.05) increased in the intrajejunal fat (20949±2395 
%*360 min) compared to the intraileal fat (12224±2943%*min) and the control 
experiment (12888±2559%*min). The difference in integrated gallbladder 
contraction during the 6 hour postprandial period was not significant between 
























Figure 1. Gallbladder emptying (%; mean±SEM) after meal ingestion during  
perfusion of intrajejunal fat (circles), intraileal fat (squares) and placebo (triangles).
Plasma CCK 
Basal plasma CCK levels were not significantly different between the saline, the  
intrajejunal and the intraileal fat experiment (0.7±0.1 pM, 0.9±0.2 pM and 
0.7±0.2 respectively; Figure 2). After meal ingestion, plasma CCK levels 
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intrajejunal and the intraileal fat experiment (0.7±0.1 pM, 0.9±0.2 pM and 
0.7±0.2 respectively; Figure 2). After meal ingestion, plasma CCK levels 
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significantly (p<0.01) increased over basal starting from 15 until 210 min in the 
control experiment and from 15 until 360 min in the intrajejunal and intraileal fat 
experiment. Postprandial peak increment in plasma CCK levels was significantly 
lower (p<0.05) in the intraileal fat experiment compared to the intrajejunal fat 
and the control experiment. Integrated plasma CCK secretion during the first 
three postprandial hours was significantly (p<0.01) higher in the intrajejunal fat 
experiment (599±61 pM*180 min) compared to the control (212±61 pM*180 
min) and the intraileal fat experiment (184±26 pM*180 min). Intergrated plasma 
CCK secretion during the 6 hour postprandial period was also significantly 
(p<0.001) higher in the intrajejunal experiment (949±96 pM*360 min) compared 
to the saline (234±134 pM*360 min) and the intraileal experiment (350±55 
pM*360 min). Intergrated plasma CCK secretion during the 6 hour postprandial 
period was not significantly different between the control and the intraileal fat 
experiment. 
Plasma PYY 
Basal plasma PYY levels were not significantly different between the control, 
the intrajejunal and the intraileal fat experiment (18.0±3.0 pM, 19.0±2.3 pM and 
18.4±1.8 respectively; Figure 3). Plasma PYY levels increased significantly 
(p<0.01) over basal from 15 min after meal ingestion until 210 min in the control 
experiment and from 15 min until 360 min in the intrajejunal and intraileal fat 
experiment (Figure 3). During the first postprandial hour, integrated plasma 
PYY secretion was significantly (p<0.05) higher in the intraileal fat experiment 
(715±110 pM*60 min) compared to the intrajejunal fat (189±57pM*60 min) and 
to the control experiment (217±54 pM*60 min). Integrated plasma PYY 
secretion during the 6 hour postprandial period was significantly (p<0.001) 
42
higher in the intraileal fat experiment (6182±1250 pM*360 min) and in the 
intrajejunal fat experiment (5452±439 pM*360 min) compared to control 
(868±216 pM*360 min). Integrated 360 min plasma PYY secretion between 






















Figure 2. Fasting and postprandial plasma CCK levels (pM; mean±SEM) during  
perfusion of intrajejunal fat (circles), intraileal fat (squares) and placebo (triangles).
Correlations
Gallbladder contraction and hormone secretion 
Intergrated postprandial gallbladder contraction significantly correlated with 
integrated plasma CCK secretions during the 6 hour postprandial period (r=0.62, 
p=0.03). In contrast, no correlation was found between postprandial gallbladder
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Figure 3. Fasting and postprandial plasma PYY levels (pM; mean±SEM) during  
perfusion intrajejunal fat (circles), intraileal fat (squares) and placebo (triangles).
contraction and integrated plasma PYY secretions during the postprandial period 
(r=0.08; p=0.7). 
Gastrointestinal motility and hormone secretion 
The duration of the fed pattern was significantly correlated with the integrated 
incremental plasma PYY secretion during the total postprandial period (r=0.58; 
p=0.005). No significant correlation was found between the duration of the fed 
pattern and the integrated postprandial CCK release (r=0.35; p=0.1). 
Antral MI was not significantly correlated with the integrated plasma CCK or 
PYY secretion. The duodenal MI strongly correlated with the integrated 
incremental plasma CCK secretion during the total postprandial period (r=0.85; 
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p<0.001) but it did not significantly correlate with the integrated plasma PYY 
secretion (r=0.41; p=0.13). In contrast, jejunal MI significantly correlated with 
the integrated incremental plasma PYY secretion during the total postprandial 
period (r=0.54; p=0.03) but did not correlate with the integrated plasma CCK 
secretion (r=0.43; p=0.10).
DISCUSSION
Results of the present study show that: 1) intrajejunal and intraileal 
administration of fat both prolong the duration of the fed pattern induced by an 
oral liquid meal. The duration of the fed pattern in the fat perfusion experiments 
correlates significantly with the integrated plasma PYY secretion but not with 
the integrated plasma CCK secretion; 2) intrajejunal fat prolongs the duration of 
the MMC length while MMC length was shortened in the intraileal fat 
experiment; 3) postprandial gallbladder emptying was significantly reduced in 
the intraileal compared to the intrajejunal fat experiment. Postprandial 
gallbladder emptying significantly correlates with postprandial plasma CCK but 
not with plasma PYY release.  
We have found in the present study that both continuous intrajejunal and 
intraileal administration of fat significantly prolonged the duration of the motility 
fed pattern induced by a liquid meal. The prolonged postprandial motility 
patterns are likely to result from delayed gastric emptying and increased small 
intestinal transit time induced by the intestinal feedback. Previous studies in 
humans have shown that intrajejunal and intraileal nutrients inhibit not only 
gastric emptying but also delay small intestinal transit time (4,5,7,8). Delayed 
gastric emptying and increased intestinal transit time result in longer intestinal 
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nutrient exposure time which may contribute to the prolonged duration of the 
digestive period. It is interesting to observe that the duration of the fed pattern 
correlated significantly only with postprandial plasma PYY but not with plasma 
CCK release. In humans, intraduodenal nutrients and subsequent CCK release 
play a central role in the transition from interdigestive to digestive motility 
pattern (19-21). On the other hand, mechanisms regulating the transition from 
digestive to interdigestive state are unclear. There is, however, evidence that the 
distal small bowel may be involved in the regulation of the late postprandial 
period and the transition to the interdigestive state (6,22-24). It has been shown 
by Keller et al (24) that the duration of the digestive motor pattern does not 
correlate with duodenal or jejunal nutrients but rather with the late postprandial 
increase in ileal nutrient concentration. Since peptide YY is released in the distal 
gut and represents ileal brake activation, our findings are in line with those of 
Keller et al (24).
It is apparent from the results that the postprandial duodenal and jejunal MI were 
reduced during intrajejunal and intraileal fat infusion while no significant 
changes were observed concerning antral MI. Furthermore the reduction in 
jejunal MI was more pronounced in the intraileal fat experiment. This finding is 
in line with those of Lin et al demonstrating that in dogs, fat induced ileal brake 
is more potent than the fat induced jejunal brake (10). Our results further show 
that duodenal MI correlated more with plasma CCK secretion than with plasma 
PYY secretion while jejunal MI correlated more with plasma PYY than with 
plasma CCK secretion. These findings suggest regional small intestinal 
heterogeneity in responsiveness to gut peptides. An earlier study in rats has 
shown that intravenous infusion of PYY had less effect on duodenal motility but 
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almost totally abolished the spiking activity in the jejunum (25). Furthermore, 
one study in humans has demonstrated that motor responses of the intestine to 
different gut peptides appear to vary regionally (26). Our results are, on the one 
hand, consistent with those found by Welch et al demonstrating that fat infusion 
into the ileum reduces the postprandial contractile activity of the jejunum (27). 
On the other hand, we also found a decrease in postprandial duodenal motility 
while in the study by Welch et al. duodenal motility was not affected. 
Differences in study design such as a shorter duration of intraileal fat infusion 
(20 min by Welch et al versus 180 min in the present study) may account for this 
difference in results. It is conceivable that the degree of activation of the ileal 
brake also determines the extent of the inhibitory action.  
Delayed gastric emptying induced by intrajejunal and intraileal fat has 
repeatedly been demonstrated. Although a reduced antral MI would be expected 
during ileal or jejunal fat perfusion, we did not observe differences in antral MI 
between the intrajejunal, intraileal fat and the control experiment. The reason 
underlying this finding is not obvious. However, delayed gastric emptying may 
result from factors other than impaired antral motor activity such as increased 
pyloric tone, disturbed antro-pyloro-duodenal coordination. In animals, 
activation of the ileal brake through infusion of PYY inhibits interdigestive but 
not postprandial antral motility (28,29). It has been shown in pigs that ileal fat 
infusion increases pyloric tone (30). In humans, the effect of the ileal brake on 
pyloric motility has not been studied .  
In contrast to the prolonged MMC cycle length induced by intrajejunal fat, 
intraileal intralipid significantly shortened MMC cycle length by reducing the 
duration of phase II. The mechanism underlying this difference is not apparent. 
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To date, we confirm the results of Layer et al reporting a shorter duration of the 
MMC cycle with shorter phase II during intraileal fat infusion (6). Moreover, 
similar changes in MMC cycle length have been observed in patients with 
malabsorption disorders with increased ileal fat delivery (31,32). These data 
consistently point to a shortened MMC cycle length during ileal brake activation.
The prolonged MMC cycle length induced by intrajejunal fat results from 
prolonged duration of phase II. This finding is difficult to explain. One 
possibility is that the plasma CCK levels that remained elevated after the 
transition from fed to a fasting motor pattern in the intrajejunal fat experiment, 
have contributed to the prolongation of phase II. This is plausible since CCK is 
known to induce fed like motor activity (20,21) and the irregular contractions 
observed during phase II resemble the fed intestinal motor pattern. This concept 
is in line with the results found by Defilippi et al showing that in dogs, MMC 
cycle length was prolonged with an increased duration of phase II during 
intraduodenal infusion of nutrients of low caloric load (33). The study by 
Defilippi et al also demonstrated that the number of MMC cycles further 
decreased and was completely suppressed when higher caloric loads were 
administered in the duodenum. Although plasma CCK levels were not measured 
in that study, the stepwise increasing inhibitory effect on the MMC cycle 
induced by intraduodenal caloric loads may well have been mediated by CCK. It 
is well known that the number of CCK producing cells is highest in the 
duodenum (34). 
Ingestion of a liquid meal significantly decreased gallbladder volumes which 
gradually returned to basal at the end of the postprandial period. Fat in the 
jejunum significantly increased postprandial gallbladder emptying compared to 
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the intraileal fat experiment and to control especially in the early postprandial 
period. A similar pattern was observed for the proximal gut hormone CCK. 
Since gallbladder contraction is merely dependent on CCK secretion (11,12) 
these results indicate that increased postprandial gallbladder emptying results 
from increased plasma CCK release. Indeed, postprandial gallbladder emptying 
strongly correlated with postprandial plasma CCK levels. Moreover, the 
significantly higher plasma CCK levels during intrajejunal fat infusion indicate 
that CCK is not only released in the duodenum but also in the more distal small 
intestine.
No significant correlations were found between gallbladder emptying and PYY 
secretion neither in the early nor in the late postprandial period. This finding is in 
line with previous studies in humans and dogs showing that PYY did not inhibit 
gallbladder contraction stimulated by exogenous or endogenous CCK (13, 35). 
However, it is worth noticing the delayed peak plasma PYY level obtained in the 
intrajejunal intralipid experiment compared to the intraileal experiment. This 
time-related difference reflects the time needed for intralipid to reach the ileum 
and stimulate PYY release.  
In conclusion, the data obtained in the present study demonstrate that intestinal 
feedback control mechanisms evoked by the fat induced ileal brake on proximal 
small intestine, postprandial gallbladder motility and hormone release differ 
qualitatively and quantitatively from those evoked by the fat induced jejunal 
brake.
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Does jejunal feeding activate exocrine
pancreatic secretion?
M. K. Vu, P. P. J. van der Veek, M. Frölich, J. H. M. Souverijn, I. Biemond, C. B. H. W. Lamers
and A. A. M. Masclee
Leiden University Medical Center, Leiden, the Netherlands
Abstract Background The upper small bowel is of pivotal importance for the stimulation of exocrine
pancreatic secretion in response to a meal. We hypothesize that more distal delivery of
nutrients into the small intestine will result in less activation of pancreatic secretion.
Materials and methods Eight healthy subjects (3male, 5 female; age 23 � 1 years)
participated in two experiments, performed in random order. Subjects were intubated
with a 4-lumen tube. Duodenal outputs of pancreatic enzymes and bilirubin were measured
by aspiration using a recovery marker. The distal opening was used for continuous
administration of a mixed liquid meal and located at either the ligament of Treitz or
60 cm further distally. Gallbladder volume was measured and blood samples were drawn for
determination of gastrointestinal hormones. The duration of each experiment was 4 h; with
1 h fasting and 3 h continuous administration of nutrients.
Results During proximal jejunal feeding, pancreatic enzyme output increased significantly
over basal levels. No significant increase over basal levels was observed during distal jejunal
feeding. Bilirubin output and gallbladder contraction were significantly (P <0·05) reduced
during distal compared to proximal jejunal feeding. No significant differences were found in
plasma levels of CCK, PYYand neurotensin between proximal and distal jejunal feeding.
Conclusion Continuous feeding in the distal jejunum does not stimulate exocrine pancrea-
tic secretion but maintains gallbladder contraction, although to a lesser extent. These effects
are not related to hormonal changes but probably reduced activation of the enteropancreatic
reflexes.
Keywords Cholecystokinin, exocrine pancreatic secretion, gallbladder contraction, jejunal
feeding, neurotensin, pancreatic polypeptide, peptide YY.
Eur J Clin Invest 1999; 29 (12): 1053–1059
Introduction
Within the last decade enteral nutrition has been accepted
as an alternative for the parenteral route in the nutritional
support of patients with gastrointestinal disorders.
Recently, several studies have yielded promising results
concerning the clinical benefits of early enteral nutrition
in patients with acute pancreatitis [1–3]. However, in
parallel with preserving the integrity of the gut, intralumi-
nal nutrients stimulate exocrine pancreatic secretion,
which may negatively influence the course of pancreatitis.
Concerning the physiology of pancreatic secretion the
intestinal phase of digestion accounts for the majority of the
postprandial exocrine pancreatic secretory output. It is well
established that the duodenum is the most important site of
stimulation where the two classical pancreatic stimulatory
hormones, CCK and secretin, are released and entero-
pancreatic reflexes are situated [4–6]. Not only the proxi-
mal but also the distal gut may participate in the regulation
of exocrine pancreatic secretion. Several studies in both
humans and animals have shown that infusion of nutrients
into the distal ileum or colon inhibits exocrine pancreatic
enzyme output [7,8].
Little is known about the influence of the site of nutrient
delivery on pancreatic secretion. Such information is of
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physiological relevance for further clinical studies on site-
specific nutrient delivery of enteral nutrition. We hypothe-
size that the more distally nutrients are delivered into the
jejunum, bypassing the duodenum, the less activation of the
exocrine pancreatic secretion will be found. This study was
therefore performed to compare, in healthy volunteers, the
effect of a commercially available nutrient solution on exo-
crine pancreatic secretion, gallbladder contraction and sub-
sequent release of proximal and distal gut hormones when
administered either in the proximal or in the distal jejunum.
Subjects and methods
Subjects
Eight healthy subjects (3 male, 5 female; age 23 � 1 years)
without a history of gastrointestinal symptoms or abdominal
surgery participated in this study. None of them were taking
any medication. Informed consent was obtained from each
individual and the protocol had been approved by the ethics
committee of the Leiden University Medical Center.
Study design
Each subject participated in two experiments, performed in
random order on separate days with an interval of at least
one week. The experiments started at 07.45 h. After an
overnight fast, subjects were intubated transnasally with a
polyvinyl 4-lumen tube consisting of two perfusion and two
aspiration ports. One perfusion port was located at the
papilla of Vater for continuous perfusion of the nonabsorb-
able marker polyethyleneglycol (PEG 4000; 15mgmL¹1).
The second perfusion port was for continuous administra-
tion of a liquid meal (Nutrison standard, Nutricia, the
Netherlands) containing 4 g emulsified fat, 12 g carbohy-
drate and 4 g protein per 100mL (1kcalmL¹1) at a rate of
100mLhour¹1. This perfusion port was either located just
proximal to the ligament of Treitz or 60 cm further distally.
Aspiration ports were located in the antrum and in the
duodenum, 15 cm distal to the papilla of Vater. After the
correct position of the tube was checked under fluoroscopy,
a cannula was inserted into the antecubital vein of one arm
for blood sampling. The PEG infusion was then started
(t ¼ –60min) and continued until the end of the experi-
ment (t ¼ 180min) at a rate of 3mLmin¹1. At t ¼ 0min,
either proximal or distal intrajejunal infusion of Nutrison
was started at a rate of 100mLh¹1 and continued until the
end of the experiment (t ¼ 180min). Gastric contents were
aspirated continuously. Duodenal contents were aspirated
in 15min portions under basal and stimulated conditions
for determination of trypsin, lipase, amylase, bilirubin and
PEG concentration.
Assays of duodenal contents
Duodenal samples were collected in ice-chilled tubes
during the experiment. Enzymatic activity of amylase and
lipase was determined as described previously [9,10].
Enzymatic activity of trypsin was determined according
to Hummel [11]. Concentrations of PEG in the aspirated
samples were determined turbidimetrically by a modified
method of Hydén [12] and were used to calculate the
outputs of amylase, trypsin, lipase and bilirubin.
Measurements of gallbladder volumes
Gallbladder volumesmeasured by real time ultrasonography
(Toshiba, 3·75MHz transducer) were calculated by the sum
of cylinders method using a computerized system [13,14].
In this method the longitudinal image of the gallbladder is
divided into series of equal height, with diameter perpendi-
cular to the longitudinal axis of the gallbladder image. The
uncorrected volume is the sum of volumes of these separate
cylinders. To correct for the displacement of the longitudinal
image of the gallbladder from the central axis, a correction
factor is calculated from the longitudinal and transversal
scans of the gallbladder. Gallbladder volume is calculated by
multiplication of the uncorrected volume with the square of
the correction factor. The mean of two measurements was
used for analysis. The assumptions and the mathematical
formula used to calculate gallbladder volume have been
described and validated previously [13,14].
Hormone assays
Blood samples for measurement of plasma pancreatic
polypeptide (PP), cholecystokinin (CCK) and peptide
YY (PYY) were drawn at t ¼ ¹15,0, 15,30, 45, 60,
90, 120, 150 and 180min during each experiment. The
blood samples were collected in EDTA containing ice-
chilled tubes. The samples were centrifuged at a rate of
3000 r.p.m. for 10min at a temperature of 4 �C. Plasma
CCK was measured by a sensitive and specific
radioimmunoassay [15]. This antibody binds to all CCK
peptides including sulfated CCK octapeptide, but not
gastrin. The detection limit of the assay is 0·1 pM
plasma. Plasma PYY was measured by radioimmunoassay.
PYYantiserum was generated in rabbits by intracutaneous
injections of synthetic human PYY (BACHEM AG,
Bubendorf, Switzerland). PYY was labelled with
125Iodine using chloramine T. There is no cross-reactivity
with PP or VIP. The detection limit is 10 pM plasma. Both
PYY [1–36] and PYY [3–36] bind to the antibody in
dilutions up to 25 000. Plasma neurotensin was measured
by a specific radioimmunoassay with a sensitivity of
4 pmolL¹1 of plasma. Neurotensin antiserum was gener-
ated in rabbits by multiple intradermal injections of syn-
thetic human neurotensin (BACHEM AG, Bubendorf,
Switzerland). Neurotensin was labelled by a modification
of the convention chloramine T. The antiserum was direc-
ted towards the amino terminal region of neurotensin.
Plasma PP was determined by radioimmunoassay as
described previously [16].
� 1999 Blackwell Science Ltd, European Journal of Clinical Investigation, 29, 1053–1059
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Statistical analysis
Basal and stimulated outputs of amylase, lipase, trypsin
and bilirubin were calculated in a 60-min period by sum-
ming up outputs of 15-min periods. Fasting gallbladder
volumes were expressed in mL. Gallbladder emptying was
calculated as percentage of fasting gallbladder volume.
Integrated incremental values for plasma hormone secre-
tion were calculated as the area under the plasma concen-
tration curve after subtraction of the basal value at time
t ¼ 0. For all parameters, multiple analysis of variance
(MANOVA) was used to test for statistical significance.
When this indicates a probability of less than 0·05 for the
null hypothesis, Newman–Keuls student t-test analyses
were performed to determine which values, between or
within subjects, differ significantly. The significant level
was set at P <0·05.
Results
Pancreatico-biliary secretion
Basal outputs of pancreatic enzymes and bilirubin were not
significantly different between the two experiments
(Table 1). Outputs of lipase and trypsin increased signifi-
cantly (P <0·01) and remained increased over basal during
3 h continuous proximal feeding, while no significant
increases over basal values were found when nutrients
were administered in the distal jejunum. Lipase and trypsin
outputs during proximal feeding were significantly (P <
0·01) higher compared to those during distal feeding
(Fig. 1). Outputs of amylase increased significantly
(P <0·05) over basal during continuous feeding in the
proximal jejunum but not during distal jejunal feeding,
and were significantly higher in the second and the third
hour of nutrition compared to the distal experiment.
Bilirubin outputs increased significantly (P <0·05) over
basal during proximal jejunal feeding. Nutrients in the
distal jejunum induced a significant rise (P <0·05) of
bilirubin output over basal level during the first hour of
nutrition. No significant increases were found during the
second and the third hour of nutrition (Fig. 1).
Gallbladder volumes
Basal gallbladder volumes were not significantly different
between the two experiments (18·4 � 2·3mL in the prox-
imal experiment vs. 18·4 � 1·9mL in the distal experi-
ment). Continuous enteral feeding either in the proximal
or distal jejunum induced a significant (P <0·01) reduction
in gallbladder volumes starting at 15min until the end of
the experiment at 180min. Gallbladder contraction from
90min until 180min was significantly (P <0·01) reduced
during distal feeding compared to proximal feeding
(Fig. 2). This finding is in agreement with the reduced
bilirubin output found with distal vs. proximal nutrient
administration.
Plasma PP
Basal plasma PP concentrations were not significantly
different between proximal feeding (21 � 4pM) and
distal feeding (20 � 2pM) (Fig. 3a). Proximal feeding
induced a significant (P <0·05) rise in plasma PP levels
throughout the 3 h stimulated period, while nutrients in the
distal jejunum induced a significant (P < 0·05) rise of
plasma PP over basal only in the last 90min of the
stimulated period. The integrated incremental PP secre-
tion during proximal feeding (3944 � 806pM × 180min)
was significantly (P < 0·05) higher compared to that during
distal feeding (2427 � 755pM × 180min).
Plasma CCK
Basal plasma CCK concentrations were not significantly
different between the proximal (0·2 � 0pM) and the distal
experiment (0·1 � 0pM). Both proximal and distal enteral
Table 1 Basal and stimulated pancreatic enzyme and bilirubin secretion during the first, second and third
hour of proximal and distal jejunal feeding in 8 healthy volunteers
Basal 1 h 2 h 3h
Proximal infusion
Lipase (kUh¹1) 130� 30 261� 50*† 270� 32*† 274� 30*†
Trypsin (Uh¹1) 65 � 18 272� 38*† 322� 44*† 267� 35*†
Amylase (kUh¹1) 17 � 5 34 � 5* 42 � 5*† 38 � 7*†
Bilirubin (mmolh¹1) 13 � 3 86 � 23* 48 � 8* 37 � 9*
Distal infusion
Lipase (kUh¹1) 93 � 31 110� 31 77 � 24 78 � 34
Trypsin (Uh¹1) 93 � 28 142� 31 108� 30 99 � 37
Amylase (kUh¹1) 20 � 5 26 � 6 24 � 6 26 � 6
Bilirubin (mmolh¹1) 16 � 2 60 � 18* 28 � 6 21 � 3
*P <0·05 compared to basal; †P <0·05 compared to distal infusion.
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feeding induced a significant (P < 0·05) rise in plasma CCK
levels throughout the 3 h stimulated period with a peak at
t ¼ 15min (Fig. 3b). The integrated incremental CCK
release during proximal feeding (154 � 35 pM × 180min)
was not significantly different from that when nutrients
were infused distally (185 � 88 pM × 180min).
Plasma PYY
Basal plasma PYY concentrations were not signifi-
cantly different between proximal (20 � 1 pM) and distal
feeding (21 � 1pM). Neither proximal nor distal feeding
significantly increased plasma PYY over basal levels
(Fig. 4a).
Plasma neurotensin
Basal plasma neurotensin concentrations were not signi-
ficantly different between the proximal experiment
(15 � 1 pM) and the distal experiment (15 � 1pM). Neither
proximal nor distal jejunal feeding significantly increased
plasma neurotensin over basal levels (Fig. 4b).
Discussion
We have demonstrated in the present study that continuous
administration of a mixed liquid meal in the distal jejunum
did not stimulate pancreatic enzyme secretion. Gallbladder
contraction, on the other hand, was induced by distal
� 1999 Blackwell Science Ltd, European Journal of Clinical Investigation, 29, 1053–1059
Figure 1 Basal and stimulated lipase (a), trypsin (b), amylase (c) and bilirubin (d) outputs in the first, second and third hour during
continuous proximal (open bars) and distal (shaded bars) jejunal feeding in 8 healthy subjects. *P <0·01 compared to basal and
†P <0·05 compared to distal jejunal feeding.
Figure 2 Percentage of gallbladder emptying during continuous
proximal (squares) and distal jejunal feeding (triangles) in 8
healthy subjects. *P <0·05 proximal vs. distal jejunal feeding.
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jejunal nutrients, though to a lesser extent compared to
when nutrients were given in the proximal jejunum.
Within the last decade there is growing interest for
enteral feeding as a route for nutritional support in patients
with various gastrointestinal disorders. The clinical benefits
of enteral feeding have been demonstrated, for instance, in
acute pancreatitis [1–3]. Recent studies suggested that
early enteral feeding is effective in severe acute pancreatitis
to prevent infections and other complications [1–3]. It is
questioned whether delivery of nutrients more distally into
the small intestine is more in line with the concept of ‘the
pancreas at rest’. Results on the effect of jejunal feeding on
basal exocrine pancreatic secretion are contradictory. In
dogs, jejunal infusion of elemental nutrients did not stimu-
late exocrine pancreatic secretion in one study while a
significant increase in exocrine pancreatic output was
found in another study [17,18]. Vidon et al. have shown
that intrajejunal infusion of nutrients stimulates pancreatic
secretion in healthy volunteers [19]. This finding was not
supported by another study which showed that exocrine
pancreatic secretion during jejunal infusion was not sig-
nificantly different from fasting [20]. An explanation for
these contrasting results is not readily available. Differences
in study results may be related to the type of nutrients and
the length of jejunum exposed to nutrients.
In contrast to proximal jejunal feeding, a significant rise
in pancreatic enzyme output over basal level was not
observed during distal jejunal feeding. Several mechanisms
may be involved such as [1]: a decreased release of stimu-
latory hormones [2]; reduced activation enteropancreatic
reflexes as a result of distal administration of nutrients [3];
and activation of an inhibitory feedback from the distal
small intestine. The proximal gut hormone CCK is gen-
erally accepted as a major hormonal regulator during the
intestinal phase of postprandial pancreatic secretion in man
[4,21]. CCK receptor antagonists reduce meal-stimulated
pancreatic enzyme response by over 60% [21]. The present
results show that plasma CCK levels during distal infusion
of nutrients were not significantly different compared to
those during proximal infusion of nutrients. These findings
exclude a role for CCK in the impaired activation of
exocrine pancreatic secretion during distal nutrient admin-
istration. PYY and neurotensin are distal gut hormones
[22,23]. PYY is considered one of the most potent hormo-
nal mediators of the so-called ‘ileal brake’, a negative
feedback loop from the distal to the proximal digestive
tract [7,8,24]. Studies in both humans and animals have
demonstrated that exogenous as well as endogenous PYY
inhibits exocrine pancreatic secretion [25,26]. Based on the
observations that large meals and intraileal infusion of
Figure 3 Continuous enteral nutrition: plasma PP levels during
continuous proximal (squares) and distal jejunal feeding (triangles)
in 8 healthy subjects (a); plasma CCK levels during continuous
proximal (squares) and distal jejunal feeding (triangles) in 8
healthy subjects (b).
Figure 4 Continuous enteral nutrition: plasma PYY levels
during continuous proximal (squares) and distal jejunal feeding
(triangles) in 8 healthy subjects (a); plasma neurotensin levels
during continuous proximal (squares) and distal jejunal feeding
(triangles) in 8 healthy subjects (b).
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nutrients activate PYY release, we hypothesized that com-
pared to proximal nutrients delivery, more distal delivery
would result in higher plasma PYY levels and in turn
inhibit exocrine pancreatic secretion. However, results of
plasma PYY levels during proximal and distal jejunal
infusion of nutrients did not support this hypothesis. The
presence of emulsified triglycerides in the test meal and the
continuous administration of nutrients may explain why
the ileal brake was not activated. Emulsified fats are more
easily dispersed and more readily and completely absorbed.
As a result, even during distal jejunal nutrient delivery the
amount of undigested nutrients reaching the ileum is
probably too small to activate distal gut hormone release.
This concept was further substantiated by the finding that
plasma neurotensin levels did not significantly increase
during distal jejunal infusion of nutrients. Neurotensin is
released in response to a fat rich meal and is found in
highest concentrations in the ileal mucosa [23]. The physio-
logical role of neurotensin in the regulation of pancreatic
secretion is not yet fully established. Exogenous neuroten-
sin stimulates pancreatic secretion in man [27] but there is
also evidence suggesting an inhibitory effect of neurotensin
on secretin and cerulein stimulated pancreatic secretion
[28]. Plasma neurotensin remained at basal levels during
proximal infusion of nutrients when pancreatic enzyme
secretion was significantly increased. These observations
are in agreement with earlier study demonstrating that
intraduodenal infusion of a mixed meal at a rate of
1kcalmin¹1 did not stimulate neurotensin release [29].
Although hormonal pathways have long been considered
the predominant mechanism controlling pancreatic secre-
tion, different studies have provided evidence that pancrea-
tic response to intestinal stimulants is to a large extent
mediated by cholinergic enteropancreatic reflexes [6,30].
When nutrients are given more distally into the small
intestine, duodenal induced neurally mediated exocrine
pancreatic responses will not be evoked. This may explain
the absence for activation of pancreatic enzyme output
during distal jejunal nutrient infusion. The reduced secre-
tion of plasma PP, a pancreatic hormone under vagal
control further supports this idea. In dogs, selective
removal of the duodenum or infusion of nutrients into
the distal small intestine decreased postprandial PP release
[31].
In contrast to pancreatic enzyme output, nutrients in the
distal jejunum induced a significant gallbladder contrac-
tion. Gallbladder emptying during the last 2 h of distal
feeding was significantly decreased compared to proximal
feeding. This finding is in line with intraduodenal bilirubin
output during distal feeding. It is not obvious which
mechanism(s) are responsible for the differences in empty-
ing response between proximal and distal feeding. The fact
that gallbladder volumes differed only during the last
90min of nutrient infusion does not favour a neurally
mediated pathway, which is responsible for the initial
phase of gallbladder emptying. With regard to a hormon-
ally mediated pathway there are several factors that
should be taken into consideration. First, plasma levels of
CCK, the major stimulator of postprandial gallbladder
contraction, were not significantly different between prox-
imal and distal nutrients. Second, plasma levels of PP,
which enhance gallbladder relaxation, were even lower
during distal jejunal infusion of nutrients [32]. Thus,
differences in gallbladder volumes between proximal and
distal feeding can not be explained based on plasma levels
of CCK and PP. With respect to the two distal gut
hormones PYY and neurotensin, the slightly, although
not significantly, higher plasma levels of PYY and neuro-
tensin may contribute to the larger gallbladder volumes
during distal jejunal feeding. It has been shown previously
that infusion of PYY induces gallbladder relaxation after
CCK stimulated gallbladder contraction [33].
The findings from the present study on site specific
activation of exocrine pancreatic secretion put forward a
concept of ‘a pancreas at rest’ that may be relevant in
certain clinical conditions. Further clinical evaluation in
acute pancreatitis may be hampered by the presence of
paralytic ileum that may impede positioning of a feeding
tube in the distal jejunum.
In summary, we have shown that a standard mixed liquid
meal when administered into the distal jejunum does not
activate exocrine pancreatic secretion. This finding is not
because of changes in hormonal responses but probably as
a result of reduced activation of the enteropancreatic
reflexes. On the other hand, gallbladder contraction was
maintained, although to a lesser extent during distal jejunal
feeding. Thus, distal jejunal delivery of nutrients does not
activate exocrine pancreatic secretion while gallbladder
motility is preserved.
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Recent studies indicate that peptide YY (PYY) influences satiety, but the role 
of PYY as a physiological regulator of satiety is under debate. This study was 
designed to compare the effects of ileal brake activation through ileal fat 
perfusion (endogenous PYY) versus exogenous PYY infusion on satiety and 
proximal gastric motor function. Two protocols were performed in both 
fasting and postprandial states. Protocol 1: ileal fat perfusion versus saline 
(control). Protocol 2: intravenous PYY3-36 infusion at low and high doses of 
15 and 30 pM/kg/hr vs. placebo. Plasma PYY (RIA), satiety scores and 
proximal gastric motility (barostat) were measured. Results: Ileal fat 
significantly (p<0.05) increased plasma PYY from 15 ± 1 to 26 ± 2 pM. 
During PYY infusion plasma levels of 28 ± 3 pM (low dose) and 55 ± 10 pM 
(high dose) were reached. Both in the fasting and postprandial state ileal fat 
induced satiety (p<0.05) in contrast to PYY3-36. Fasting gastric volume 
(barostat) increased significantly (p<0.01) in response to ileal fat (from 150 ± 
14 ml to 433 ± 54 ml) but not in response to PYY3-36 infusion. In all 
experiments meal ingestion resulted in identical increments in proximal 
gastric volume. Only ileal fat, not PYY3-36 significantly (p�0.01) enhanced 
postprandial gastric relaxation. Conclusions: Ileal fat induces satiety and 
results in proximal gastric relaxation, in contrast to exogenous PYY3-36 at 
identical plasma levels. These data do not support a role for PYY as a 
physiological mediator in ileal brake induced satiety or ileal brake induced 
proximal gastric relaxation. 
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ABSTRACT 
Recent studies indicate that peptide YY (PYY) influences satiety, but the role 
of PYY as a physiological regulator of satiety is under debate. This study was 
designed to compare the effects of ileal brake activation through ileal fat 
perfusion (endogenous PYY) versus exogenous PYY infusion on satiety and 
proximal gastric motor function. Two protocols were performed in both 
fasting and postprandial states. Protocol 1: ileal fat perfusion versus saline 
(control). Protocol 2: intravenous PYY3-36 infusion at low and high doses of 
15 and 30 pM/kg/hr vs. placebo. Plasma PYY (RIA), satiety scores and 
proximal gastric motility (barostat) were measured. Results: Ileal fat 
significantly (p<0.05) increased plasma PYY from 15 ± 1 to 26 ± 2 pM. 
During PYY infusion plasma levels of 28 ± 3 pM (low dose) and 55 ± 10 pM 
(high dose) were reached. Both in the fasting and postprandial state ileal fat 
induced satiety (p<0.05) in contrast to PYY3-36. Fasting gastric volume 
(barostat) increased significantly (p<0.01) in response to ileal fat (from 150 ± 
14 ml to 433 ± 54 ml) but not in response to PYY3-36 infusion. In all 
experiments meal ingestion resulted in identical increments in proximal 
gastric volume. Only ileal fat, not PYY3-36 significantly (p�0.01) enhanced 
postprandial gastric relaxation. Conclusions: Ileal fat induces satiety and 
results in proximal gastric relaxation, in contrast to exogenous PYY3-36 at 
identical plasma levels. These data do not support a role for PYY as a 
physiological mediator in ileal brake induced satiety or ileal brake induced 
proximal gastric relaxation. 
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INTRODUCTION
Feelings of hunger and satiety are associated with gastrointestinal signals. 
Stimulation of gastric mechanoreceptors through balloon distension results in 
relaxation of the proximal stomach and is associated with feelings of fullness 
and a reduction in hunger and wish to eat (1-3). After meal ingestion the 
proximal stomach is able to accommodate a large volume meal. In patients 
with early satiety type dyspepsia the accommodation response of the proximal 
stomach is impaired (4). Not only mechanical but also chemical stimulation 
results in gastric relaxation and induces satiety. For instance, duodenal fat 
induces relaxation of the proximal stomach and results in feelings of fullness 
and satiation (5). 
In the last decade evidence has become available indicating that not only the 
proximal gut but also the distal gut participates in the regulation of 
gastrointestinal motor and sensory functions and satiety. Perfusion of the 
ileum with nutrients delays gastric emptying, prolongs small intestinal transit 
time and inhibits pancreatico biliary secretion (6-8). This phenomenon, called 
the “ileal brake”, is a negative feedback loop from the distal to the proximal 
gut. There is evidence suggesting that the ileal brake is mediated through 
hormonal factors. Peptide YY (PYY) is considered an important mediator of 
the ileal brake (6,9). This 36-amino acid peptide first isolated from pig 
intestine, is localized in the endocrine cells of the ileal, colonic and rectal 
mucosa (10,11). The number of PYY secretory cells increases going more 
distally in the gut (11). PYY is released into the circulation in response to 
meals. The postprandial increase in plasma PYY levels is proportional to 
meal size with a peak response about an hour after food ingestion (11). In 
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both animals and humans intravenous infusion of PYY delays gastric 
emptying and inhibits pancreatico biliary secretion (12,13). Recently evidence 
has become available suggesting that PYY has an important role in satiety 
and eating behaviour. Batterham et al demonstrated that PYY3-36, when 
infused intravenously reduced food intake in both humans and rodents 
(14,15). More recently Degen et al also found that intravenous infusion of 
PYY3-36 reduced food intake but only at supraphysiological plasma PYY 
levels (16). The physiological role of PYY in the regulation of satiety 
therefore remains to be defined. Furthermore, up till now, little is known 
about the effect of ileal brake activation and PYY release on proximal gastric 
motor function
The present study was therefore performed to compare the effects of ileal 
brake activation with ileal fat (endogenous PYY release) versus exogenous 
PYY3-36 infusion on satiety and on proximal gastric motor function. We 
therefore used two experimental protocols. In the first protocol we studied the 
effect of ileal fat and subsequent endogenous PYY release and in the second 
protocol we investigated the dose-response relationship of exogenous PYY. 
In both protocols satiety and motor and sensory function of the proximal 
stomach were monitored. PYY was infused at doses reaching plasma PYY 
levels comparable to those obtained during ileal fat perfusion. 
SUBJECTS AND METHODS 
Subjects
Fourteen healthy subjects (6 male; 8 female; mean (±SEM) age 29±3 year; 
mean (±SEM) BMI 22±3) without a history of gastrointestinal symptoms or 
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abdominal surgery participated in the study. For each experiment 8 subjects 
were studied. Two subjects participated in both experiments. None of them 
were taking any medication. Informed consent was obtained from each 
individual and the protocol had been approved by the ethics committee of the 
Leiden University Medical Center.  
Gastric barostat 
An electronic barostat (Medtronic Visceral Stimulator; Medtronic, Skovlunde, 
Denmark) was used to distend the stomach. A polyethylene bag (1000 mL 
maximum capacity) was tied to the end of a multilumen tube (16 French). This 
catheter was connected to the barostat. The barostat keeps the pressure in the 
intragastric bag at a preselected level. When the stomach relaxes, the system 
injects air. When the stomach contracts, the system aspirates air. Thus, the 
barostat measures gastric motor activity as changes in intragastric volume at a 
constant intragastric pressure (17). 
Pressure (mmHg) and volume (ml) are constantly monitored and recorded on a 
personal computer connected to the barostat. On the day of the experiments, 
subjects were intubated with the barostat catheter through the mouth into the 
fundus. To unfold the bag, air was inflated to a volume of 200 ml and the 
catheter was carefully pulled back until its passage was restricted by the 
oesophageal sphincter. Then the tube was introduced another 2 cm. The 
correct position was checked under fluoroscopy at the start and the end of 
each experiment.  
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Study design 
Experiment 1: ileal fat 
Two experiments were performed in random order on two consecutive days 
in a double blind manner. The experiments started at 7:45 AM.
Day 0: Catheter intubation  
In the morning subjects were intubated transnasally with an ileal catheter. The 
catheter (outer diameter 4 mm; length 350 cm) consists of a central perfusion 
port, a stainless steel tip weight and a distal inflatable balloon. Once the tip had 
passed the ligament of Treitz, the distal balloon was inflated with 10 ml air to 
facilitate further progression of the tube through the small intestine. 
Progression of the tube through the gut was monitored by fluoroscopy. The 
tip of the tube with the central perfusion port was located in the ileum. The 
time required for the tube to reach the distal ileum varied between 8-22 hours. 
Correct position was verified by fluoroscopy on day 0 and at the start and end 
of day 1 and 2.
Day 1 and day 2: ileal saline or fat
After an overnight fast subjects were intubated with the barostat catheter with 
bag through the mouth into the fundus, as described previously. An 
intravenous cannula was inserted into the antecubital vein of one arm for 
blood sampling. During measurements subjects were seated in a comfortable 
lying chair in a semi-recumbent position with the lower extremities just above 
abdominal level.  
A commercially available fat emulsion (Intralipid 20%; Pharmacia & Upjohn 
BV, Woerden, The Netherlands) was used to perfuse the ileum. Intralipid 
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20% consists of 20 g soybean oil, 1.2 g purified egg phospholipids, and 2.2 g 
glycerol anhydrous per 100 ml. The perfusion rate was 1 ml/min (2 kcal/min). 
In random order either Intralipid 20%  or placebo (saline 0.9%), was given 
into the ileum on day 1 and day 2.
A 200 ml liquid meal (Nutridrink; Nutricia Zoetermeer, Holland) containing 
10g protein, 36g carbohydrates and 13g fat was used as test meal (300 kcal).  
The following procedures with the barostat were performed:  
1- Minimal distending pressure (MDP) was determined by stepwise 
increasing pressures in steps of 1 mmHg every 90 sec from 0 mmHg until. 
MDP was defined as the first pressure level at which the intragastric bag 
volume was more than 30 ml. 
2- Barostat procedure: The barostat was set at a pressure of MDP+2 
mmHg. The basal intragastric bag volumes were measured during the first 
15 min. Then ileal infusion of either saline or fat was started. The 
intragastric bag volumes were continuously measured for 60 min after the 
start of the ileal perfusion. 
3- Recovery period of two hours. During this period the ileum was perfused 
with saline at a rate of 1ml/min. 
4- Isobaric distension: Stepwise increasing bag pressures in steps of 1 
mmHg every 90 sec from 0 mmHg to a maximum of 14 mmHg or when a 
maximum bag volume of 750 ml was reached. Thereafter the intragastric 
bag was deflated.
5- Recovery period of three hours. During this period the ileum was 
perfused with saline at a rate of 1ml/min 
6- Meal: The barostat was set at a pressure of MDP+2 mmHg. After 15 min 
recording under fasting conditions, the liquid test meal was ingested 
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within 3 min. At the start of meal ingestion ileal infusion of either saline 
(1 ml/min) or fat was also started. Measurements were continued for 90 
min after the start of the ileal perfusion and meal ingestion. 
Experiment 2: PYY3-36 infusion 
The three experiments were performed in double-blind randomized order. The 
experiments were separated by intervals of at least 7 days. Each subject 
received an intravenous infusion of: A) saline, B) PYY3-36 at a dose of 15 
pM/kg/hour and C) PYY3-36 at a dose of 30 pM/kg/hour. PYY3-36 was 
purchased from Clinalfa, Switzerland. The doses of PYY3-36 we choose were 
based on results of previous studies (11,18,19). The low dose results in 
plasma PYY levels seen after ingestion of a regular meal, whereas the high 
dose results in plasma PYY levels that have been observed after meal 
ingestion in patients with malabsorptive disorders. On the day of the 
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3- Recovery period (15 min) 
4- Isobaric distention: Stepwise increasing pressures in steps of 1 mmHg 
every 90 sec from 0 mmHg to a maximum of 14 mmHg or when a 
maximum bag volume of 750 ml was reached. 
5- Recovery period (15 min)
6- Meal: The barostat procedure was started at a pressure of MDP+2 mmHg. 
After 15 min recording under fasting conditions, the test meal was 
ingested within 3 min. At the start of meal ingestion intravenous infusion 
with either saline or PYY3-36 was also started. Measurements were 
continued for 90 min after the start of intravenous PYY infusion and meal 
ingestion.
Perception scores 
Subjective feelings of fullness, hunger, desire to eat and nausea were scored 
at 15 min intervals throughout experiment 1 and 2 using 100 mm visual 
analogue scales (VAS).
Plasma PYY 
Blood samples for measurement PYY were drawn at time t=-15, 0, 15, 30, 45, 
60 min during the fasting barostat procedure and at time t=-15, 0, 15, 30, 45, 60, 
75 and 90 min after meal ingestion. Plasma PYY was measured by 
radioimmunoassay. PYY antiserum was generated in rabbits by intracutaneous 
injections of synthetic human PYY (BACHEM Biochemica GmbH, 
Switzerland). PYY was labeled with 125Iodine with chloramine T. The assay is 
highly specific. There is no cross-reactivity with PP or VIP. The detection limit 




Intragastric volumes measured while pressure was set at MDP+2 mmHg are 
given as average values over 5 min periods. Intragastric volumes during the 
isobaric distension were determined as mean volumes during the last 60 sec of 
each pressure step. Perception scores during volume measurements at set 
pressure (MDP+2 mmHg) were calculated relative to the perception scores 
obtained at 0 min, immediately before the onset of the infusion. Perception 
scores obtained prior to the meal were used as zero reference points for the 
calculation of postprandial perception scores.  
Statistical analysis 
Results are expressed as mean±SEM. All data between and within groups 
were analysed for statistical significance using multiple analysis of variance 
(MANOVA). When this indicated a probability of less than 0.05 for the null 
hypothesis, Student-Newman Keuls analyses were performed to determine 
which values between or within groups differed significantly. Coefficient of 
linear correlation (Spearman) was used to calculate correlations between 
intragastric volumes, plasma PYY levels and perception scores. The 
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RESULTS
Experiment 1: ileal fat 
Barostat, fasting 
The MDP was not significantly different between the ileal saline (6.0�0.4
mmHg) and the ileal fat (6.1�0.9 mmHg) experiment. Intragastric volumes at 
MDP+2 mmHg before the start of ileal infusion at time 0 min were similar 
between the ileal saline (149±14 ml) and the ileal fat experiment (148±23 ml). 
Intragastric volumes increased significantly (p<0.01) during ileal fat 
perfusion compared to basal and compared to the ileal saline experiment from 
time t=10 min until the end of the procedure at time t=60 min (Figure 1, left 
panel).
Stepwise isobaric distension resulted in progressive increments in intragastric 
bag volume in both the saline and the ileal fat experiments. Intragastric 
volumes during pressure distension from level 6-11 mmHg were significantly 
(p<0.01) higher in the ileal fat compared to the ileal saline experiment (Figure 
2; left panel).
Barostat, postprandial 
Basal intragastric volumes at MDP+2 mmHg were not significantly different 
between the ileal saline (142±10 ml) and the ileal fat experiment (146±13 ml). 
After meal ingestion, intragastric volumes increased significantly (p<0.01) in 
both the experiments (Figure 3, left panel). In the ileal saline experiment, 
intragastric volumes reached a maximal volume at 15 min after meal 
ingestion and gradually returned to basal value at the end of the postprandial 
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period. On the other hand, intragastric volumes in the ileal fat experiment 
remained significantly (p<0.01) increased over basal during the 90 min 
postprandial period. Furthermore, intragastric volumes in the ileal fat 
experiment were significantly (p<0.01) higher compared to those in the ileal 
saline experiment during the period from 15 min until 90 min postprandially.  
Satiety, fasting 
During ileal fat perfusion, fullness increased significantly (p<0.05) over basal 
starting from 15 min while no significant changes were observed in the ileal 
saline experiment (Figure 4, upper left panel). Scores of hunger (Figure 4, 
lower left panel) and desire to eat (data not shown) were significantly 
(p<0.05) decreased in the ileal fat compared to the ileal saline experiment. 
Nausea scores were not affected. 
Satiety, postprandial 
In both the ileal saline and fat experiment, scores of fullness increased 
significantly (p<0.01) over basal value starting from 15 min after meal 
ingestion (Figure 5, upper left panel). In the saline experiment the perception 
of fullness gradually returned to basal values. The perception of fullness 
during ileal fat perfusion, on the other hand, remained significantly (p<0.01) 
increased compared to the basal value and compared to the saline experiment. 
Perception scores of hunger (Figure 5, lower left panel) and desire to eat (data 
not shown) were significantly (p<0.05) decreased in the ileal fat experiment 
compared to the saline experiment and compared to baseline values. Nausea 
was not affected (data not shown).
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Plasma PYY, fasting 
Basal plasma PYY levels were not significantly different between the ileal 
saline (13±1 pM) and the ileal fat experiment (15±1 pM). Plasma PYY levels 
gradually increased during ileal fat perfusion and were significantly (p<0.05) 
increased over basal from 30-60 min after the start of ileal fat perfusion (26�2
pM at 60 min). No significant changes compared to basal were observed in 
the ileal saline experiment (Figure 6, left panel).
Plasma PYY, postprandial 
Plasma PYY levels before meal ingestion were not significantly different 
between the ileal saline (15±2 pM) and the ileal fat experiment (16±1 pM). 
Plasma PYY levels in response to meal ingestion were significantly (p<0.05) 
increased over basal from 15 min to 45 min in the ileal saline experiment. 
Ileal fat infusion resulted in significantly (p<0.01) higher plasma PYY levels 
compared to those in the ileal saline experiment during the period from 15 to 
90 min (Figure 7, left panel).  
Correlations
Perception of fullness at t= 60 min during fasting correlated significantly with 
gastric bag volume (r=0.5; p=0.05). In addition, postprandial fullness at t= 90 
min also correlated significantly with postprandial gastric bag volume (r=0.4; 
p=0.05). Postprandial perception of hunger was significantly inversely 
correlated with gastric volume (r=-0.6; p=0.04). No significant correlations 
were found between satiety scores and plasma PYY levels neither in the 
fasting nor in the fed state. The correlation between plasma PYY and 
postprandial gastric volume (r=0.4; p=0.09) was not statistically significant. 
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Figure 1: Intragastric bag volume at MDP+2 mmHg. Upper panel: during ileal 
perfusion of saline (diamonds) and fat (squares). Lower panel: during intravenous 
infusion of saline (diamonds), low dose PYY (squares) and high dose PYY 










































Figure 1: Intragastric bag volume at MDP+2 mmHg. Upper panel: during ileal 
perfusion of saline (diamonds) and fat (squares). Lower panel: during intravenous 
infusion of saline (diamonds), low dose PYY (squares) and high dose PYY 










































Figure 2: Intragastric bag volume in response to stepwise pressure distension. 
Upper panel: during ileal perfusion of saline (diamonds) and fat (squares). Lower 
panel during intravenous infusion of saline (diamonds), low dose PYY (squares) and 


































Figure 3: Intragastric volume at MDP+2 mmHg in response to meal ingestion. 
Upper panel: during ileal perfusion of saline (diamonds) and fat (squares). Lower 
panel: during intravenous infusion of saline (diamonds), low dose PYY (squares) and 












































Figure 3: Intragastric volume at MDP+2 mmHg in response to meal ingestion. 
Upper panel: during ileal perfusion of saline (diamonds) and fat (squares). Lower 
panel: during intravenous infusion of saline (diamonds), low dose PYY (squares) and 












































Figure 4: Satiety score of fullness and hunger during fasting. Left panel: during ileal 
perfusion of saline (diamonds) and fat (squares). Right panel: during intravenous 
infusion of saline (diamonds), low dose PYY (squares) and high dose PYY 



































































Figure 5: Satiety score of fullness and hunger in response to meal ingestion. Left 
panel: during ileal perfusion of saline (diamonds) and fat (squares). Right panel: 
during intravenous infusion of saline (diamonds), low dose PYY (squares) and high 



































































Figure 5: Satiety score of fullness and hunger in response to meal ingestion. Left 
panel: during ileal perfusion of saline (diamonds) and fat (squares). Right panel: 
during intravenous infusion of saline (diamonds), low dose PYY (squares) and high 



































































Figure 6: Plasma PYY level during fasting. Upper panel: during ileal perfusion of 
saline (diamonds) and fat (squares). Lower panel: during intravenous infusion of 
saline (diamonds), low dose PYY (squares) and high dose PYY (triangles). Results












































Figure 7: Plasma PYY level in response to meal ingestion. Left panel: during ileal 
perfusion of saline (diamonds) and fat (squares). Right panel: during intravenous 
infusion of saline (diamonds), low dose PYY (squares) and high dose PYY 














































Figure 7: Plasma PYY level in response to meal ingestion. Left panel: during ileal 
perfusion of saline (diamonds) and fat (squares). Right panel: during intravenous 
infusion of saline (diamonds), low dose PYY (squares) and high dose PYY 














































Experiment 2: PYY3-36 infusion
Barostat, fasting 
The MDP was not significantly different between the saline (6.4±0.6 mmHg), 
the low dose PYY (6.8±0.5 mmHg) and the high dose PYY experiment 
(6.5±0.7 mmHg). Intragastric volumes at MDP+2 mmHg before the start of 
the infusion were similar between the saline (155±14ml), the low dose PYY 
(159±18 ml) and the high dose PYY experiment (167±22 ml). During PYY 
infusion intragastric volume did not change significantly (Figure 1, right 
panel). Stepwise isobaric distension resulted in progressive increments in 
intragastric bag volume in all experiments. No significant differences in 
intragastric bag volume were observed between the saline, the low dose and 
the high dose PYY experiment (Figure 2, right panel).  
Barostat, postprandial 
Basal intragastric volumes at MDP+2 mmHg were not significantly different 
between the saline (148±24 ml), the low dose PYY (151±30 ml) and the high 
dose PYY experiment (195±27 ml). After meal ingestion, intragastric 
volumes increased significantly (p<0.01) in all experiments. No significant 
differences in intragastric bag volume were observed between the saline, the 
low dose PYY and the high dose PYY experiment (Figure 3, right panel).  
Satiety, fasting 
During PYY infusion scores of fullness, hunger, desire to eat and nausea did 
not change significantly over basal.  No significant differences in perception 
scores were observed between the three experiments (Figure 4, right upper 
and lower panel). 
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Satiety, postprandial 
After meal ingestion scores of fullness, hunger, desire to eat changed 
significantly (p<0.05) at time 15 min compared to basal. Nausea was not 
affected.  No significant differences in fullness, hunger, desire to eat or 
nausea were observed between the three experiments (Figure 5, right upper 
and lower panel).
Plasma PYY, fasting 
Basal plasma PYY levels before the start of infusion were not significantly 
different between the three experiments, respectively 16±1 pM in the saline 
experiment, 14±1 pM in the low dose PYY experiment and 13±2 pM in the 
high dose PYY experiment. During infusion of PYY, plasma PYY levels 
increased significantly (p<0.01) over basal and compared to the saline 
experiment (Figure 6, right panel). Note that the plasma PYY levels obtained 
during low dose PYY infusion are in the range of those reached with ileal fat 
(25-30 pM). The plasma levels obtained during high dose PYY infusion are in 
the range of those reached after meal ingestion in patients with maldigestion 
that is 50-60 pM. 
Plasma PYY, postprandial 
Meal ingestion resulted in significantly (p<0.05) increases in plasma PYY 
levels during saline infusion from 15 to 60 min (Figure 7, right panel). Plasma 
PYY levels during intravenous infusion of both the low dose PYY and high 
dose PYY were significantly higher compared to the control experiment. 
Plasma PYY levels of the high dose PYY experiment were significantly 
(p<0.01) higher compared to those of the low dose PYY experiment.  
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DISCUSSION 
Recently much attention has been given to PYY as potential anorexogenic 
substance. PYY is mainly present in the ileocolonic region expressed by 
endocrine L cells and secreted in response to nutrient ingestion (11). PYY 
immunoreactivity has also been reported to be present in the central nervous 
system. Animal studies indicate that PYY can transmit signals via central Y2 
receptors to which PYY binds with high affinity (20). Several animal 
experiments have shown that truncated PYY3-36 reduces food intake and 
impairs a gain in body weight (14,21). Recently, human studies with PYY 
infusion have obtained similar results: infusion of PYY3-36 reduced food 
intake and appetite not only lean but also in obese subjects (15). Subsequent 
studies failed to reproduce the anorexogenic effect of PYY3-36 (22). More 
recently, Degen et al again attempted to solve the issue by performing 
classical experiments with graded doses of PYY infusion reaching plasma 
levels in the physiological range (16). These authors clearly observed an 
anorexogenic effect of PYY because food intake was decreased by 30%. It 
should be noted that this effect was present only at supraphysiological plasma 
PYY levels.
The design we have chosen was based on the following research question: 
compare effects of exogenous PYY infusion and of ileal brake activation 
(endogenous PYY) by aiming at comparable plasma PYY levels with satiety 
(fasted, fed) and proximal gastric motor function as parameters. In doing so 
we have shown that in healthy volunteers: 1) ileal fat induces satiety in the 
fasting state and increases satiety in the fed state 2) ileal fat significantly 
increases proximal gastric volume and enhances postprandial proximal gastric 
relaxation and 3) exogenous PYY3-36 infusion did not affect satiety nor 
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proximal gastric motor and sensory function.  
Our findings that ileal fat significantly increased gastric compliance and 
fasting gastric volume are in agreement with a previous study in dogs 
demonstrating that nutrients in the distal small bowel elicit a gastric 
relaxatory response (23).  Several studies have shown that ileal fat activates 
the so called ileal brake with subsequent inhibition of gastric emptying and 
delay in intestinal transit (6,7). An increased postprandial fundic relaxation 
may contribute to the delay in gastric emptying induced by ileal fat since the 
proximal stomach accommodates food after meal ingestion and regulates the 
transfer of food to the distal stomach. It is not clear by which mechanism(s) 
the ileal fat induced gastric relaxatory response is mediated. Several distal gut 
hormones such as PYY, GLP-1 and enteroglucagon may be involved. PYY is 
considered to be an important hormonal mediator of the ileal brake. In 
humans, i.v. administration of exogenous PYY delays gastric emptying (12). 
In response to ileal fat, endogenous PYY is released resulting in higher 
plasma levels (6). In the present study infusion of PYY3-36, to plasma levels 
reached during ileal brake activation did not result in changes in gastric 
volume neither in the fasting nor in the fed state. These findings do not 
support a role for PYY as mediator of ileal fat induced gastric relaxation and 
accommodation. Gastric emptying results from coordinated motor activities 
of different parts of the stomach, pylorus and duodenum. It is therefore 
conceivable that other factors apart from proximal gastric tone may contribute 
to delayed gastric emptying induced by PYY. To date, it is not known 
whether PYY affects antral, pyloric or duodenal motility. Not only hormonal 
but also neural factors may be involved in the gastric relaxatory response to 
ileal fat, for instance vagal afferent neural reflexes triggered by luminal osmo- 
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and chemosensitive receptors (24,25).  
We have demonstrated that ileal fat induces satiety. We did not assess food 
intake, but quantified sensations related to eating behaviour such as fullness, 
hunger and desire to eat in both the fasting and the fed state. The finding of 
ileal fat induced satiety can be explained in a number of ways. First, satiety 
may have been induced by ileal fat through an increase in gastric volume. It is 
known that afferent fibers of the vagus nerve express mechanoreceptors 
(stretch receptors) which are sensitive to volume and to luminal pressure (26). 
The activated vagus then in turn activates centers in the brainstem, eliciting 
reflexes that control satiety and eating behaviour. In support of this concept is 
the significant correlation we observed between sensations of fullness, hunger 
and intragastric bag volumes. In addition, previous studies have shown that 
gastric distension is one of the most powerful triggers that decrease hunger 
(27,28). Penagini et al found a significant inverse correlation between 
postprandial hunger and proximal gastric volume and the increase in 
sensation of fullness paralled the increase in gastric volume in patients with 
reflux disease (29). Second, satiety induced by ileal fat can be mediated by 
gut peptides through endocrine, paracrine or neurocrine routes. Activation of 
the ileal brake stimulates release of PYY and Glucagon-like peptide-1 (GLP-
1) from the endocrine L cells located primarily in the ileum and colon (6,30). 
Of these peptides, especially PYY is of interest because PYY reduces food 
intake and elicits satiety in humans and animals (14-16).  
Concerning PYY and satiety, the satiating effect of ileal fat perfusion could 
not be reproduced during infusion of PYY (15 pM/kg/hr) which resulted in  
similar plasma PYY levels ranging from 25 pM to 30 pM. Neither did the 
high dose of PYY (30 pM/kg/hr) affect satiety. With this dose PYY levels 
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were reached in the range of 50-60 pM, comparable to postprandial levels in 
patients with malabsorption (18,19). In line with this observation is the 
finding that infusion of PYY neither at low nor at high doses did affect 
proximal gastric motor function. 
The mechanisms that regulate gut-brain signalling are poorly understood. 
CCK, but also PYY3-36 may act as a neurocrine rather than as an endocrine 
substance. Animal studies indicate that gut PYY can transmit signals to the 
CNS but only via an intact vagus nerve (31). Previously several authors have 
clearly demonstrated the satiating effect of PYY with a marked reduction in 
food intake (14-16). An explanation for the discrepancy in results of studies 
may be related, for instance, to the doses of PYY given. Degen et al recently 
showed that exogenous PYY3-36 only at a high, pharmacological doses of 48 
pM/kg/hr significantly reduced feelings of hunger and decreased food intake. 
These authors could not demonstrate any effect of PYY when infused at doses 
of 12 or 24 pM/kg/hour (16). In the studies of Batterham et al, a reduction in 
food intake was observed after PYY infusion at doses of above 35 pM/kg/hr 
(14,15). Taken together, we suggest that the doses of PYY required to 
produce a significant effect on satiety and food intake are in the 
supraphysiological range.
In conclusion, we have shown that ileal fat induces satiety and results in 
proximal gastric relaxation , in contrast to exogenous PYY at identical plasma 
levels. These data do not support a role for PYY as physiological mediator in 
ileal brake induced proximal gastric relaxation. 
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Antroduodenal motility in chronic pancreatitis:
are abnormalities related to exocrine insufficiency?
M. K. VU,1 J. VECHT,1 E. H. EDDES,2 I. BIEMOND,1
C. B. H. W. LAMERS,1 AND A. A. M. MASCLEE1
Departments of 1Gastroenterology-Hepatology and 2General Surgery,
Leiden University Medical Center, 2300 RC Leiden, The Netherlands
Vu, M. K., J. Vecht, E. H. Eddes, I. Biemond, C. B. H. W.
Lamers, and A. A. M. Masclee. Antroduodenal motility in
chronic pancreatitis: are abnormalities related to exocrine
insufficiency? Am. J. Physiol. Gastrointest. Liver Physiol. 278:
G458–G466, 2000.—In patients with chronic pancreatitis
(CP) the relation among exocrine pancreatic secretion, gastro-
intestinal hormone release, and motility is disturbed. We
studied digestive and interdigestive antroduodenal motility
and postprandial gut hormone release in 26 patients with CP.
Fifteen of these patients had pancreatic insufficiency (PI)
established by urinary para-aminobenzoic acid test and fecal
fat excretion. Antroduodenal motility was recorded after
ingestion of a mixed liquid meal. The effect of pancreatic
enzyme supplementation was studied in 8 of the 15 CP
patients with PI. The duration of the postprandial antroduo-
denal motor pattern was signi• cantly ( P � 0.01) prolonged in
CP patients (324 � 20 min) compared with controls (215 � 19
min). Antral motility indexes in the • rst hour after meal 
ingestion were signi• cantly reduced in CP patients. The 
interdigestive migrating motor complex cycle length was
signi• cantly ( P � 0.01) shorter in CP patients (90 � 8 min)
compared with controls (129 � 8 min). These abnormalities
were more pronounced in CP patients with exocrine PI. After
supplementation of pancreatic enzymes, these alterations in
motility reverted toward normal. Digestive and interdiges-
tive antroduodenal motility are abnormal in patients with CP
but signi• cantly different from controls only in those with 
exocrine PI. These abnormalities in antroduodenal motility in
CP are related to maldigestion.
pancreatic enzyme supplementation; cholecystokinin; pep-
tide YY
IN THE FASTING STATE gastrointestinal motility is charac-
terized by cyclic reoccurrence of a typical motor pat-
tern, the migrating motor complex (MMC) (14, 38).
Interdigestive exocrine pancreatic secretion cycles in
close association with the various phases of the MMC in
the duodenum (12, 27) but is dissociated from the MMC
in chronic pancreatitis (CP) (29). After meal ingestion,
gastrointestinal motility is converted to a feeding pat-
tern and exocrine pancreatic secretion increases. The
control of interdigestive and digestive motility and
pancreatic secretion includes neural and hormonal
components, several of which regulate both motility
and pancreatic secretion (35, 37). Recent studies indi-
cate that in CP patients with impaired exocrine func-
tion alterations in gastrointestinal hormonal release
and motility can be observed. Postprandial release of
CCK and pancreatic polypeptide (PP) is reduced in
patients with exocrine pancreatic insufficiency (PI) (10,
15), gallbladder contraction is impaired (24), and gas-
tric emptying is accelerated (20). It has been suggested
that the pancreas has a role in controlling antroduode-
nal motility (4, 17, 21–23). In patients with CP and PI
interdigestive and digestive motility may be affected,
as well as gastrointestinal transit (4, 17, 22).
However, results of studies on antroduodenal motil-
ity in patients with CP have been controversial. Both
normal and increased interdigestive MMC cycle fre-
quency have been observed (17, 22, 23). Duration of
postprandial motility was reduced in one study (17),
whereas in another study the postprandial antroduode-
nal motor pattern in patients with CP was not different
from controls (23). These differences in results may be
related to the presence of exocrine PI in CP patients.
Therefore, we have investigated digestive and inter-
digestive antroduodenal motility and release of the
gastrointestinal hormones CCK, PP, and peptide YY
(PYY) in a large group of CP patients. The patients
were divided into groups with and without exocrine PI.
To further elucidate the role of exocrine PI and subse-
quent maldigestion, we also studied the effect of exo-
crine pancreatic enzyme supplementation on the afore-
mentioned parameters. Results were compared with
those obtained in healthy control subjects.
METHODS
Subjects
Two groups of subjects were studied: 26 patients with CP
(21 male, 5 female; mean age 47 � 3 yr) and 15 healthy
control subjects (9 male, 6 female; mean age 39 � 5 yr). None
of the patients with CP or control subjects had previously
undergone abdominal surgery. The diagnosis of CP had been
established in all patients by typical clinical history and
characteristic abnormalities on ultrasonography, computed
tomography, and endoscopic retrograde cholangiopancreati-
cography. Exocrine pancreatic function was assessed by the
indirect para-aminobenzoic acid (PABA) test and fecal fat
excretion. Fifteen of twenty-six patients with CP had evi-
dence of impaired exocrine pancreatic function, showing
urinary PABA recovery of �50% and/or fecal fat excretion of
�7 g/24 h. These patients were classi• ed as having exocrine 
PI. Eleven patients with CP had no evidence of exocrine PI
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(urinary PABA recovery �50% and fecal fat excretion �7
g/24 h). Six patients had had insulin-dependent diabetes
mellitus for 5, 6, 7, 9, 10, and 23 yr, respectively. None of them
had autonomic neuropathy as assessed by cardiovascular
re• ex tests described by Ewing and Clarke (6). Patient 
characteristics are listed in Table 1. Pancreatic enzyme
supplementation and other medication possibly in• uencing 
antroduodenal motility were discontinued at least 4 days
before the study. In eight patients with CP and exocrine PI,
the study was repeated with pancreatic enzyme supplementa-
tion. Informed consent was obtained from each subject, and
the study protocol was approved by the local ethical commit-
tee.
Antroduodenal Manometry
Antroduodenal motility was recorded using a multilumen
water-perfused polyvinyl catheter (outer diameter 5 mm).
The catheter incorporated eight side holes located at 3, 8, 13,
18, 23, 28, 33, and 38 cm from the distal tip. The manometry
catheter was passed transnasally into the stomach and from
there positioned into duodenum-jejunum under • oroscopicu
control. The tip of the catheter was located just distal to the
ligament of Treitz so that one or two side hole openings were
in the jejunum, three to four side hole openings were in the
duodenum, and at least two were in the antrum. When the
correct position had been veri• ed, the catheter was taped to 
the nose. At the end of each experiment, position of the
catheter was checked again by • oroscopy. Each lumen wasu
connected to a pressure transducer and perfused with dis-
tilled water by a low-compliance pneumohydraulic perfusion
system (Arndorfer Medical Systems) at a rate of 0.5 ml/min.
Outputs from pressure transducers were recorded by a poly-
graph (Synectics Medical, Stockholm, Sweden), displayed on
a monitor, and stored on a personal computer for automated
and manual analysis.
Study Design
All subjects presented at our laboratory at 800 AM after an
overnight fast. The manometry catheter was positioned as
described in Antroduodenal Motility, and manometric record-
ing was started. An intravenous cannula was inserted into
the antecubital vein of one arm for blood sampling. At 0 min
(around 900 AM) the study was started with oral ingestion of
400 ml of a commercially available polymeric liquid meal
(Nutrison; Nutricia Zoetermeer) containing 16 g of casein, 48
g of carbohydrates (polysaccharides), and 12 g of saturated
and unsaturated triglycerides (400 ml � 1,680 kJ; osmolality
260 mosmol/kg). Antroduodenojejunal motility was recorded
for at least 7 h after ingestion of the liquid meal.
To determine the effect of pancreatic enzyme supplementa-
tion on antroduodenojejunal motility and gut hormone re-
lease, the study was repeated in 8 of 15 CP patients with
exocrine PI. Each patient received the same liquid meal
together with pancreatic enzymes [Pancrease, 30,000 Federal
International Pharmaceutical (FIP) units lipase, 17,400 FIP
units amylase, and 1,980 FIP units protease; Janssen-Cilag].
Hormone Assays
Blood samples for measurement of plasma CCK, PP, and
PYY were drawn at �15 min, 0 min before meal ingestion,
and thereafter at 15, 30, 45, 60, 90, 120, 150, 180, 240, 300,
and 360 min. Plasma CCK was measured by a sensitive and
speci• radioimmunoassay. This antibody binds to all CCKc
peptides, including sulfated CCK octapeptide, but not with
gastrin. The detection limit of the assay is 0.3 pmol/l plasma.
The intra-assay variation ranges from 4.6 to 11.5% and the
interassay variation from 11.3 to 26.1% (9). Plasma PP
concentrations were measured by a sensitive and speci• c
radioimmunoassay as described previously (16). Plasma PYY
was measured in our laboratory by a recently developed
radioimmunoassay. PYY antiserum was generated in rabbits
by intracutaneous injections of synthetic human PYY (Bachem
Biochemica). PYY was labeled with 125I with chloramine T.
The assay is highly speci• . There is no cross-reactivity withc
PP or VIP. The detection limit is 10 pmol/l. Both PYY-(1–36)
and PYY-(3–36) bind to the antibody in dilutions up to
1:250,000.
Analysis of Manometric Data
Motility patterns from antroduodenal manometry were
analyzed both visually and by computer. The individual
tracings were processed by special software (Polygram, Synec-
tics Medical, Stockholm, Sweden) for adjusting baselines and
extracting respiratory artifacts. However, the computer pro-
gram does not recognize simultaneous pressure events as
artifacts. Therefore, remaining artifacts caused by incre-
ments in intra-abdominal pressure were identi• d visuallye
and excluded from analysis. Duodenal phases of the MMC
were de• ed as follows:n phase I, no more than 2 contrac-
tions/10 min for at least 5 min and preceded by phase III;
phase II, irregular contractile activity at a frequency of �2/10
min and amplitude �12 mmHg; phase III, regular contractile
activity at a frequency of 10–12 contractions/min for at least 2
min. Phase III activity had to be propagated over at least 2
recording sites. Antral phase III activity was de• n d ase
rhythmic contractile activity at maximum frequency (3 con-
tractions/min) for at least 1 min in temporal relationship with
duodenal phase III activity (14). Duration of the MMC cycle
was taken as the interval between the beginning of phase III
in the duodenum and the beginning of the next phase III
cycle. Antral or duodenal origin, duration, mean amplitude,
Table 1. Clinical characteristics of patients with
chronic pancreatitis and control subjects
Chronic Pancreatitis
ControlsAll With PI Without PI
n 26 15 11 15
Age 47 (22–67) 48 (22–67) 45 (31–66) 39 (21–50)
Gender, M/F 21/5 12/3 9/2 9/6
Etiology of CP
Alcoholic, no.
of subjects 16 9 7
Unknown, no.
of subjects 10 6 4
Exocrine insufficiency
Urinary PABA
recovery �50% 15 15 0
Fecal fat �7




recovery, % 42 (3–89) 27 (3–44) 56 (54–89)
Fecal fat, g/24 h 22 (2–95) 36 (8–95) 5 (2–7)
Endocrine insufficiency
Impaired glucose
tolerance 10 6 4
Insulin dependent 6 5 1
Mean (range) parameter values are given; n, no. of subjects. CP,
chronic pancreatitis; PI, pancreatic insufficiency; PABA, para-
aminobenzoic acid.
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contraction frequency, propagation velocity, and area under
the curve of phase III of the MMC were measured.
The postprandial period was de• ed as the time intervaln
between the end of the meal and the occurrence of the • rst 
duodenal phase III propagated over at least two channels.
Only pressure waves with an amplitude �10 mmHg and a
duration �1.5 s were considered true contractions. The
motility indexes (MI) of the postprandial period in antrum
and duodenum were calculated as area under the contraction
curves (expressed in mmHg·s ·h�1).
Data and Statistical Analysis
Integrated incremental CCK, PP, and PYY secretion in
response to the meal were determined by calculating the area
under the plasma concentration time curve after subtraction
of the basal value at 0 min. Possible in• uences of diabetes 
mellitus on gastrointestinal motility and secretion were
analyzed in two ways: 1) by comparing the results between
patients with and without diabetes within the group of CP
patients with PI and 2) by comparing the results between CP
patients with and without PI after excluding the six patients
with insulin-dependent diabetes mellitus. For all param-
eters, differences between and within groups were analyzed
by repeated ANOVA. When this indicated a probability of
�0.05 for the null hypothesis, Student-Newman-Keuls analy-
sis was performed to determine which values between or
within groups differed signi• cantly. Statistical signi• cance  
was de• ned as a P value �0.05.
RESULTS
Antroduodenal Motility
Postprandial state. The duration of the fed motility
pattern was signi• cantly ( P � 0.01) prolonged in CP
patients (324 � 20 min) compared with control subjects
(215 � 19 min). No signi• cant difference in the dura- 
tion of the fed motility patterns was found between
patients with (345 � 25 min) and without (294 � 33
min) PI. The postprandial antral MI during the • str
hour after the meal was signi• cantly ( P � 0.01) reduced
in the CP patient group compared with the control
group (Table 2). Moreover, within the patient group,
patients with PI had a signi• antly (c P � 0.01) smaller
MI compared with CP patients without PI. During the
subsequent hourly intervals after the meal, the antral
MI was not signi• cantly different between CP patients 
and control subjects or between CP patients with and
without PI (Table 2).
The postprandial duodenal MI was not different
between CP patients and control subjects during the
• rst three subsequent hourly intervals after the meal 
or during the total fed period (Table 2). No differences
were found in duodenal MI between CP patients with
and without PI.
Interdigestive state. After transition from a digestive
into an interdigestive motility pattern, 21 complete
MMC cycles in the patient group and 22 complete MMC
cycles in the control subjects were registered. The
duration of complete MMC cycles was signi• cantly ( P �
0.01) reduced in CP patients compared with control
subjects. The shorter duration of the MMC cycle in the
patient group resulted from a signi• cantly ( P � 0.05)
shorter phase II (Table 3). These differences were more
pronounced in CP patients with PI compared with
those without PI (Table 3). The amplitude of phase III
in the CP patients (31 � 3 mmHg) was signi• cantly 
(P � 0.01) lower compared with the control group (39 �
3 mmHg), but no signi• cant difference was found 
between patients with and without exocrine PI (29 � 4
mmHg vs. 32 � 3 mmHg). Other phase III characteris-
tics such as origin, duration, and propagation velocity
were not signi• cantly different between patients and 
controls (data not shown).
Pancreatic Enzyme Supplementation and
Antroduodenal Motility
Digestive state. The duration of the fed motility
pattern in the eight CP patients with PI was signi• - 
cantly (P � 0.05) shorter with enzyme supplementation
Table 2. Postprandial antral and duodenal motility index in 60-min periods and for total fed period after
ingestion of a liquid meal in CP patients and control subjects
MI
Chronic Pancreatitis
Controls (n�15)All (n�26) PI� (n�15) PI� (n�11)
Antrum 0–60 min 825�427* 305�80*† 1,553�1,004 2,473�980
Antrum 60–120 min 1,299�432 1,156�488 1,507�818 2,501�688
Antrum 120–180 min 3,229�1,229 3,327�1,758 3,109�1,795 2,760�1,505
Antrum, total fed period 2,809�702 2,357�781 3,542�1,366 3,468�762
Duodenum 0–60 min 4,298�864 4,001�1,228 4,760�1,180 4,325�956
Duodenum 60–120 min 4,292�613 4,121�834 4,537�943 4,096�1,000
Duodenum 120–180 min 4,133�658 4,145�854 4,061�1,103 4,013�603
Duodenum, total fed period 4,377�965 4,628�1,454 3,968�1,026 4,634�752
Values (in mmHg·s) are means � SE; n, no. of subjects. MI, motility index; PI�, with PI; PI�, without PI. *P � 0.05 vs. controls; †P � 0.01
vs. PI�.
Table 3. Characteristics of interdigestive











MMC duration, min 90�8* 72�11* 104�10 129�8
Phase I, min 24�3 20�5 24�5 22�2
Phase II, min 62�8* 47�9* 77�11 102�9
Phase III, min 4�0.4 5�0.5 3�0.6 5�0.3
Values are means � SE; n, no. of subjects. MMC, migrating motor
complex. *P � 0.05 vs. controls.
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(254 � 38 min) than without enzyme supplementation
(356 � 43 min). The duration of the fed pattern after
enzyme supplementation was not signi• cantly differ- 
ent from that in healthy controls (215 � 19 min).
Pancreatic enzyme supplementation markedly (P �
0.05) increased antral MI during the • rst postprandial 
hour compared with that without enzyme supplementa-
tion (Table 4). During the subsequent hourly intervals
after the meal no signi• cant differences were found in 
antral MI between PI patients with and without en-
zyme substitution. Furthermore, pancreatic enzyme
substitution did not affect duodenal motility index
(Table 4).
Interdigestive state. Pancreatic enzyme supplementa-
tion signi• cantly ( P � 0.01) increased the duration of
the MMC cycle to values not different from controls
(Table 5). This increase in MMC cycle length resulted
from a prolonged duration of phase II. No changes were
found in phase I or phase III characteristics when
pancreatic enzymes were added.
Hormonal Responses
Plasma CCK. Basal plasma CCK levels in patients
with CP (1.7 � 0.2 pmol/l) were not signi• cantly 
different from control subjects (1.9 � 0.3 pmol/l; Fig.
1A). In both groups, plasma CCK levels increased
signi• cantly over basal levels starting from 15 min 
after meal ingestion and remained signi• cantly in- 
creased until 120 min in the controls and 180 min in the
patient group. Plasma CCK secretion during the • rst 
postprandial hour was signi• cantly ( P � 0.05) reduced
in the CP patients (118 � 14 pmol· l�1 ·60 min�1)
compared with the control group (168 � 20 pmol· l�1 ·60
min�1). No difference in CCK secretion was found
between patients with and without PI (Fig. 1B).
Plasma PP. Basal plasma PP levels in the CP pa-
tients (37 � 7 pmol/l) were not signi• cantly different 
from controls (41 � 5 pmol/l; Fig. 2A). After meal
ingestion plasma PP levels increased signi• antly (c P �
0.005–P � 0.05) in both groups and remained signi• - 
cantly elevated for 180 min. Postprandial PP secretion
during the • rst hour was signi• cantly (  P � 0.01)
reduced in CP patients (2,220 � 397 pmol· l�1 ·60
min�1) compared with controls (3,198 � 709 pmol·l�1·60
min�1). Compared with that in CP patients without PI,
plasma PP secretion during the • st postprandial hourr
was signi• cantly ( P � 0.01) reduced in CP patients
with PI (2,993 � 756 vs. 1,640 � 345 pmol· l�1 ·60
min�1; Fig. 2B).
Plasma PYY. Basal plasma PYY levels were not
signi• cantly different between CP patients (20 � 2
pmol/l) compared with controls (18 � 1 pmol/l). After
meal ingestion plasma PYY levels increased signi• - 
Table 4. Postprandial antral and duodenal motility
index in 60-min periods and for total fed period after
ingestion of a liquid meal in PI patients with and








Antrum 0–60 min 271�79 1,429�318* 2,473�980
Antrum 60–120 min 1,022�241 1,296�390 2,501�688
Antrum 120–180 min 2,414�643 2,217�935 2,760�1,505
Antrum, total fed period 2,592�389 3,007�1,107 3,468�762
Duodenum 0–60 min 3,160�961 3,584�808 4,325�956
Duodenum 60–120 min 3,738�564 3,570�542 4,096�1,000
Duodenum 120–180 min 4,022�528 4,000�636 4,013�603
Duodenum, total fed period 4,311�542 3,881�935 4,634�752
Values (in mmHg·s) are means � SE; n, no. of subjects. *P � 0.05
vs. no enzymes.
Table 5. Characteristics of interdigestive
antroduodenal motility in PI patients with and







MMC duration, min 89�10 119�13* 129�8
Phase I, min 18�6 17�4 22�2
Phase II, min 66�6 96�11* 102�9
Phase III, min 5�1.0 6�1.0 5�0.3
Values are means � SE; n, no. of subjects. *P � 0.01 vs. no
enzymes.
Fig. 1. A: fasting and postprandial plasma CCK levels (means � SE)
in patients with chronic pancreatitis (CP; n � 26) and controls (n �
15). B: fasting and postprandial plasma CCK levels in CP patients
with exocrine pancreatic insufficiency (PI) (n � 15), CP patients
without exocrine PI (n � 11), and controls (n � 15).
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cantly (P � 0.01) over basal levels starting from 15 min
until 240 min in controls and until 300 min in the CP
patients (Fig. 3A). Plasma PYY levels in CP patients
were signi• cantly ( P � 0.05) increased over controls
from 30 to 180 min after meal ingestion. Integrated
postprandial PYY secretion in CP patients was also
signi• cantly ( P � 0.05) higher compared with controls
(2,840 � 470 vs. 1,380 � 340 pmol· l�1 ·360 min�1).
When analyzed separately according to exocrine func-
tion, only in the patients with PI were plasma PYY
levels signi• cantly increased over those in controls. 
This was true for basal plasma PYY levels and those
from 15 to 240 min after meal ingestion (Fig. 3B).
Plasma PYY levels were higher in CP patients with
exocrine PI compared with patients without PI, al-
though this difference was not statistically signi• cant. 
Pancreatic Enzyme Supplementation
and Hormone Responses
Plasma CCK. Pancreatic enzyme supplementation
signi• cantly ( P � 0.05) increased postprandial plasma
CCK levels in CP patients over those without enzyme
supplementation (Fig. 4). After enzyme supplementa-
tion integrated plasma CCK secretion during the • str
postprandial hour (148 � 16 pmol· l�1 ·60 min�1) was
not signi• cantly different from controls (168 � 20
pmol· l�1 ·60 min�1) but was signi• cantly ( P � 0.05)
higher compared with those without enzyme supple-
mentation (77 � 17 pmol· l�1 ·60 min�1).
Fig. 2. A: fasting and postprandial plasma PP levels (means � SE) in
patients with CP (n � 26) and controls (n � 15). B: fasting and
postprandial plasma PP levels in CP patients with exocrine PI (n �
15), CP patients without exocrine PI (n � 11), and controls (n � 15).
Fig. 3. A: fasting and postprandial plasma peptide YY (PYY) levels
(means � SE) in patients with CP (n � 26) and controls (n � 15). B:
fasting and postprandial plasma PYY levels in CP patients with
exocrine PI (n � 15), CP patients without exocrine PI (n � 11), and
controls (n � 15).
Fig. 4. Fasting and postprandial plasma CCK levels (means � SE) in
8 PI patients with and without enzyme supplementation and controls
(n � 15).
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Plasma PP. Supplementation of pancreatic enzymes
did not alter postprandial PP release. The integrated
plasma PP secretions during the • rst postprandial 
hour were 1,205 � 515 and 1,242 � 335 pmol · l�1 ·60
min�1, respectively, with and without addition of pancre-
atic enzymes.
Plasma PYY. Postprandial plasma PYY decreased
signi• cantly ( P � 0.05) to levels comparable with controls
after supplementation of pancreatic enzymes (Fig. 5).
Integrated postprandial PYY release after enzyme
supplementation (839 � 127 pmol· l�1 ·360 min�1) was
signi• cantly ( P � 0.05) lower compared with that
without enzyme supplementation (2,683 � 315
pmol· l�1 ·360 min�1) and was not signi• cantly different 
from healthy controls (1,380 � 340 pmol·l�1·360 min�1).
Role of Endocrine Insufficiency
Of the 15 CP patients with exocrine PI, 5 patients
had insulin-dependent diabetes mellitus. Within this
group, the mean duration of the fed pattern was not
signi• cantly different between CP patients with exo- 
crine PI either with (361 � 37 min) or without (345 �
32 min) diabetes compared with controls (215 � 19
min). Antral hypomotility during the • rst hour of the 
fed period was present (P � 0.05) in both groups
compared with controls (2,473 � 980 mmHg·s·h�1),
but no signi• cant difference was found between CP 
patients with (368 � 165 mmHg·s·h�1) and without
(257 � 92 mmHg·s·h�1) diabetes mellitus. In addition,
no signi• cant differences in the duration of MMC cycle 
phases I, II, and III were found between patients with
exocrine PI with and without diabetes (data not shown).
When the results were analyzed between CP patients
with and without exocrine PI after excluding six CP
patients with diabetes mellitus from the study, differ-
ences in gastrointestinal motility and secretion still
existed and remained signi• cant between CP patients 
with and without exocrine PI (Table 6).
DISCUSSION
Our results demonstrate that antroduodenal motility
is altered in patients with CP. The duration of the
postprandial motor pattern was signi• cantly prolonged 
and the interdigestive motility pattern was character-
ized by shorter duration of the MMC cycle because of a
reduction in duration of phase II. These abnormalities
were more pronounced in CP patients with PI. After
addition of pancreatic enzymes, these alterations in
antroduodenal motility reverted toward normal.
Recently, several studies were published about antro-
duodenal motility in patients with chronic pancreatitis.
Malfertheiner et al. (22, 23) and Pieramico et al. (29)
did not observe any changes in interdigestive motility
in patients with CP vs. controls, whereas Layer et al.
(17) found that the duration of the interdigestive motor
cycle was signi• antly reduced. We were able to con-c
• rm the results of Layer et al . by • ding a shortern
duration of the MMC cycle with shorter phase II in CP
patients. Differences in results between the studies of
Layer et al. (17) and ours compared with those of
Malfertheiner (22, 23) and Pieramico (29) may be
related to several factors. First, the degree of exocrine
PI in CP patients may have an important role. Whereas
Malfertheiner et al. and Pieramico et al. studied 15 CP
patients without steatorrhoea, Layer et al. investigated
patients with severely impaired exocrine function. In
the present study, the duration of the MMC cycle was
shorter compared with controls only in patients with
and not in those without exocrine PI. Several explana-
tions could be considered. This • nding could be caused 
by autonomic neuropathy secondary to diabetes melli-
tus. However, none of the six patients with insulin-
dependent diabetes mellitus had evidence of autonomic
neuropathy and similar motility results were obtained
between patients with and without diabetes. Therefore,
the possibility that autonomic neuropathy affects antro-
duodenal motility seems unlikely. Furthermore, Sam-
son and Smout (33) showed that MMC cycle length is
actually prolonged, not shortened, in diabetic patients
with autonomic neuropathy. Second, the presence of
endocrine PI and subsequent hyperglycemia may be a
confounding factor because it has been demonstrated
that hyperglycemia shortens MMC cycle length by
Fig. 5. Fasting and postprandial plasma PYY levels (means � SE) in
8 PI patients with and without enzyme supplementation and controls
(n � 15).
Table 6. Parameters that remain different between CP
patients with and without PI after excluding 6 patients









tern, min 331�35* 326�34* 215�19
MI antrum 0–60
min, mmHg·s 295�105*† 1,671�1,115 2,473�980
MMC duration, min 77�16* 106�12 129�8
Plasma PP,
pmol · l�1 ·60 min�1 1,788�222*† 2,476�422* 3,918�709
Plasma CCK,
pmol · l�1 ·60 min�1 120�17* 133�19 168�20
Plasma PYY,
pmol · l�1 ·360
min�1 2,915�154* 2,218�479 1,380�340
Values are means � SE; n, no. of subjects. PP, pancreatic polypep-
tide; PYY, peptide YY. *P � 0.05 vs. controls; †P � 0.05 vs. PI�.
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shortening the duration of phase II (7). During the
experiments plasma glucose levels were kept in the
euglycemic range of 4–8 mmol/l. It is more likely that
exocrine PI and subsequent malabsorption activated
‘‘ileal brake’’ mechanisms that facilitate the occurrence
of phase III and thereby shorten MMC cycle length.
Normalization of the MMC cycle length after pancre-
atic enzyme supplementation further supports this
idea.
The occurrence of antroduodenal phase III activity is
associated with peaks in plasma motilin concentrations
but is also dependent on vagal cholinergic neural input
(11). Pieramico et al. (29) found a dissociation between
interdigestive antroduodenal motility and cyclic exo-
crine pancreatic enzyme output and PP secretion. It is
not known whether cyclic • uctuations in plasma moti- 
lin concentrations occur at higher frequency in patients
with PI. Output of pancreaticobiliary juice into the
duodenum releases plasma motilin (28). Although pan-
creatic enzyme output to the duodenum is reduced in
PI, this does not affect plasma motilin concentrations
(22). In dogs after total pancreatectomy, plasma motilin
concentrations remain unchanged and continue to cycle
in association with the duodenal MMC (21). However, it
should be noted that in dogs total pancreatectomy has
little effect on cycling and characteristics of the MMC.
Apart from motilin, plasma PP concentrations cycle
synchronously with interdigestive antroduodenal mo-
tor activity (27). Interdigestive PP release is already
impaired in early stages of CP (30). PP is known to
inhibit pancreatic secretion and gallbladder motility
but does not appear to have a role in the regulation of
interdigestive motility (21).
The duration of the fed pattern was signi• antlyc
prolonged in patients with CP. When analyzed sepa-
rately, the difference compared with controls was signi• - 
cant only in CP patients with and not in those without
exocrine PI. This • nding is not in line with a recent 
study by Layer et al. (17), who reported that the
duration of the fed pattern was signi• cantly shorter in 
CP patients compared with controls. This discrepancy
could be explained by differences in the degree of
exocrine PI and subsequent malabsorption. In cases of
severe exocrine PI the amount of unabsorbed nutrients
in the distal gut will be higher compared with mild
exocrine PI, resulting in different effects on gastrointes-
tinal motility and secretion. Layer et al. (19) showed
that intraileal infusion with nutrients at a rate of 4
kcal/min converted the fed motility to the interdiges-
tive motility pattern. On the other hand, Keller et al.
(13) suggested a positive correlation between the dura-
tion of the fed pattern and relative increase in ileal
nutrient concentration after ingestion of a semiliquid
meal. Apart from the duration, differences in postpran-
dial motor pattern were also observed. In the CP
patients with PI the antral motility index in the • str
postprandial hour was signi• cantly reduced. As a conse- 
quence of antral hypomotility gastric emptying of nutri-
ents may be delayed. Recently, Layer et al. (17) found
that in the late postprandial phase gastric emptying
was accelerated but in the early postprandial phase
gastric emptying in patients with PI was delayed
compared with controls. Our results of an initial post-
prandial antral hypomotility are in line with the ob-
served delay in gastric emptying in the early postpran-
dial phase (17).
The differences in antroduodenal interdigestive and
digestive motility pattern that we found between pa-
tients with and without exocrine PI suggest that the
observed abnormalities are related to exocrine PI and
subsequent maldigestion but not to CP per se. The
observed changes in the duration of the fed pattern,
MMC cycle, and phase II toward normal with the
addition of pancreatic enzymes support this concept.
Recently, Bassotti et al. (5) reported abnormalities in
interdigestive antroduodenal pattern in adult patients
with untreated celiac sprue similar to those we have
observed in CP patients with PI. Combining the results
of these studies, it is tempting to relate the abnormali-
ties in antroduodenal motility to intraluminal condi-
tions rather than to the disease per se.
Ingestion of the liquid meal induced a rapid increase
in plasma CCK levels both in patients and controls.
CCK may be involved in the conversion of a fasted into
a fed antroduodenal motor pattern (25, 35, 37). Post-
prandial CCK release is impaired in CP patients with
PI (10, 24). In the present study, integrated plasma
CCK secretion was signi• antly reduced in CP patientsc
in the • rst postprandial hour. Maldigestion of triglycer- 
ides and proteins as a result of exocrine PI could be
responsible for this • nding. Hildebrand et al . (8) showed
that an adequate digestion of triglycerides by pancre-
atic lipase is necessary for release of CCK in response to
food, particularly during the immediate postprandial
phase. In support of this concept and in line with earlier
studies (10, 24) we have found that pancreatic enzyme
supplementation increased postprandial plasma CCK
levels toward control values. Postprandial CCK levels
remained elevated over basal for a longer period in CP
patients than in controls, possibly contributing to pro-
longed duration of the fed motor pattern. Our • ndings 
contrast with those of others who found a signi• cantly 
shorter duration of the fed motility pattern in CP (17).
These differences are not easily explained and may
have been in• uenced by patient characteristics, degree 
of exocrine PI, meal composition (higher fat and caloric
content in our study), CCK secretion, or activation of
the ileal brake.
In contrast to the proximal gut hormone CCK, basal
and postprandial plasma levels of the distal gut hor-
mone PYY were signi• cantly increased in CP patients 
with exocrine PI. PYY is found in highest concentra-
tions in the mucosa of the distal gut (2) and is consid-
ered one of the mediators of the so-called ileal brake
(18, 31). In the present study, PYY was chosen as a
marker of the ileal brake because there is substantial
evidence suggesting that plasma PYY levels correlate
with ileal fat-induced delayed gastric emptying (31),
prolonged small intestinal transit, and inhibition of
small intestinal motility (32, 36). In humans, infusion
of PYY delays gastric emptying and small intestinal
transit in a dose-dependent manner (34). Elevated
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plasma PYY levels have been found in diseases associ-
ated with malabsorption such as celiac sprue, cystic
• brosis, and dumping syndrome (1, 3, 26). These • d-n 
ings support the idea that alterations in plasma PYY
secretion in PI patients result from malabsorption. The
presence of undigested and unabsorbed nutrients in
the distal gut activates the ileal brake with concomi-
tant PYY release. This results in feedback regulation of
proximal gut motor function such as prolongation of the
fed pattern to optimize nutrient uptake and absorption.
Normalization of postprandial plasma PYY secretion
and duration of the fed pattern after pancreatic enzyme
supplementation should be considered as evidence sup-
porting this concept.
It is concluded that in patients with CP and exocrine
PI, but not in those with normal exocrine function, 1)
duration of postprandial antroduodenal motility is sig-
ni• cantly prolonged and early postprandial antral mo- 
tility is signi• cantly reduced; 2) interdigestive MMC
cycle length is signi• cantly reduced because of shorten- 
ing of phase II; 3) endogenous secretion of CCK and PP
is decreased, whereas PYY secretion is increased; and
4) alterations in antroduodenal motility and hormone
responses in CP patients are related to intraluminal
maldigestion and malabsorption and revert toward
normal with enzyme supplementation.
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and H. Ditschuneit. Gastrointestinal motility in chronic pancre-
atitis. In: Chronic Pancreatitis, edited by H. G. Beger, M.
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Gastrointestinal (GI) symptoms are common in systemic sclerosis (SSc). It is 
not known whether GI involvement differs between limited SSc and diffuse 
SSc. The aim of the study was to evaluate GI motility and gut hormone 
secretion in SSc patients of both subtypes. Motility of the oesophageal, antrum 
and proximal small intestine and secretion of cholecystokinin (CCK), motilin 
and peptide YY (PYY) were studied in 23  patients with SSc (limited form 
N=11, diffuse form  N=12). Fifteen healthy subjects served as controls. Results:
All SSc patients had prolonged duration of the postprandial motor pattern 
322±22 min vs 215±19 min in controls (p<0.01). Postprandial antral and 
duodenal motility indices (MI) were significantly (p<0.05) reduced in the SSc 
patient group compared to controls (1203±225 vs 3468±762 mmHg*sec per 
hour and 2195±305 vs 4634±752 mmHg*sec per hour respectively). Duodenal 
MI was significantly reduced in the limited subtype compared to the diffuse 
subtype (1406±280 vs 2591±480 mmHg*sec per hour). Interdigestive motility 
represented by migrating motor cycles was also reduced in SSc patients. 
Esophageal motility was affected in all SSc patients. In SSc patients, 
postprandial plasma CCK was significantly (p<0.05) reduced while motilin and 
PYY secretion was significantly (p<0.05) increased compared to controls. 
Conclusions: Whereas oesophageal and gastric motility is affected to a similar 
extent in the limited and diffuse SSc, alterations in intestinal motility are more 
pronounced in patients with limited SSc. Qualitatively, intestinal motility in the 
limited type is characterised by myopathic changes and in the diffuse type 
neuropathic changes.  
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INTRODUCTION
Systemic sclerosis (SSc) is a multisystem disorder characterized by excessive 
deposition of collagen and other matrix elements in skin and frequently also in 
tissue of other organs. Two main subsets of scleroderma have been identified: 
the limited and diffuse cutaneous form of SSc. Limited cutaneous SSc (lSSc) is 
characterised by skin involvement limited to the face, hand, forearms and feet 
and includes the CREST variant (calcinosis, Raynaud’s phenomenon, 
esophageal dysmotility, sclerodactyly, teleangiectasia). Diffuse cutaneous SSc 
(dSSc) is characterised by diffuse skin involvement including the trunk.
Gastrointestinal (GI) tract involvement is common in SSc and frequently gives 
rise to intestinal symptoms. Esophageal motor abnormalities leading to 
dysphagia and reflux esophagitis are observed in up to 90% of patients with 
systemic sclerosis (1-3). Involvement of the stomach and small intestine is less 
common but abdominal symptoms are reported by 25%-50% of SSc patients (3-
6). Not only gastrointestinal motor function, secretory function including gut 
peptide release may also be affected in SSc (7,8).  It has been assumed that GI 
tract involvement occurs late in the course of the disease of patients with limited 
SSc while in the diffuse cutaneous form visceral involvement occurs at an early 
stage. However, up to now studies have not dealt with a comparison of subsets 
of SSc patients with respect to GI motility. 
The aim of the present study was to investigate antroduodenojejunal motility 
and proximal and distal gut peptide release in a group of patients with SSc and 
compare data from patients with limited and diffuse cutaneous form of  
scleroderma and healthy controls.  
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SUBJECTS 
Two groups of subjects were studied: 23 patients with SSc (eight males, 15 
females; mean age 51±4 yr) and 15 healthy control subjects (nine males, six 
females; mean age 39±5 yr). Twelve out of 23 patients had diffuse cutaneous 
SSc and eleven patients suffered from the limited type of systemic sclerosis. 
None of the patients or controls had taken any kind of proton pump inhibitors, 
motility modulating drugs or antacids up to three days prior to the investigation. 
Patient characteristics are listed in Table 1. Disease severity score was 
calculated as described previously (9) 
METHODS 
Oesophageal manometry 
Oesophageal body motility and lower esophageal sphincter pressure (LESP) 
were recorded by perfusion manometry with a small polyvinyl multi-lumen 
composite side-hole catheter using a low-compliance capillary tube perfusion 
pump (Arndorfer Medical Specialist, Greendale, WI). A stepwise pull-through 
technique was used to record end- expiratory LESP. Intraluminal esophageal 
pressures were recorded at 5, 10, 15 and 20 cm above the upper margin of the 
lower esophageal sphincter (LES).  
Antroduodenojejunal  manometry 
Antroduodenojejunal (ADJ) motility was recorded using a multilumen water 
perfused polyvinyl catheter (outer diameter 5 mm). The catheter incorporated 
eight side holes located at 3, 8, 13, 18, 23, 28, 38 and 43 cm from the distal tip. 
The manometry catheter was passed transnasally into the stomach and from 
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there positioned into duodenum-jejunum under fluoroscopic control. The tip of 
the catheter was located 5-10 cm distal to the ligament of Treitz so that one or 
two side hole openings were in the jejunum, three to four side hole openings 
were in the duodenum and at least two in the antrum. When the correct position 
had been verified the catheter was taped to the nose. At the end of each 
experiment position of the catheter was checked again by fluoroscopy. Each 
lumen was connected to a pressure transducer and perfused with distilled water 
by a low compliance pneumohydraulic perfusion system (Arndorfer Medical 
Systems) at a rate of 0.5 ml/min. Outputs from pressure transducers were 
recorded by a polygraph (Synectics Medical, Skovlunde, Denmark), displayed 
on a monitor, stored on a personal computer for automated and manual analysis. 
Study design 
All subjects presented at our laboratory at 08.00 AM after an overnight fast. The 
manometry catheter was positioned as described above and manometric 
recording was started. An intravenous cannula was inserted into the antecubital 
vein of one arm for blood sampling. At time 0 min (around 09.00 AM) the study 
was started with oral ingestion of 400 ml of a commercially available polymeric 
liquid meal (Nutrison; Nutricia Zoetermeer, The Netherlands) containing 16 g 
long chain triglyceride (LCT) fat, 48 g lactose-free carbohydrates and 16 g 
protein per 400 ml (400 ml = 1680 kJ; osmolality 260 mOsm). Antro-duodeno-
jejunal motility was recorded for at least 6 hr after ingestion of the liquid meal. 
Hormone assays 
Blood samples for measurement of plasma cholecystokinin (CCK) and peptide 
YY (PYY) were drawn at time -15, and 0 min before meal ingestion and at 
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regular intervals thereafter at  15, 30, 45, 60, 90, 120, 150, 180, 240, 300 and 
360 min. Plasma CCK was measured by a sensitive and specific 
radioimmunoassay (10).  The detection limit of the assay is 0.1 pM plasma. 
Plasma PYY was measured by radioimmunoassay. PYY antiserum was 
generated in rabbits by intracutaneous injections of synthetic human PYY 
(BACHEM AG, Bubendorf, Switzerland). PYY was labelled with 125 Iodine 
using chloramine T. There is no cross-reactivity with pancreatic polypeptide 
(PP) or vasoactive intestinal peptide (VIP). The detection limit is 10 pM plasma. 
Both PYY (1-36) and PYY (3-36) bind to the antibody in dilutions up to 25000 
(11). Plasma motilin was measured by  a specific radioimmunoassay using 125I-
labelled motilin and rabbit antiserum to highly purified porcine motilin (both: 
Euro-diagnostica AB, Malmo, Sweden). The antiserum was directed towards the 
middle portion of the motilin molecule and did not show any-reactivity with 
gastrin, human synthetic secretin (Sigma, St. Louis, MO, USA), CCK, 
vasoactive intestinal peptide, gastric inhibitory polypeptide, neuropeptide Y or 
PYY. 125I-motilin binds in a reverse proportion to the concentration of motilin in 
standards and samples. The sensitivity of the radioimmunoassay is 10 pM of 
plasma (12). 
Analysis of manometric data 
Motility patterns from antroduodenojejunal manometry were analyzed both 
visually and by computer. The individual tracings were processed by special 
software (PolygramR, Synectics Medical, Skovlunde, Denmark) for adjusting 
baselines and extracting respiratory artifacts. Artifacts due to increments in 
intra-abdominal pressure were identified visually and excluded from analysis. 
Duodenal phases of the motor migrating complex (MMC) were defined as 
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follows: phase I, no more than 1 contractions per 5 min  and preceded by phase 
III; phase II: irregular contractile activity at a frequency of more than 1 per 5 
min and amplitude above 12 mmHg; phase III: regular contractile activity at a 
frequency of 10-12 contractions per min for at least 2 min. Phase III activity had 
to be propagated over at least 2 recording sites. Antral phase III activity was 
defined as rhythmic contractile activity at maximum frequency (3 
contractions/min) for at least 1 min in temporal relationship with duodenal phase 
III activity (13). Duration of the MMC cycle was taken as the interval between 
the beginning of phase III in the duodenum until the beginning of the next phase 
III cycle. Duration, mean amplitude, contraction frequency, propagation velocity 
and areas under the curve (AUC) of phases III of the MMC's were measured. 
The postprandial period was defined as the time interval between the end of the 
meal and the occurrence of the first duodenal phase III propagated over at least 
two channels. Only pressure waves with an amplitude � 10 mmHg and duration 
� 1.5 s were considered as true contractions. The motility indices (MI) of the 
postprandial period in antrum and duodenum were calculated as area under the 
contraction curves and expressed in mmHg.sec per hour. 
Statistical analysis 
Results are expressed as mean±SEM. Parameters of digestive and interdigestive 
antroduodenojejunal motility and plasma CCK, PYY and motilin secretion 
between and within groups were analyzed by repeated analysis of variance. 
When this indicated a probability of less than 0.05 for the null hypothesis 
Student-Newman-Keuls analyses were performed to determine which values 
between or within groups differed significantly. Coefficient of linear 
correlation (Spearman) was used to calculate the correlation between the 
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disease duration and motility parameters. Statistical significance was defined 
as a P value <0.05. 
RESULTS
Baseline characteristics of the SSc patients 
There were no significant differences in age, disease duration and disease 
severity score between patients with lSSc and dSSc (Table 1). Upper 
gastrointestinal symptoms such as heartburn and dysphagia were reported by 
83% and 25% respectively in dSSC patients vs 90% and 36% respectively in 
lSSc patients. Intestinal symptom such as diarrhea was present in 33% of 
patients with dSSc en in 54% of patients with lSSc (Table 1). 





Age, years (mean±SEM) 50±4 52±5 
Male/Female ratio 4/8 4/7 
Disease duration, years (mean±SEM) 6.2±1 6.0±1 
Severity score (mean±SEM) 6.8±0.6 6.6±0.8 
Heartburn  10/12 10/11 
Dysphagia 3/12 4/11 
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The duration of the postprandial motility pattern was significantly (p<0.01) 
prolonged in the SSc patient group (322±22 min) compared to control subjects 
(215±19 min). No significant differences were observed in the duration of the 
postprandial pattern between patients with limited versus diffuse type 
scleroderma (328±28 min and 316±36 min respectively). Postprandial antral and 
duodenal motility indices (MI) were significantly (p<0.05) reduced in the SSc 
patient group compared to controls (Table 2). No significant difference in 
postprandial antral MI was found between patients with diffuse and limited 
disease. Postprandial duodenal MI was, on the other hand, significantly reduced 
in patients with limited disease compared to patients with diffuse scleroderma 
(Table 2). This difference resulted from  a significant reduction in the number of 
contractions in patients with limited disease (Table 2).  
Neither disease duration nor disease severity score was correlated with motility 
parameters such as the duration of the fed pattern (r=0.3, p=0.5 and r= -0.2; 
p=0.4 respectively), antral MI (r=-0.3; p=0.4 and r=0.05, p=0.8 respectively) 
and duodenal MI (r=-0.3, p=0.4 and r=0.2, p=0.3 respectively).  
With respect to a qualitative motility analysis we observed that the 
characteristics of the postprandial antroduodenojejunal motility patterns were 
different between the patient group with diffuse and limited disease. 
Postprandial antroduodenojejunal motility in 7 out of 12 patients (58%) with 
diffuse type scleroderma was characterised by the occurrence of non-propagated 
clustered contractions and duodenal discrete clustered contractions (Figure 1; 
upper panel). Patients with limited type scleroderma exhibited a motility pattern 
characterised by  periods of motor quiescence in the duodenum and jejunum 
(Figure 1; lower panel). This motility pattern was seen in six out of eleven  
patients (54%) with limited scleroderma. 
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Table 2. Antral and duodenal postprandial motility characteristics in systemic 
sclerosis patients and healthy controls. * p<0.05 compared to controls; # 
p<0.05 compared to diffuse disease. MI: Motility Index 
Controls  
(N=15)






Antrum     
Contractions (number/hour) 32±6 19±2* 17±3* 20±5* 
Amplitude (mmHg) 50±5 35±4* 34±5* 36±7* 
MI (mmHg*sec) per hour 3468±762 1203±225* 948±177* 1482±257*
Duodenum     
Contractions (number/hour) 122±14 56±9* 71±9* 41±7*# 
Amplitude (mmHg) 29±1 22±1* 21±1* 23±1* 
MI (mmHg*sec) per hour 4634±752 2195±305* 2591±580* 1406±280*# 
Interdigestive state 
After transition from a digestive into an interdigestive motility pattern, 11  
complete MMC cycles in the patient group and 22 complete MMC cycles in the 
control subjects were registered. Of the 11  MMC cycles in the SSc patient 
group 8  MMC cycles were observed in five patients with the diffuse type SSc. 
The other three MMC cycles were found  in two patients with the limited type 
SSc. The duration of the MMC cycles was not significantly different between 
the SSc patient group and controls (Table 3). In addition, no significant 
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differences were found in the duration of phase I, II and III between the patient 
and control group. However, the amplitude of phase III was significantly 
reduced (p<0.05) in the SSc patient group (25±5 mmHg) compared to controls 
(39±3 mmHg).  
Esophageal manometry 
Mean LESP was 8.4±1.4 mmHg (normal range 15-25 mmHg). There was no 
significant difference in LESP between patients with diffuse and limited diease 
(8.5±2.1 mmHg and verus 8.3±1.8 mmHg respectively). Peristaltic wave  
amplitude of the SSC patients was 33±4.8 mmHg (normal 50-60mmHg) in the 
upper portion, 6.7±2.8 mmHg (normal 40-50 mmHg) in the mid portion and 
6.4±3.4 mmHg (normal 50-60 mmHg) in the distal portion of the esophagus. No 
significant differences were found between patients with limited and diffuse 
scleroderma. 
Table 3. Characteristics of the migrating motor complex (MMC) cycles (mean±SEM) 
found in patients with  systemic sclerosis and in 15 healthy controls 
SSc patients Diffuse SSc Limited SSc Controls 
Number of cycles 11 8 3 22 
MMC cycle duration (min) 132±36 122±25 140±39 129±9 
Phase I (min) 14±2 16±3 13±2 21±3 
Phase II (min) 112±35 98±26 123±29 101±9 
Phase III (min) 6±0.9 6±0.8 5±0.6 5±0.5 
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Figure 1. Postprandial antroduodenojejunal motility in patients with diffuse type 
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Figure 2. Fasting and postprandial plasma CCK levels (mean±SEM) in patients with 
systemic sclerosis (n=23; triangles) and controls (n=15; small squares) (upper panel) 
and  in SSc  patients with the diffuse type scleroderma (n=12; big squares), patients 













































Figure 3. Fasting and postprandial plasma PYY levels (mean±SEM) in patients with 
systemic sclerosis (n=23; triangles) and controls (n=15; small squares) (upper panel) 
and  in SSc  patients with the diffuse type scleroderma (n=12; big squares), patients 
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Figure 4. Fasting and postprandial plasma motilin levels (mean±SEM) in patients with 
systemic sclerosis (n=23; triangles) and controls (n=15; small squares) (upper panel) 
and  in SSc  patients with the diffuse type scleroderma (n=12; big squares), patients 



















































Basal plasma CCK levels in patients with SSc (1.3±0.6 pM) were not 
significantly different from control subjects (1.5±0.2 pM). In both groups 
plasma CCK levels increased significantly (p<0.05) over basal starting from 15 
min after meal ingestion and remained significantly increased until time 120 
min (Figure 3; upper panel). Postprandial plasma CCK levels at t=15 min and 
t=30 min were significantly (p<0.05) reduced  in the patient group compared to 
controls (Figure 2; upper panel). These differences resulted from significant 
(p<0.05) reductions in plasma CCK levels of the patients with limited disease 
and not of those with diffuse type disease (Figure 2; lower panel).  
Plasma PYY 
Basal plasma PYY levels were not significantly different between SS patients 
(21±1 pM) compared to controls (18±1 pM). After meal ingestion plasma PYY 
levels increased significantly (p<0.01) over basal starting from 15 min until 120 
min in the controls and until 180 min in the SSc patients (Figure 3, upper panel). 
No significant difference was found in postprandial plasma PYY secretion 
between SSc patients and controls. When comparing the subsets of SSc patients, 
in those with limited disease, basal plasma PYY levels were higher compared to 
controls (although not statistically significant) and postprandial plasma PYY 
levels at t=15, 30 and 45 min were significantly (p<0.05) higher compared to 
controls (Figure 3; lower panel).  
Plasma motilin 
Basal and postprandial motilin levels were significantly (p<0.05) higher in the 
scleroderma patients compared to control subjects (Figure 4; upper panel). 
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min in the controls and until 180 min in the SSc patients (Figure 3, upper panel). 
No significant difference was found in postprandial plasma PYY secretion 
between SSc patients and controls. When comparing the subsets of SSc patients, 
in those with limited disease, basal plasma PYY levels were higher compared to 
controls (although not statistically significant) and postprandial plasma PYY 
levels at t=15, 30 and 45 min were significantly (p<0.05) higher compared to 
controls (Figure 3; lower panel).  
Plasma motilin 
Basal and postprandial motilin levels were significantly (p<0.05) higher in the 
scleroderma patients compared to control subjects (Figure 4; upper panel). 
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There was no significant difference in basal and postprandial plasma motilin 
levels between patients with limited and diffuse type scleroderma (Figure 4; 
lower panel). 
DISCUSSION 
The results of the present study show that small intestinal motility is more 
severely affected in patients with limited compared to those with diffuse type 
scleroderma, irrespective of disease duration and disease severity score. 
Esophageal and gastric motor function are, on the other hand, equally impaired 
among patients with diffuse and limited SSc.  
Although GI motility disorders in patients with SSc have been well documented, 
it is not clear whether the frequency and type GI dysmotility differ between 
patients with diffuse and limited type scleroderma. Esophageal motility was 
impaired in all but one patient with SSc and the degree of impairment was equal 
among patients with diffuse and limited disease. Antral motility was impaired in 
both groups of patients to an equal extent. With respect to duodenojejunal 
motility, disturbance was, however, more pronounced in patients with limited 
type scleroderma.  
It has been suggested that gastrointestinal changes in SSc occur in various 
stages. Neural dysfunction appears to be the earliest gastrointestinal change 
induced by SSc. The second stage is muscle atrophy and the final stage is 
characterized by muscle fibrosis (3,14). In a study of eight patients with diffuse 
type SSc, Greydanus et al have demonstrated two distinct gastrointestinal 
motility patterns (15). One was characterized by non-propagated, uncoordinated 
clustered contractions, suggestive of the neuropathic stage. These motility 
abnormalities resemble those observed in diseases associated with neuropathy 
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such as diabetes mellitus (16). The other motility pattern was characterized by a 
reduced number of contractions with low amplitude, suggestive of the 
myopathic lesions of the small intestine (15). Another study by Sjölund et al
showed that small intestinal motility patterns in eight out of ten patients with 
diffuse and limited SSc were characterized by both neuropathic and myopathic 
patterns (17). In a most recent study Marie et al have shown a rapid 
deterioration of small bowel motor function with neurogenic abnormalities 
preceding myopathic motility pattern in eight SSc patients (two with diffuse and 
six with limited SSc) at 5-year follow-up (18). However, it is not clear from 
these aforementioned studies whether small intestinal motility differs between 
patients with limited and diffuse SSc. In the present study patients with limited 
SSc exhibited a myopathic pattern with postprandial hypomotility whereas the 
majority of patients with diffuse SSc had a neuropathic pattern characterised by 
the presence of non-propagated, uncoordinated clustered contractions. 
According to the concept that the neuropathic stage occurs early in the course of 
SSc and precedes the myopathic stage in SSc, these findings imply that 
scleroderma  is in a more advanced stage in patients with limited compared to 
diffuse disease.  Against this concept is the observation that neither disease 
severity score nor disease duration differed significantly between the two groups 
of SSc patients. Therefore one could also argue that the differences in GI 
motility between patients with diffuse and limited type scleroderma represent 
the natural course of two variants of the disease and are not related to the 
duration or the stage of scleroderma. There are arguments in favor of the 
concept that the diffuse and limited forms of scleroderma are different diseases: 
1) the two classical SSc-selective autoantibodies clearly identify the SSc 
subsets.The limited SSc is associated with anticentromere antibodies and the 
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diffuse SSc with antitopoisomerase antibodies; 2) the transition from one form 
of SSc to the other is seldom seen (19).  
Not only gastrointestinal motility but also gastrointestinal peptide secretion was 
abnormal in patients with SSc. Plasma levels of the proximal gut hormone CCK 
were significantly decreased in SSc. When analysed separately, only the patients 
with limited disease showed a significant reduction in plasma CCK levels 
compared to controls. This reduction in plasma CCK levels can be due to 
several factors such as: 1) reduced number of CCK producing cells in the upper 
small intestine as a result of fibrosis and atrophy or 2) inadequate intraluminal 
nutrient stimulation. Previous studies have shown that fatty acids rather than 
intact triglycerides stimulate CCK release (20). One may argue that the 
hydrolysis of triglycerides to fatty acids is reduced or delayed in these patients 
due to changes in intraluminal contents resulting from delayed gastric emptying, 
reduced intraluminal exocrine pancreatic enzyme and gallbladder bile acid 
concentrations. The observation that 73% of the patients with limited disease 
had intestinal involvement with diarrhea supports this concept. 
In contrast with plasma CCK, plasma levels of the distal gut peptide PYY 
during the first 45 min of the postprandial period were significantly higher in the 
patients with limited scleroderma compared to controls. PYY represents the so-
called “ileo-colonic brake”, a negative feedback control mechanism from the 
distal to the proximal gut (21-23). Increased plasma PYY levels are found in 
diseases associated with malabsorption such as exocrine pancreatic 
insufficiency, coeliac sprue and dumping syndrome (11,24,25). The observation 
that a majority of the patients with limited disease had gastrointestinal 
symptoms including steatorrhoea is in line with findings in other gastrointestinal
disorders with malabsorption. We therefore believe that changes in CCK and 
146 
PYY secretion are secondary to changes in GI function induced by SSc and do 
not primarily relate to SSc. 
Basal and postprandial plasma levels of motilin were significantly higher in SSc 
patients compared to healthy controls. Motilin is released from the proximal 
bowel and cyclically peaks in close association with phase III of the MMC cycle 
(26-28). Based on the action of motilin in the interdigestive state we hypothesize 
that increased plasma motilin levels in SSc patients result from a prolonged 
postprandial motility period and the delayed occurrence or complete absence of 
phase III in these patients. Our results are in line with those of Akesson et al
who found that plasma motilin levels were higher in SSc patients compared to 
controls (8). There was no difference between patients with diffuse and limited 
type scleroderma.   
It is concluded that alterations in gastrointestinal motility and gut hormone 
secretion are frequent in patients with systemic sclerosis. Whereas esophageal 
and gastric motility are affected to the same extent in the limited and diffuse 
type SSc, alterations in duodenojejunal motility and gut hormone secretion are 
more pronounced among patients with the limited type SSc. Qualitatively, 
intestinal motility in the limited type scleroderma is characterized by myopathic 
changes and the diffuse type by neuropathic changes.  
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Background: Patients with Crohn disease (CD) have an increased risk of developing gallstones. Among
other factors, gallbladder motility may have a role in the pathogenesis of gallstone formation. We have
evaluated whether gallbladder motor function is affected in Crohn disease with special emphasis on the
influence of disease localization and previous bowel resection. Methods: Thirty-seven patients (20
females and 17 males, age 36 � 2 years) with inactive Crohn disease (CDAI � 150) were studied: 15
patients after ileocecal resection and 22 non-operated patients; 12 had small bowel disease and 10 had
large bowel disease. Nineteen healthy subjects (10 female; 9 male, age 30 � 2 years) served as controls.
Gallbladder volumes were measured in the fasting state and at regular intervals for 2 h after ingestion of a
solid meal (780 kcal). Blood samples were drawn at regular intervals for determination of cholecystokinin
(CCK) and peptide YY (PYY). Results: Fasting gallbladder volumes were significantly (P � 0.05)
reduced in patients with large bowel disease (20.8 � 2.1 ml) or after ileocecal resection (18.3 � 2.4 ml)
compared to patients with small bowel disease (28.0 � 2.1 ml) and controls (27.2 � 1.8 ml). Fasting
plasma CCK levels were significantly (P � 0.05) higher in patients with large bowel disease or after
ileocecal resection compared to patients with small bowel disease and controls. Postprandial gallbladder
emptying and endogenous plasma CCK and PYY secretion in patients with Crohn disease were not
different from controls. Conclusions: Fasting gallbladder volume is decreased and fasting plasma CCK
levels are increased in patients with Crohn disease of the large bowel and patients after ileocecal resection.
Postprandial gallbladder motility, CCK and PYY release were not affected in patients with Crohn disease.
Key words: Gallbladder motility; Crohn disease; cholecystokinin; peptide YY
A. A. M. Masclee, M.D., Ph.D., Dept. of Gastroenterology–Hepatology, Leiden University Medical
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Patients with Crohn disease have an increased risk ofdeveloping gallstones (1–5). Several studies havereported a gallstone prevalence of about 30% in
patients with Crohn disease compared to 8% among age-
matched healthy subjects (1–3). This reported prevalence is,
however, not equally distributed among the group of
patients with Crohn disease. Patients with Crohn disease
confined to the ileum or after ileal resection have a higher
prevalence of gallstones of around 34% while the pre-
valence is only 5% in patients with the disease confined to
the colon (1, 2).
Pathophysiological factors underlying cholesterol gallstone
disease in general are: excess biliary cholesterol secretion
resulting in cholesterol supersaturation; increase in nuclea-
tion-promoting factors; and alterations in gallbladder motility
(6, 7). In patients with Crohn disease, disturbances in the
enterohepatic circulation of bile salts owing to disease or
resection of the ileum resulting in bile salt malabsorption and
increased biliary cholesterol have been proposed as the most
important mechanism (8, 9). The role of gallbladder motility
in the pathogenesis of gallstone formation in Crohn disease is
less clear because the published data are conflicting (10–13).
In three studies, impaired postprandial gallbladder contrac-
tion in patients with Crohn disease was reported while no
evidence for abnormal gallbladder emptying was found in
other studies (10–13). The aim of the present study was,
therefore, to evaluate fasting and meal-stimulated gallbladder
motility in a large group of Crohn disease patients with
different disease localization and with or without ileocecal
resection. As the gallbladder motor response to a meal is
mainly controlled by various gut hormones released during
the intestinal phase, basal and meal-stimulated plasma
concentrations of proximal and distal gut hormones were
also measured.
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Thirty-seven patients with inactive Crohn disease (Crohn
disease activity index (CDAI) median 63; range, 15–149)
were included. Patients with concomitant diseases such as
diabetes mellitus and hypertension were excluded from the
study. None of the patients had clinical symptoms or
ultrasonographical evidence of gallstones. Fifteen of the 37
patients had previously undergone ileocecal resection (med-
ian 6 years; range, 2–10 years). The mean length of the
resected ileocecal segment was 42 � 10 cm. Twelve of the
remaining 22 patients had small bowel disease and 10 had
colonic disease. At the time of the experiment 26 patients
were on medication among which 6 patients were on
prednisone, 9 on 5-ASA derivatives and 11 on both
prednisone and 5-ASA derivatives. Nine of the female
patients used oral contraceptives. All medications were
continued except on the morning of the experiment. Further
clinical characteristics of the three patient groups are
presented in Table I.
Nineteen healthy subjects without any history of gastro-
intestinal disease or abdominal surgery served as controls
(Table I). The use of oral contraceptives was reported in 7 of
the 9 female healthy subjects. Studies were performed
irrespective of the time of the menstrual cycle. The study
protocol had been approved by the ethics committee of the
Leiden University Medical Center.
Study protocol
All subjects were studied at 0830 h after an overnight fast.
After two measurements of basal gallbladder volume an
intravenous cannula was inserted into the antecubital vein of
one arm for blood sampling. A solid meal consisting of 50 g
fat, 42 g protein and 38 g carbohydrates (780 kcal) was
ingested at time t = 0 min. Gallbladder volumes were
measured and blood samples for determination of gut hor-
mones cholecystokinin (CCK), pancreatic polypeptide (PP)
and peptide YY (PYY) were drawn at t = �15, 0, 10, 20,
30, 45, 60, 75, 90, 105 and 120 min after meal ingestion.
Gallbladder volume
Gallbladder volumes measured by real-time ultrasonogra-
phy (Toshiba, 3.5 MHz transducer) were calculated by the
sum of cylinders method using a computerized system (14,
15). In this method the longitudinal image of the gallbladder
is divided into series of equal height, with diameter
perpendicular to the longitudinal axis of the gallbladder
image. The uncorrected volume is the sum of volumes of
these separate cylinders. To correct for the displacement of
the longitudinal image of the gallbladder from the central
axis, a correction factor is calculated from the longitudinal
and transversal scans of the gallbladder. Gallbladder volume
is calculated by multiplication of the uncorrected volume with
the square of the correction factor. The mean of two
measurements was used for analysis. The assumptions and
the mathematical formula used to calculate gallbladder
volume have been described and validated previously (14,
15).
Hormone assays
Blood samples for measurement of plasma pancreatic
polypeptide (PP), cholecystokinin (CCK) and peptide YY
(PYY) were drawn at time t = �15, 0, 15, 30, 45, 60, 90, 120,
150 and 180 min during each experiment. The blood samples
were collected in EDTA containing ice-chilled tubes. The
samples were centrifugated at a rate of 3000 rpm for 10 min at
a temperature of 4 °C. Plasma CCK was measured by a
sensitive and specific radioimmunoassay (16). This antibody
binds to all CCK peptides including sulphated CCK octapep-
tide, but not gastrin. The detection limit of the assay is 0.3 pM
plasma. Plasma PYY was measured by radioimmunoassay.
PYY antiserum was generated in rabbits by intracutaneous
injections of synthetic human PYY (BACHEM A.G.,
Switzerland). PYY was labelled with 125I using chloramine
T. There is no cross-reactivity with PP or VIP. The detection
limit is 10 pM plasma. Both PYY (1–3) and PYY (3–36) bind
to the antibody in dilutions up to 25,000. Plasma PP was
determined by radioimmunoassay as described previously
(17).
Data and statistical analysis
Data are expressed as mean � standard error of the mean.
Postprandial gallbladder emptying was calculated as the
percentage of the basal volume. Integrated incremental values
for plasma hormone secretion were calculated as the area
under the plasma concentration curve after subtraction of the
basal value at t = 0. Multiple analysis of variance (MANO-
Table I. Characteristics of the three patient groups and of the healthy controls. Disease duration and CDAI are expressed as medians and









Age (years) 30 � 2 34 � 4 40 � 4 37 � 4
Sex (F/M) 9/10 5/7 7/3 6/9
Body mass index (kg/m2) 23 � 1 22 � 3 24 � 3 23 � 2
Disease duration (years) — 6 (2–23) 7 (3–22) 6 (2–25)
CDAI — 76 (9–149) 90 (18–134) 80 (12–139)
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VA) was used to compare gallbladder volume, plasma PP and
CCK levels between and within groups and to analyse the
influence of age, gender and the use of medication on
gallbladder volume. Coefficient of linear correlation (Spear-
man) was used to calculate the correlations between fasting
gallbladder volumes and the length of the resected segment
and CDAI. The level of significance was set at P � 0.05.
Results
Fasting gallbladder volume
Mean basal gallbladder volume was significantly
(P � 0.05) smaller in patients with large bowel disease and
after ileocecal resection compared to patients with small
bowel disease and to controls (Table II). Individual data of
fasting gallbladder volumes are shown in Fig. 1. No corre-
lation was found between fasting gallbladder volume and
CDAI (r = 0.16; P = 0.2) or length of the resected segment
(r = 0.048; P = 0.7).
Postprandial gallbladder emptying
After meal ingestion, gallbladder volume decreased sig-
nificantly (P � 0.01) in all Crohn disease patients and healthy
controls (Fig. 2). The degree of postprandial gallbladder
emptying was not significantly different between the patient
groups and controls. Residual gallbladder volumes and
maximal postprandial gallbladder emptying for all groups
are given in Table II.
Plasma PP
Basal plasma PP levels were not significantly different
between the four groups (Table III). Plasma PP levels
significantly increased (P � 0.001) in response to the meal
in all patients and control subjects. Postprandial integrated
plasma PP concentration was not significantly different
between the groups (Table III).
Plasma CCK
Basal plasma CCK levels were significantly (P � 0.05)
higher in patients with large bowel Crohn disease and after
ileocecal resection compared to patients with small bowel
disease and controls (Table III). Plasma CCK levels sig-
nificantly (P � 0.01) increased in response to the meal in all
four groups (Fig. 3). Postprandial-integrated plasma CCK
concentrations were not significantly different between
patients and controls (Table III).
Table II. Fasting and residual gallbladder volumes and maximal percentage of postprandial gallbladder emptying in the three patient groups









Fasting volume (ml) 27.2 � 1.8 28.0 � 3.3 20.8 � 2.1* 18.3 � 2.4*
Residual volume (ml) 8.0 � 0.9 9.6 � 2.8 7.0 � 1.3 6.0 � 1.0
Maximal emptying (%) 70 � 4 66 � 8 67 � 4 68 � 3
* P � 0.05 compared to patients with ileal Crohn disease (CD) and controls.
Fig. 1. Individual data of fasting gallbladder volume (ml; mean
� standard error of the mean) in patients with Crohn disease of the
ileum and colon, patients after ileocecal resection and healthy
controls.
Fig. 2. Gallbladder volume (ml; mean � standard error of the mean)
during fasting and after meal ingestion in patients with Crohn
disease of the ileum (closed triangles), of the colon (big squares), in
patients after ileocecal resection (crosses) and healthy controls
(small squares). * P � 0.05 compared to patients with ileal Crohn
disease and controls.
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Plasma PYY
Basal plasma PYY levels were not significantly different
between Crohn disease patients and control subjects (Table
III). A significant (P � 0.05) rise in plasma levels of PYY was
found in the last 30 min after meal ingestion (t = 90, 105 and
120 min) in all the patient groups and in the healthy controls.
Postprandial-integrated plasma PYY concentrations were not
significantly different between the four groups (Table III).
Discussion
The results of the present study show that fasting gallbladder
volume is significantly smaller in patients with Crohn disease
of the large bowel and in patients after ileocecal resection
compared to patients with small bowel disease and to
controls. On the other hand, gallbladder emptying in response
to a meal is not significantly different between the patients
and the controls. We have included in this study only patients
with inactive Crohn disease and without evidence of
cholesterol gallstones. Patients who had developed cholester-
ol gallstones were excluded since it has been documented that
cholesterol gallstones affect gallbladder motility (18).
Fasting gallbladder tone and volume are controlled by both
hormonal and neural pathways. Alterations in one of these
factors may affect gallbladder motility. Indeed, plasma CCK
levels were significantly higher in patients with large bowel
disease or after ileocecal resection compared to patients with
small bowel disease and to controls. CCK is released from the
upper small bowel and is the most important hormonal
mediator of gallbladder motility (19). CCK is not only
involved in postprandial gallbladder motility but also plays
an important role in regulating basal gallbladder volume. In
humans, administration of the CCK antagonist loxiglumide
significantly increases gallbladder volume (20). The elevated
fasting plasma CCK levels in patients with large bowel
disease and after ileocecal resection correlate with small
fasting gallbladder volume found in these groups. This finding
is in agreement with a previous study by Salemans et al. (21)
who found that basal plasma CCK is increased and fasting
gallbladder volume is decreased in patients after protoco-
lectomy with ileal pouch anal anastomosis, suggesting a role
for the colon in controlling plasma CCK release from the
proximal gut.
Gastrointestinal peptides are released also from the distal
small bowel and large bowel. Peptide YY (PYY) is such a
distal gut hormone. It is a mediator of the so-called ileal and
colonic brake–a negative feedback from the distal to the
proximal gastrointestinal tract (22, 23). The highest concen-
trations of PYY-producing cells are found in the ileum, colon
and rectum (23). It has been shown in dogs that PYY infusion
induces gallbladder relaxation after CCK-stimulated gall-
bladder contraction (24). In the present study fasting plasma
PYY levels were not significantly different between patients
with large bowel disease or after ileocecal resection compared
to patients with small bowel disease and to controls,
suggesting that PYY does not account for the differences in
fasting gallbladder volume found between these patient
groups.
The vagus nerve is an important cholinergic neural
mediator of fasting gallbladder motor activity (25). In both
humans and dogs, gallbladder volume is increased after
truncal vagotomy or during cholinergic blockage with
atropine while it is decreased during administration of the
vagal cholinergic stimulus bethanechol (26, 27). Lindgren et
al. have shown that autonomic nerve dysfunction is frequently
Table III. Basal and postprandial integrated plasma concentrations of PP, CCK and PYY in patients with small and large bowel Crohn disease,









Fasting PP (pM) 49 � 3 52 � 6 41 � 9 43 � 8
Fasting CCK (pM) 0.7 � 0.2 0.8 � 0.1 1.6 � 0.3* 1.5 � 0.2*
Fasting PYY (pM) 19 � 1 21 � 3 15 � 1 21 � 1
AUC PP (pM*120 min) 8908 � 1597 7732 � 1190 7697 � 1203 7929 � 717
AUC CCK (pM*120 min) 137 � 15 145 � 46 217 � 33 204 � 40
AUC PYY (pM*120 min) 406 � 120 515 � 200 514 � 133 400 � 107
* P � 0.05 compared to patients with ileal Crohn disease and to controls.
Fig. 3. Basal and postprandial plasma CCK levels (pM; mean
� standard error of the mean) in patients with Crohn disease of the
ileum (closed triangles), of the colon (big squares), in patients after
ileocecal resection (open triangles) and healthy controls (small
squares). * P � 0.05 compared to patients with ileal Crohn disease
and controls.
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present in patients with Crohn disease especially vagus
dysfunction (28). Based on the results of these studies
theoretically, the gallbladder volume should be increased in
patients with Crohn disease compared to controls. However,
the finding of a smaller fasting gallbladder volume in patients
with large bowel disease and after ileocecal resection does not
support the hypothesis of autonomic dysfunction as a factor
accounting for the smaller fasting gallbladder volume.
In contrast to fasting gallbladder volume, no significant
difference was found in postprandial gallbladder emptying
between patients with colonic disease or after ileocecal
resection compared to patients with small bowel disease and
controls. Although several studies on postprandial gallbladder
emptying in patients with Crohn disease have been per-
formed, no consistent results have been obtained (10–13).
Murray et al. documented that gallbladder emptying in
response to a fatty meal is impaired in patients with Crohn
disease. The most pronounced impairment has been observed
in patients with both large and small bowel disease or after a
previous resection (10). Consistent with the results of Murray
et al., Damiao et al. have shown that gallbladder emptying in
response to a solid meal is significantly reduced in patients
with Crohn disease, an abnormality which is not influenced by
gastric emptying (13). Unfortunately, differences in gallblad-
der emptying related to the localization of the disease or after
resection were not analysed in the latter study. On the other
hand, Maurer et al. found no evidence for abnormal
postprandial gallbladder emptying in a group of 17 Crohn
disease patients with small and/or large bowel disease or after
previous resection (12). The discrepancy in results between
these studies could be related to differences in the composi-
tion of the test meals and differences in patient population. It
has previously been shown that the pattern and magnitude of
postprandial gallbladder emptying are determined by the type,
composition and caloric value of the meal (29). Differences in
patient population due to the heterogeneous nature of Crohn
disease with respect to disease duration and localization,
bowel resection and the use of medication are probably the
most important factors contributing to the different results
found between the studies. In the present study, we have
measured gallbladder volume in patients with inactive Crohn
disease and data were analysed according to disease
localization and bowel resection.
Since no differences were found in postprandial gallbladder
emptying and residual volume, questions must be raised
concerning the role of gallbladder motility in the formation of
gallstones in patients with Crohn disease. Residual volume
and fractional emptying have been documented to be the most
important factors promoting stasis and gallstone formation
(30). It is not known whether smaller fasting gallbladder
volumes are relevant for gallstone formation. Instead, there is
evidence suggesting that patients with cholesterol gallstones
are characterized by enlarged fasting gallbladder volumes
(31). Given the higher prevalence of gallstones in patient with
Crohn ileitis or after ileocecal resection, it is obvious that
other pathogenetic factor(s) for gallstone formation must be
involved. Excess of biliary cholesterol in relation to phos-
pholipids and bile acids due to bile acid malabsorption in
patients with Crohn disease in the ileum or after ileocecal
resection has been reported (8, 9). However, recent studies
have documented that cholesterol saturation of bile is not
increased in patients with Crohn disease after ileocecal
resection (32, 33). Not only the size but also the composition
of the bile acid pool is relevant for cholesterol gallstone
formation. The secondary bile acid deoxycholic acid stimu-
lates cholesterol secretion to a larger extent than primary bile
acids (34). The biliary concentration of deoxycholic acid is
decreased in patients with Crohn colitis who have a low
incidence of gallstones (35, 36). Data on the concentration of
deoxycholic acid in patients with Crohn disease of the ileum
or after ileocecal resection are less consistent (32, 36, 37).
Lapidus & Einarsson have found that in addition to the
decreased concentration of deoxycholic acid in duodenal bile,
the amount of ursodeoxycholic acid is increased in patients
after ileocecal resection (32). It is also possible that pigment
rather than cholesterol gallstones are present in patients with
ileal dysfunction or after ileal resection. It has been shown in
animal models that after ileal resection especially pigment
gallstones are formed (38). More recently, Brink et al. have
shown that gallbladder bile of patients with ileal Crohn
disease is saturated with unconjugated bilirubin (39).
In conclusion, patients with inactive Crohn disease of the
large bowel and patients after ileocecal resection have smaller
fasting gallbladder volumes and increased basal plasma CCK
levels. Gallbladder motility and subsequent hormone release
in response to a meal are, on the other hand, not affected in
patients with inactive Crohn disease irrespective of disease
localization and previous bowel resection. Gallbladder
(dys)motility does not seem to contribute to gallstone
formation in patients with Crohn disease.
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Since its initial description in 1984, several aspects of the action of the ileal 
brake have been investigated in animal models but  information on the ileal 
brake  in humans is still scarce and the obtained results are not always 
consistent. The studies presented in this thesis were performed to gain more 
insight into the physiology and the pathophysiology of the ileal brake in 
humans. 
Ileal brake under physiological conditions 
In chapter II, we studied and compared the effects of the fat induced ileal and 
jejunal brake on digestive and interdigestive motor patterns and postprandial 
gallbladder motility.  Intrajejunal and intraileal administration of fat both 
prolonged the duration of the fed pattern induced by an oral liquid meal and 
reduced duodenal and jejunal motility index (MI). The reduction in MI was 
more pronounced during intraileal compared to intrajejunal fat perfusion. The 
observation that the duration of the fed pattern correlated significantly only with 
postprandial plasma PYY but not with plasma CCK release may suggest a role 
of PYY in the transition from the digestive into the interdigestive state. This is in 
contrast with CCK which has a  role in the transition from fasting into fed 
motility patterns. Concerning the interdigestive motor pattern, intraileal fat 
shortened the MMC cycle length while this was prolonged in the intrajejunal fat 
experiment. Although the underlying mechanisms are not obvious, these 
findings are in support of previous results and are in line with the observation 
that MMC cycle length is shortened in malabsorptive diseases with increasing 
ileal fat delivery. Up to now, little is known about the effects of ileal and jejunal 
162 
brakes on gallbladder motility. Our results showed that ileal fat significantly 
decreased postprandial gallbladder emptying while this was enhanced during 
intrajejunal fat infusion. The observation that, postprandial gallbladder emptying 
significantly correlated with postprandial plasma CCK but not with plasma PYY 
release, suggests an insignificant role of PYY in the regulation of postprandial 
gallbladder motility. These findings are in agreement  with previous results 
demonstrating that PYY did not inhibit gallbladder contraction stimulated by 
exogenous or endogenous CCK. Altogether, results of the  study in chapter II 
demonstrate that intestinal feedback control mechanisms evoked by the fat 
induced ileal brake on proximal small intestine, postprandial gallbladder 
motility and hormone release differ qualitatively and quantitatively from those 
evoked by the fat induced jejunal brake.  
In line with the concept of a braking mechanism from the distal gut, we 
hypothesized that the more distally the nutrients are delivered into the intestine, 
the less activation of the exocrine pancreatic secretion will be found. This 
concept is of particular importance in the treatment of acute pancreatitis since 
the ideal therapy for these patients should consist of enteral nutrients thereby 
maitaining gut barrier function without affecting exocrine pancreatic secretion. 
The study in chapter III was, therefore, designed to compare the effect of a 
commercially available nutrient solution on exocrine pancreatic secretion in 
healthy volunteers, gallbladder contraction and subsequent release of proximal 
and distal gut hormones, when administered either in the proximal or in the 
distal jejunum. We used Nutrison standard as the test meal which was given 
continuously at the same rate as clinically used in patients on enteral nutrition. 
Our results demonstrated that continuous  administration of a mixed liquid meal 
in the distal jejunum did not stimulate pancreatic enzyme secretion in contrast to 
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nutrients in the proximal jejunum. Gallbladder contraction, on the other hand, 
was induced by distal jejunal nutrients, though to a lesser extent compared to 
when nutrients were given in the proximal jejunum. The decrease in gallbladder 
contraction was in parallel with the decrease in intraduodenal bilirubin output 
during distal enteral nutrient delivery. Because no differences were found in 
plasma CCK, neurotensin and PYY release during proximal and distal jejunal 
nutrient infusion, it seems unlikely that these changes were regulated by a 
hormonal mediated pathway but probably due to reduced activation of the 
enteropancreatic reflexes. From a clinical point of view, results of this study 
have provided useful information concerning the nutritional support route in the 
acute phase of pancreatitis. Distal jejunal delivery of nutrients does not activate 
exocrine pancreatic secretion while gallbladder motility is preserved. We do not 
know whether these findings can be extrapolated to patients with acute 
pancreatitis. This concept needs to be further explored  in patients with acute 
pancreatitis
Although recently much attention has been focused on PYY as a potential 
anorexogenic substance, an association between ileal brake activation and 
satiety has not been clearly defined. Since PYY is a candidate hormonal 
mediator of the ileal brake, it is conceivable that activation of the ileal brake 
with subsequent endogenous PYY release also induces satiety and inhibits 
food intake. Therefore in chapter IV we compared the effects of ileal brake 
activation with ileal fat (endogenous PYY release) versus exogenous PYY3-36
infusion on satiety and on proximal gastric motor function using two 
protocols. In the first protocol, the effect of ileal fat and subsequent 
endogenous PYY release was studied and in the second protocol, we 
investigated the dose-response relationship of exogenous PYY. The results 
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clearly demonstrated that, in healthy volunteers, ileal fat induced satiety in the 
fasting state and increased satiety in the fed state. Furthermore, ileal fat 
significantly increased fasting proximal gastric volume, enhanced 
postprandial proximal gastric relaxation and stimulated PYY release. In 
contrast, exogenous PYY3-36 infusion, at both low and high doses, did not 
affect satiety nor proximal gastric motor and sensory function. These 
findings, therefore, do not support a role for PYY as a physiological mediator 
of ileal fat induced gastric relaxation and accommodation. Our data 
concerning exogenous PYY and satiety were not in agreement with previous 
results showing that PYY markedly reduced food intake. The most likely 
explanation for this discrepancy may be related to the doses of PYY given. 
Indeed, a recent study showed that exogenous PYY3-36 only significantly 
reduced feelings of hunger and decreased food intake at high, 
pharmacological doses. The plasma levels of  PYY reached with exogenous 
PYY in our study were in the physiological postprandial range. Thus , based 
on the  results of our  study, we suggest that the doses of PYY required to 
produce a significant effect on satiety and food intake are in the 
supraphysiological or pharmacological range.  
In chapter V we used the existence of the ileal brake with subsequent PYY 
release to test the hypothesis that  medium chain triglycerides (MCT) are less 
rapidly absorbed, in contrast to the general believe that the absorption of 
MCT is  more rapid and complete compared to long chain triglycerides 
(LCT). This hypothesis derived from the observations that patients receiving 
MCT frequently complain of nausea, borborygmi, cramps, abdominal pain 
and diarrhoea. The results confirmed that MCT significantly accelerated small 
intestinal transit compared to saline and LCT. Furthermore, intraduodenally 
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administered MCT induced a significant increase in the plasma levels of the 
distal gut hormone PYY but not of the proximal gut hormone CCK. The 
elevated plasma levels of PYY after intraduodenal administration of MCT 
even at the low dose suggest that MCT were not completely absorbed but 
reached the distal gut and stimulated PYY release. These findings have raised 
questions about the concept of rapid hydrolysis and absorption of MCT. 
Furthermore, the accelerated small intestinal transit induced by MCT may 
even have detrimental effects on absorption since small intestinal transit is 
often already accelerated in disorders associated with malabsorption. 
Altered activation of the ileal brake with enhanced endogenous PYY release has 
been reported in malabsorptive diseases. This could be due to increased loads of 
unabsorbed nutrients in the distal gut. However, increased levels of plasma PYY 
may also be related to, or result from the underlying disease. The study in 
chapter VI was performed to investigate whether artificially induced 
accelerated transit with reduced intestinal absorption of nutrients per se is able to 
stimulate PYY release and activate the ileal brake mechanism. The osmotic 
laxative magnesium sulphate (MgSO4) was used to induce the artificial 
malabsorptive state in healthy subjects. Antroduodenal and gallbladder motility 
and proximal and distal gut hormone secretion were measured. In order to 
differentiate between the effects of reduced intraluminal nutrient absorption and 
those of MgSO4 itself on gastrointestinal motility and secretion, experiments 
with MgSO4 were performed both in the fed and fasted state. The results 
showed that oral magnesium sulphate significantly accelerated small intestinal 
transit both in the fasting and fed state. During the interdigestive state, MgSO4
significantly modulates antroduodenal motility without changes in intestinal 
hormone secretion. On the other hand, postprandial antroduodenal motility 
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remains unaffected after the administration of MgSO4. When given in 
combination with a fatty meal, MgSO4 induced diarrhoea in all healthy subjects 
with a significantly higher faecal weight and faecal fat excretion compared to 
placebo. Postprandial plasma levels of the distal gut hormone PYY were 
significantly increased in parallel with an increase in gallbladder volume 
(relaxation) after the administration of MgSO4. The increase in plasma PYY 
levels and gallbladder relaxation in the late postprandial phase can be considered 
as evidence which indicates that MgSO4  induced malabsorption activates the 
ileal brake mechanism in healthy subjects.  
Ileal brake under pathophysiological conditions 
Chronic pancreatitis with exocrine pancreatic insufficiency is one of many 
causes leading to maldigestion and malabsorption. Gastrointestinal motility 
and hormonal changes have been reported in association with chronic 
pancreatitis but results of published studies  are not in line. We hypothesized 
that these differences in results may be related to the presence of exocrine 
insufficiency in chronic panreatitic patients. Therefore we investigated in 
chapter VII digestive and interdigestive antroduodenal motility and release of 
gastrointestinal hormones  CCK, PP and peptide YY (PYY) in a large group of 
CP patients. The patients were divided into groups with and without exocrine 
pancreatic insufficiency. In order to further elucidate the role of exocrine 
insufficiency and subsequent maldigestion, we also studied the effect of 
exocrine pancreatic enzyme supplementation on the aforementioned parameters. 
Results were compared with those obtained in healthy controls. Our results 
demonstrated that in patients with chronic pancreatitis 1) the duration of 
postprandial antroduodenal motility is significantly prolonged and early 
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postprandial antral motility was significantly reduced; 2) the interdigestive
MMC cycle length is significantly reduced due to shortening of phase II and 3) 
endogenous secretion of CCK and PP is decreased while PYY secretion was 
increased. These abnormalities were found in patients with exocrine pancreatic 
insufficiency but not in those with normal exocrine pancreatic function. 
Differences in antroduodenal interdigestive and digestive motility pattern and 
enhanced PYY release that we found between patients with and without 
exocrine insufficiency suggest that the observed abnormalities are related to 
exocrine insufficiency and subsequent maldigestion but not to chronic 
pancreatitis per se. Normalization of antroduodenal motility and postprandial 
plasma PYY secretion after pancreatic enzyme supplementation should be 
considered as evidence supporting this concept. 
Malabsorption and abdominal symptoms are also frequently found in systemic 
sclerosis (SSc), a multisystem disorder, with gastrointestinal (GI) tract 
involvement. There are two forms of SSc, the limited and the diffuse cutaneous 
form. It has been assumed that GI tract involvement occurs late in the course of 
the disease of patients with limited SSc whereas in the diffuse cutaneous form  
there is early visceral involvement. However, there are no data available 
comparing GI motility disturbances between these two subsets of SSc patients. 
In Chapter VIII we investigated antroduodenojejunal motility and proximal 
and distal gut hormone release in patients with SSc with limited and diffuse 
cutaneous forms.  Data were related to esophageal manometry findings and 
gastrointestinal symptoms. We found that esophageal motor function 
abnormalities (low LESP and peristaltic wave amplitudes) were equally 
distributed among patients with diffuse and limited type disease.  Alterations in 
antroduodenojejunal motility, on the other hand, were more pronounced among 
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patients with the limited type SSc. In addition, our results also demonstrated that 
antroduodenojejunal motility differed qualitatively between patients with limited 
and diffuse cutaneous forms of SSc. Intestinal motility in the limited type 
scleroderma is characterized by myopathic changes (reduced number of 
contractions with low amplitude) and the diffuse type by neuropathic changes 
(non-propagated, uncoordinated contractions). Not only gastrointestinal motility 
but also gastrointestinal hormone secretion was affected in patients with SSc.  
Plasma levels of CCK were significantly decreased in patients with limited 
disease. This might be explained by the reduced number of CCK producing cells 
in the upper small intestine as a result of fibrosis and atrophy or an inadequate 
intraluminal nutrient stimulation due to pancreaticobiliairy insufficiency which 
is frequently found in patients with SSc. The observations that plasma levels of 
PYY were only increased in patients with limited disease and that a majority of 
these patients had gastrointestinal symptoms including steatorrhoea suggest that 
the enhanced PYY releas is secondary, resulting from changes in GI function 
induced by SSc and not primarily related to SSc. 
Apart from changes associated with maldigestion and malabsorption, the 
feedback function of  the ileal brake could also be altered due to mucosal defects 
or after resection of distal small intestine, as in patients with Crohn’s disease. 
The fact that the prevalence of gallstones is higher in Crohn’s patients compared 
to age-matched healthy subjects gives rise to questions concerning possible 
mechanisms underlying the gallstone formation in these patients. Because the 
role of gallbladder motility in the pathogenesis of gallstone formation in 
Crohn’s disease is not clearly ascertained the study in chapter IX was 
performed to evaluate fasting and meal-stimulated gallbladder motility in 
Crohn’s disease. In order to answer the question whether changes in 
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gallbladder motility are explained by altered ileal brake function due to 
disease localisation or bowel resection we investigated gallbladder motility in 
a large group of Crohn’s disease patients with different disease localisation 
(ileal or colonic) and with or without ileocecal resection. As the gallbladder 
motor response to a meal is mainly controlled by various gut hormones 
released during the intestinal phase, basal and meal-stimulated plasma 
concentrations of proximal and distal gut hormones are also measured. The 
results showed that patients with inactive Crohn’s disease of the large bowel 
and patients after ileocecal resection have smaller fasting gallbladder volumes 
and increased basal plasma CCK levels. Although in line with previous 
results demonstrating that basal plasma CCK was increased and fasting 
gallbladder volume was decreased in patients after protocolectomy with 
ilealpouch anal anastomosis, the functional significance of these findings 
remains unclear. Furthermore, the observation that fasting plasma PYY levels 
were not significantly different between the patient groups compared to 
controls suggests that PYY did not account for the differences in fasting 
gallbladder volume found between these patient groups. In addition, 
gallbladder motility and subsequent hormone release in response to a meal 
were not affected in patients with inactive Crohn’s disease irrespective of 
disease localization and previous bowel resection. Thus, we conclude that 
gallbladder (dys)motility does not seem  to be a factor contributing  to 
gallstone formation in patients with Crohn’s disease.  
CONCLUSIONS AND CONSIDERATIONS 
1. Feedback control mechanisms from the distal to the proximal gut differ with 
respect to the site of stimulation. Effects of the fat induced ileal brake on 
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proximal small intestine, postprandial gallbladder motility and hormone 
release are qualitatively and quantitatively different from those evoked by 
the fat induced jejunal brake.  
2. Nutrients in the distal jejunum do not activate exocrine pancreatic secretion 
while gallbladder motility is preserved. From a clinical point of view, this 
provides useful information concerning the nutritional support route in the 
acute phase of pancreatitis. Future study in patients with acute pancreatitis is 
needed to elaborate on this concept. 
3. Activation of the ileal brake reduces gallbladder emptying, or in other 
words, stimulates gallbladder relaxation, especially in the late postprandial 
phase. It remains, however, debatable wherether this action is hormonally 
mediated through PYY release.  
4. Gallbladder (dys)motility does not seem to contribute to gallstone formation 
in patients with Crohn’s disease. Disease localisation and ileacecal resection 
do not appear to significantly affect fasting nor meal stimulated plasma PYY 
release.
5. Ileal brake induced satiety and proximal gastric relaxation are not mediated 
through PYY release. In order to produce a significant effect on satiety and 
food intake the dose of exogenous PYY infusion must probably be in the 
supraphysiological range.  
6. Medium chain triglycerides accelerate intestinal transit and stimulate PYY 
release. The latter implies that MCT are not completely absorbed but 
reached the distal gut. This observation, thus, casts doubt on the concept of 
rapid hydrolysis and absorption of MCT.  
7. Activation of the ileal brake with subsequent PYY release in malabsorptive 
diseases is most likely secondary, resulting from malabsorption rather than 
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primarily due to the underlying disease. The findings that laxative induced 
malabsorption activates the ileal brake mechanism in healthy subjects and 
that pancreatic enzyme supplementation normalises antroduodenal motility 
and postprandial plasma PYY secretion in chronic pancreatitic patients with 




Sinds de eerste omschrijving van de “ileal brake” in 1984 zijn verscheidene 
aspecten ervan in diermodellen onderzocht. Over de “ileal brake” bij de mens 
is echter weinig bekend en de huidige gegevens spreken elkaar vaak tegen. De 
experimenten die in dit proefschrift staan beschreven werden verricht om 
meer inzicht te krijgen in de fysiologie en de pathofysiologie van de “ileal 
brake” bij de mens.  
De “ileal brake” onder fysiologische omstandigheden 
In hoodfstuk II wordt een vergelijkend onderzoek beschreven naar het effect 
van de door  vet geinduceerde “ileal brake” en “jejunal brake”op de motoriek 
van de maag, de dunne darm en de galblaas in de nuchtere toestand en na de 
maaltijd. Intra-jejunale en intra-ileale toediening  van vet verlengt  de duur 
van het gevoed patroon en vermindert de duodenale en jejunale 
motiliteitsindex (MI). De afname in MI is meer uitgesproken tijdens intra-
ileale dan tijdens intra-jejunale vettoediening. De bevinding dat de duur van 
het gevoed patroon alleen met  postprandiale plasma PYY maar niet met 
postprandiale plasma CCK spiegels correleert, doet een rol van PYY in de 
overgang van gevoed naar nuchter motoriek patroon vermoeden. Dit staat 
tegenover de rol die CCK speelt bij de overgang van nuchter naar gevoed 
patroon.  De zogenaamde “migrating motor complex” cycli (MMC), het 
interdigestieve motoriek patroon, zijn korter tijdens intra-ileale vet infusie 
terwijl intra-jejunale vet infusie de MMC cyclus verlengt. Hoewel de 
onderliggende mechanismen niet geheel duidelijk zijn, komen deze 
bevindingen overeen met de resultaten van eerdere studies. De MMC 
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cycluslengte is bijvoorbeeld korter bij patiënten met malabsorptie met 
toegenomen hoeveelheid onverteerd voedsel in de distale dunne darm. Tot op 
heden is er weinig bekend over de effecten van de aanwezigheid van vet in 
het ileum op de motoriek van de galblaas. De resultaten van deze studie laten 
zien dat intra-ileale vet infusie een significante afname van de postprandiale 
galblaascontractiliteit geeft terwijl intra-jejunale vet infusie tot een toename 
van de galblaascontractie leidt. Onze bevinding dat de galblaasmotiliteit 
alleen met plasma CCK spiegels maar niet met plasma PYY spiegels 
correleert, suggereert dat PYY geen belangrijke rol speelt bij de regulatie van 
de postprandiale galblaasmotoriek. Ook eerdere studies hebben aangetoond 
dat PYY geen inhiberend effect heeft op de CCK geinduceerde 
galblaascontractie.  Samengevat laten de resultaten beschreven in hoofdstuk II 
zien dat in het geval van de door vet geinduceerde “ileal brake” het feedback 
mechanisme op de proximale dunne darm motoriek, de postprandiale 
galblaasmotoriek en de hormoon afgifte zowel kwalitatief als kwantitatief 
anders verloopt dan bij de door vet geinduceerde “jejunal brake”.
Uitgaande van het concept dat het distale darmkanaal een remmende werking 
heeft op het proximale deel veronderstelden we stimulatie van de exocriene 
pancreassecretie afneemt als nutriënten distaler in de dunne darm worden 
toegediend. Dit is vooral van belang bij de behandeling van acute pancreatitis 
aangezien de beste behandeling voor deze patiënten bestaat uit het behouden 
van de intergriteit van het darmslijmvlies en tegelijkertijd minimale stimulatie 
van de exocriene enzymsecretie. De studie beschreven in hoofdstuk III werd 
uitgevoerd om het effect te vergelijken van nutriënten in het proximale versus 
het distale jejunum op de exocriene pancreassecretie, galblaas contractie en 
hormoonsecretie in gezonde vrijwilligers. Als testmaaltijd gebruikten we 
174 
cycluslengte is bijvoorbeeld korter bij patiënten met malabsorptie met 
toegenomen hoeveelheid onverteerd voedsel in de distale dunne darm. Tot op 
heden is er weinig bekend over de effecten van de aanwezigheid van vet in 
het ileum op de motoriek van de galblaas. De resultaten van deze studie laten 
zien dat intra-ileale vet infusie een significante afname van de postprandiale 
galblaascontractiliteit geeft terwijl intra-jejunale vet infusie tot een toename 
van de galblaascontractie leidt. Onze bevinding dat de galblaasmotiliteit 
alleen met plasma CCK spiegels maar niet met plasma PYY spiegels 
correleert, suggereert dat PYY geen belangrijke rol speelt bij de regulatie van 
de postprandiale galblaasmotoriek. Ook eerdere studies hebben aangetoond 
dat PYY geen inhiberend effect heeft op de CCK geinduceerde 
galblaascontractie.  Samengevat laten de resultaten beschreven in hoofdstuk II 
zien dat in het geval van de door vet geinduceerde “ileal brake” het feedback 
mechanisme op de proximale dunne darm motoriek, de postprandiale 
galblaasmotoriek en de hormoon afgifte zowel kwalitatief als kwantitatief 
anders verloopt dan bij de door vet geinduceerde “jejunal brake”.
Uitgaande van het concept dat het distale darmkanaal een remmende werking 
heeft op het proximale deel veronderstelden we stimulatie van de exocriene 
pancreassecretie afneemt als nutriënten distaler in de dunne darm worden 
toegediend. Dit is vooral van belang bij de behandeling van acute pancreatitis 
aangezien de beste behandeling voor deze patiënten bestaat uit het behouden 
van de intergriteit van het darmslijmvlies en tegelijkertijd minimale stimulatie 
van de exocriene enzymsecretie. De studie beschreven in hoofdstuk III werd 
uitgevoerd om het effect te vergelijken van nutriënten in het proximale versus 
het distale jejunum op de exocriene pancreassecretie, galblaas contractie en 
hormoonsecretie in gezonde vrijwilligers. Als testmaaltijd gebruikten we 
175
Nutrison standaard sondevoeding welke continu en in dezelfde hoeveelheid 
gegeven werd bij patiënten met acute pancreatitis. De resultaten tonen aan dat 
continu toediening van sondevoeding in het distale jejunum de exocriene 
pancreassecretie niet stimuleert, terwijl toediening van sondevoeding in het 
proximale jejunum dit wel doet. Toediening van nutriënten in het distale 
jejunum induceert een grotere mate van galblaascontractie dan toediening in 
het proximale jejunum. De afname van galblaascontractie gaat gepaard met 
een daling van de intraduodenale bilirubine uitscheiding tijdens distale 
enterale voeding. Omdat er geen verschillen in plasma CCK, neurotensin en 
PYY concentraties gevonden worden, is het onwaarschijnlijk dat de 
beschreven veranderingen hormonaal gemedieerd  worden maar eerder het 
gevolg zijn van verminderde activatie van enteropancreatische reflexen. Deze 
bevindingen kunnen een belangrijke bijdrage leveren aan de vraag hoe 
patiënten met acute pancreatitis gevoed moeten worden. Toediening van 
voeding in  het distale jejunum leidt niet tot exocriene pancreas 
enzymensecretie terwijl de galblaasmotoriek gehandhaafd blijft. Dit concept 
kan echter niet zomaar naar de klinische praktijk worden vertaald en dient dan 
ook verder in patiënten met acute pancreatitis te worden onderzocht.
Hoewel de laatste jaren veel aandacht is besteed aan het hormoon PYY als 
potentiële eetlust remmer, is een duidelijke associatie tussen de “ileal brake” 
en verzadiging niet beschreven. Aangezien PYY de “ileal brake” mogelijk 
medieert, is het denkbaar dat  activatie van de “ileal brake” met endogene 
PYY secretie ook tot verzadiging leidt en voedselinname remt. Om dit te 
onderzoeken wordt in hoofdstuk IV het effect van “ileal brake” activatie 
door middel van intra-ileale vet infusie (endogene PYY secretie) vergeleken 
met exogene infusie van PYY-36 op verzadiging en op proximale maag 
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motoriek. Ten eerste werd het effect van intra-ileale vet infusie en de daarop 
volgende  endogene PYY secretie bestudeerd. Vervolgens onderzochten we 
het dosis-respons effect van exogeen PYY. De resultaten laten duidelijk zien 
dat in nuchtere gezonde vrijwilligers intra-ileale vet infusie verzadiging en het 
verzadigingsgevoel in de gevoede toestand versterkt. Voorts leidt intra-ileale 
vet infusie tot een significante toename van het  nuchtere proximale 
maagvolume en de proximale maagrelaxatie  na de maaltijd en wordt de 
endogene  PYY secretie gestimuleerd. Toediening van lage en hoge 
doseringen exogeen PYY heeft echter geen invloed op verzadiging, noch op 
motoriek en sensibiliteit van de proximale maag. Deze resultaten zijn in 
tegenstelling tot exogene PYY welke bij zowel lage als hoge dosering, geen 
invloed heeft op verzadiging noch proximale maag motoriek en secretie 
functies. Deze bevindingen pleiten daarom tegen een rol voor PYY als 
fysiologische mediator van de door intra-ileale vet infusie geinduceerde 
relaxatie en accomodatie van de maag. Onze bevindingen wat betreft exogene 
PYY infusie zijn niet in overeenstemming met eerdere studies waarin wordt 
beschreven dat PYY duidelijk de  voedselinname remt. De meest 
waarschijnlijke verklaring voor deze discrepantie is een verschil in de 
dosering van exogene PYY.  Een recente studie toonde aan dat alleen een 
hoge, farmacologische dosering  van PYY een significante toename van 
verzadiging en een significante afname van voedselinname geeft. In onze 
studie zijn de plasma spiegels van PYY na exogene toediening in de 
fysiologische postprandiale range. Waarschijnlijk zijn suprafysiologische 
doseringen van PYY vereist om een effect op verzadiging en voedselinname 
uit te oefenen.
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In hoofdstuk V gebruiken we het concept van de “ileal brake” en endogene 
PYY secretie om de hypothese te testen dat middellange-keten triglyceriden 
(MCT) minder snel worden geabsorbeerd, hoewel in het algemeen vanuit 
wordt gegaan, dat de absorptie van MCT vollediger en sneller is dan van 
lange-keten triglyceriden (LCT). Deze hypothese komt voort uit de observatie 
dat  patiënten die MCT gebruiken vaak klagen over misselijkheid, 
borborygmi, krampen, buikpijn en diarree. De resultaten bevestigen dat MCT 
een significante afname van de dunne darm passagetijd geeft in vergelijking 
met LCT en fysiologisch zout. Intraduodenale toediening van MCT leidt tot 
een significante stijging in de plasma concentratie van het distale darm 
hormoon PYY maar niet van het proximale darm hormoon CCK. De stijging 
van plasma PYY, ook bij een lage dosering  MCT in het duodenum, 
suggereert dat  MCT niet volledig geabsorbeerd wordt maar gedeeltelijk de 
distale dunne darm bereikt en aldaar de secretie van PYY stimuleert. Deze 
bevindingen roepen vragen op omtrent de veronderstelling dat MCT volledig 
en snel geabsorbeerd wordt. De versnelde dunne darm passage, geinduceerd 
door MCT, kan zelfs de absorptie aanzienlijk verslechteren aangezien de 
dunne darm passage reeds versneld is bij patiënten met malabsorptie.  
Veranderde activatie van de “ileal brake” en toegenomen endogene PYY 
secretie zijn reeds beschreven bij patiënten met malabsorptie. Dit kan 
veroorzaakt worden door een toegenomen hoeveelheid onverteerd voedsel in 
de distale dunne darm. Toegenomen PYY secretie kan echter ook gerelateerd 
zijn aan of juist het gevolg zijn van de onderliggende ziekte. De studie 
beschreven in hoofdstuk VI onderzoekt of een kunstmatig geinduceerde 
versnelde dunne darm passagetijd en de bijbehorende afgenomen intestinale 
absorptie in staat is om PYY secretie te stimuleren en de”ileal brake” te 
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activeren. Het osmotisch laxans magnesiumsulfaat (MgSO4) werd gebruikt 
om een malabsorptieve toestand bij gezonde vijwilligers te creëren. 
Antroduodenale motiliteit, galblaasmotoriek en proximale en distale hormoon 
secretie door de dunne darm werden gemeten. De experimenten met MgSO4 
werden uitgevoerd zowel in gevoede als in nuchtere toestand om onderscheid 
te kunnen maken tussen het effect van verminderde intraluminale absorptie  
en het effect van MgSO4 op gastrointestinale motiliteit en secretie. De 
resultaten laten zien dat orale toediening van MgSO4 een significante 
versnelling geeft van de dunne darm passagetijd zowel in gevoede als in 
nuchtere toestand. Antroduodenale motiliteit wordt beduidend beinvloed door 
magnesiumsulfaat  in de nuchtere toestand terwijl de hormoon secretie 
onveranderd blijft. Postprandiale antroduodenale motiliteit daarentegen 
verandert niet na toediening van magnesiumsulfaat. In combinatie met een 
vetrijke maaltijd veroorzaakt  MgSO4 in alle gezonde vrijwilligers diarree 
met een beduidend hoger fecaal gewicht en toegenomen fecale vet excretie in 
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hormoon PYY zijn significant hoger na toediening van MgSO4. Hogere 
plasma PYY spiegels gaan gepaard met een stijging van galblaas volumina. 
Deze bevindingen wijzen erop dat de door MgSO4 veroorzaakte malabsorptie 
de “ileal brake” in gezonde vrijwilligers activeert.  
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Chronische pancreatitis (CP) met exocriene insufficiëntie is één van vele 
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gatrointestinale motiliteit en hormoonsecretie zijn beschreven bij patiënten 
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Mogelijkerwijs is de aanwezigheid van exocriene insufficiëntie bij patiënten 
met CP de oorzaak van de verschillen in  eerdere resultaten. Daarom 
onderzochten we in hoofdstuk VII de digestieve en interdigestieve 
antroduodenale motiliteit en secretie van de gastrointestinale hormonen CCK, 
PP en PYY in een grote groep CP patiënten. Patiënten werden verdeeld in een 
groep met en een groep zonder exocriene insufficiëntie. Om de rol van 
exocriene pancreasinsufficiëntie en  maldigestie te onderzoeken bestudeerden 
wij ook het effect van exocriene pancreasenzymsuppletie op de 
bovengenoemde parameters. De resultaten werden vergeleken met die 
verkregen in gezonde controles. We vonden dat bij patiënten met chronische 
pancreatitis 1) de duur van het gevoed patroon langer is en de postprandiale 
antrale motiliteit verminderd is in de vroeg postprandiale fase; 2) de 
interdigestieve MMC cycluslengte beduidend korter is door een verkorting 
van fase II en 3) de secretie  van CCK en PP afgenomen is terwijl de PYY 
secretie toegenomen is. Deze bevindingen zijn gevonden bij patiënten met 
exocriene pancreasinsufficiëntie maar niet bij die met normale exocriene 
pancreasfunctie. De gevonden verschillen in interdigestieve en digestieve 
antroduodenale motiliteit en PYY secretie tussen patiënten met en zonder 
exocriene pancreasinsufficiëntie suggereren dat deze vooral samenhangen met 
exocriene insufficiëntie en bijbehorende maldigestie, en niet zozeer met 
chronische pancreatitis zelf. De normalisering van de antroduodenale 
motiliteit en de postprandiale PYY secretie na pancreasenzymsuppletie 
ondersteunt deze hypothese. Malabsorptie en buikklachten komen vaak voor 
bij systemische sclerose (SSc), een systeemziekte waarbij de tractus 
digestivus betrokken is. SSc komt voor in de gelimiteerde en de diffuus-
cutane vorm. Hoewel gesuggereerd is dat de tractus digestivus pas laat in de  
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ziekte betrokken raakt bij patiënten met gelimiteerd SSc  maar vroeg bij 
diffuus SSc, zijn er geen vergelijkende beschikbaar. In hoofdstuk VIII
onderzochten we de antroduodenojejunale motiliteit en  de proximale en 
distale darmhormoonsecretie in patiënten met gelimiteerd en diffuus SSc. De 
resultaten werden gecorreleerd met bevindingen bij slokdarmmanometrie en 
gastrointestinale symptomen. Wij vonden dat afwijkingen in de 
slokdarmmotoriek (lage druk in de onderste slokdarmsfincter en peristaltische 
amplitude) niet verschilden tussen patiënten met diffuus en gelimiteerd SSc. 
Veranderingen in antroduodenojejunale motiliteit zijn echter meer 
uitgesproken bij patiënten met gelimiteerd SSc. Bovendien verschilt de 
antroduodenojejunale motiliteit kwalitatief tussen patiënten met gelimiteerd 
en diffuus SSc. Intestinale motiliteit in gelimiteerd SSc wordt gekenmerkt 
door myopathische veranderingen (verminderd aantal contracties met lage 
amplitude) en die van het diffuse type wordt gekenmerkt door neuropathische 
veranderingen (niet-voortgeleide, ongecoördineerde contracties). Niet alleen 
gastrointestinale motiliteit maar ook gastrointestinale hormoonsecretie is 
veranderd in patiënten met SSc. Plasma CCK spiegels zijn aanzienlijk lager in 
patiënten met gelimiteerd SSc. Dit zou verklaard kunnen worden door een 
afgenomen aantal CCK-producerende cellen in de proximale dunne darm als 
gevolg van bindweefsel-formatie en atrofie, of een onvoldoende intraluminale 
vertering van voedsel door pancreasinsufficiëntie die vaak bij patiënten met 
SSc wordt gevonden. De observatie dat plasma PYY spiegels alleen verhoogd 
zijn in patiënten met gelimiteerd SSc en dat de meerderheid van deze 
patiënten gastrointestinale symptomen heeft suggereert dat toegenomen PYY 
secretie het gevolg is van een SSc-gerelateerde verandering in 
gastrointestinaal functioneren  maar niet primair gerelateerd is aan de ziekte 
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zelf.
De terugkoppelingsfunctie van de “ileal brake” wordt niet alleen beinvloed 
door maldigestie en malabsorptie, maar ook door mucosale afwijkingen en/of 
darmresecties, zoals bij  patiënten met de ziekte van Crohn. Het feit dat de 
prevalentie van galstenen hoger is in Crohn patiënten in vergelijking met een 
gezonde groep van gelijke leeftijd roept vragen op omtrent de mogelijke 
mechanismen die aan de galsteenvorming in deze patiënten ten grondslag 
liggen. Omdat de rol van galblaasmotiliteit bij het ontstaan van galsteen bij de 
ziekte van Crohn nog niet duidelijk is  wordt in hoofdstuk IX een onderzoek 
naar nuchtere en maaltijd-gestimuleerde galblaasmotiliteit in patiënten met de 
ziekte van Crohn uitgevoerd. Om de vraag te beantwoorden of veranderingen 
in de galblaasmotiliteit toe te schrijven zijn aan de veranderingen in de “ileal 
brake” die het gevolg zijn van ziektelocalisatie of darmresectie, onderzochten 
wij de galblaasmotiliteit in een groep patiënten met de ziekte van Crohn met 
verschillende ziektelocalisaties (ileum of dikke darm) en met of zonder 
ileocecaal-resectie. Aangezien postprandiale galblaasmotiliteit door diverse 
darmhormonen gereguleerd wordt, werden de nuchtere en postprandiale 
plasmaconcentraties van proximale en distale darmhormonen gemeten. Deze 
laten zien dat patiënten met een inactieve Crohn van de dikke darm en 
patiënten na ileocecaal-resectie kleinere nuchtere galblaasvolumina en hogere 
nuchtere plasma CCK spiegels hebben. Hoewel deze bevindingen in 
overeenstemming zijn met eerdere studies, waarin gevonden werd dat 
nuchtere plasma CCK spiegels verhoogd en nuchtere galblaasvolumina 
verlaagd zijn  bij patiënten na  een protocolectomie met een ileo-anale 
anastomose met aanleggen van een pouch, blijft de functionele betekenis 
ervan onduidelijk. Voorts suggereren de gelijke nuchtere plasma PYY 
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spiegels in patiënten en controles dat PYY niet verantwoordelijk is voor het 
gemeten verschil in nuchtere galblaasvolumina. Postprandiale 
galblaasmotiliteit en hormoonsecretie zijn bovendien niet veranderd bij  
patiënten met inactieve Crohn, ongeacht localisatie van de ziekte en/of 
voorafgaande darmresectie. De conclusie van deze studie luidt dan ook dat 
galblaas (dis)motiliteit waarschijnlijk geen rol speelt bij de vorming van 
galsteen bij patiënten met de ziekte van Crohn.
CONCLUSIES  
1. Het terugkoppelingsmechanisme van het distale naar het proximale deel 
van de tractus digestivus hangt af van het punt waar stimulatie plaatsvindt. De 
effecten van vet infusie in het ileum  op de proximale dunne darm, 
postprandiale galblaasmotoriek en  hormoonsecretie zijn  kwalitatief en 
kwantitatief verschillend van die geinduceerd door intrajejunale vet infusie. 
2. De aanwezigheid van nutriënten in het distale jejunum leidt niet tot 
activatie van exocriene pancreasenzymsecretie terwijl galblaasmotoriek 
gehandhaafd blijft. Voor de kliniek levert dit gegeven een belangrijke 
bijdrage aan de vraag hoe patiënten met acute pancreatitis het beste gevoed 
kunnen worden. 
3. Activatie van de “ileal brake” remt de galblaascontractie en bevordert de 
galblaasrelaxatie vooral in de vroege postprandiale fase. Het blijft echter 
onduidelijk of dit effect hormonaal gemedieerd wordt door PYY secretie. 
4. Galblaas (dis)motiliteit lijkt niet bij te dragen aan galsteenvorming bij 
patiënten met de ziekte van Crohn. De localisatie van de ziekte en voorgaande 
ileocecaal-resectie beinvloeden de nuchtere en postprandiale PYY secretie 
niet.
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5. De door de “ileal brake” veroorzaakte verzadiging en proximale 
maagrelaxatie worden niet gemedieerd door PYY secretie. Om een significant 
effect op verzadiging en voedselinname te bereiken moet de exogene PYY 
infusie zich waarschijnlijk in de suprafysiologische range bevinden. 
6. Middellange-keten triglyceriden (MCT) induceren een versnelde dunne 
darm passage en stimuleren PYY secretie. Dit laatste impliceert dat MCT niet 
volledig geabsorbeerd worden en de distale darm kunnen bereiken. Deze 
bevinding pleit tegen het concept van een snelle hydrolyse en absorptie van 
MCT.
7. Activatie van de “ileal brake” met PYY secretie in aandoeningen die 
gepaard gaan met malabsorptie is zeer waarschijnlijk  het gevolg van de 
malabsorptie zelf en niet primair als gevolg van de onderliggende ziekte. Dit 
concept wordt ondersteund door de bevindingen dat 1) de “ileal brake” bij 
gezonde vrijwilligers kan worden geactiveerd  door malabsorptie ten gevolge 
van laxantia-gebruik en 2) suppletie van exocriene pancreasenzymen bij 
patiënten met exocriene pancreasinsufficiëntie de antroduodenale motiliteit en 
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